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All artificial organ systems and medical devices that operate in direct contact with 
blood elicit activation of coagulation and platelets, and their long-term use often 
necessitates antithrombotic therapies that carry significant cost and bleeding risk.  Since 
the clinical inception of fabric grafts in 1952, none of the existing synthetic arterial 
substitutes perform comparably to autologous conduits in small-caliber (< 6 mm id) 
revascularization, a cornerstone in the fields of cardiac, vascular, and plastic surgery.  
Two key factors behind this status quo are the mechanical mismatch between the native 
vasculature and synthetic conduits, as well as acute occlusion resulting from elaboration 
of undesired thrombotic reactions initiated at the blood-material interface. 
Although major advances in tissue engineering approaches have yielded 
biomaterials that mimic the bulk biomechanical properties of native tissue, many of 
which have been translated to clinical use, there is still no generally acceptable blood 
compatible material.  Moreover, it is increasingly recognized that long term failure of 
synthetic vascular grafts is largely driven by incomplete reendothelialization decades 
after implantation due to a persistent foreign body response at the blood-material 
interface that impairs healing, which may be elicited or augmented by interfacial 
activation of thrombotic cascades.  The combination of ongoing efforts to develop 
biofunctional materials that induce spontaneous endothelialization, as well as attenuation 
of acute thrombotic activation cascades, could ultimately improve the long term 
performance of these materials in blood contacting applications.   
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Molecular engineering of the blood-material interface to actively control the 
evolution of the healing response subsequent to implantation is a central paradigm in the 
development of new blood-compatible materials.  The production of thrombin 
downstream of coagulation activation cascades elicited by implanted materials may be a 
key driver behind maladaptive host responses, due to the multifaceted activity of 
thrombin to crosslink fibrin, activate platelets, and induce the onset and elaboration of 
inflammatory responses, which, in the context of small-diameter revascularization, 
contributes to acute thrombotic occlusion and possibly impaired reendothelialization in 
the long term.  Therefore, optimal attenuation of acute thrombotic activation cascades on 
synthetic materials could hinge on surface engineering strategies that inhibit thrombin 
and its production. 
 In this dissertation, we developed surface engineering platforms inspired by 
natural mechanisms contained in the endothelial lining of the circulatory system that 
attenuate thrombosis.  Thrombomodulin (TM) is an endogenous inhibitor of thrombin 
production localized on the endothelial cell surface.  We developed covalent chemical 
coupling strategies to immobilize TM on blood-contacting interfaces, and validated their 
capacity to inhibit platelet deposition in a clinically relevant animal model of thrombosis.  
Moreover, we further demonstrated a reversible chemoenzymatic approach to regenerate 
depleted surface activity by rapid removal and “recharging” of surfaces using a mutant 
transpeptidase, the S. Aureus sortase A, which exhibited dramatically enhanced catalytic 
activity. 
 Following a brief overview of the research in the first chapter, chapter 2 of this 
dissertation provides an extensive background review of current synthetic materials used 
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in construction of artificial blood vessels, the interplay between platelets, coagulation, 
and inflammation, as well as the surface engineering strategies that have been explored to 
date in an effort to fulfill the blood compatibility gap in the design of implantable devices 
and artificial organ systems.  We then discuss in chapter 3 our initial efforts to develop 
conformal coatings through layer-by-layer assembly of polyelectrolyte multilayer films 
on solid supports, as a means to generate chemically reactive anchor sites for 
immobilizing bioactive molecules.  This system provides a facile method to modify 
medical device materials with a conformal coating, whose properties may be engineered 
by selection or modification of appropriate polyelectrolyte components.   
In chapter 4, we detail our first surface engineering platform to functionalize the 
luminal surface of commercial 4 mm i.d. ePTFE vascular grafts with azide-tagged 
recombinant human TM, by site-specific Staudinger Ligation reaction with immobilized 
triphenylphosphine anchors.  This single-point immobilization approach would maximize 
the bioactivity of the surface enzyme assembly by minimizing undesirable modification 
of residues contained near the catalytically active site.  Significantly, the TM modified 
grafts generated through this strategy reduced the level of platelet deposition in an 
arteriovenous (A-V) shunt model in nonhuman primates.  To our knowledge, this is the 
first study reporting in vivo therapeutic function of a site-specifically immobilized 
anticoagulant enzyme on clinically relevant medical device surfaces since the 
development of end-point attachment methods for heparin. 
 We discuss in Chapter 5 our efforts to optimize the production of azide-tagged 
TM, as well as surface chemistry schemes that would enable the site-specific 
immobilization of TM in a manner that facilitates terminal sterilization of medical device 
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surfaces.  Through this process we developed a general method to conjugate a single 
azide motif to the C-terminus of TM using the bacteria transpeptidase Sortase A.  This 
approach facilitates expression of TM without the use of non-natural azido-tagged amino 
acid analogues, and is compatible with eukaryotic expression systems typically used in 
the biopharmaceutical industry.  Moreover, we developed a surface modification strategy 
whereby sterically strained cyclooctyne motifs covalently immobilized on the luminal 
surface of 4 mm i.d. ePTFE grafts retained their capacity undergo [3+2] cycloaddition 
with azide-tagged TM after ethylene oxide sterilization, the current industry standard 
used in sterilization of synthetic vascular grafts.  We demonstrated for the first time the 
superior efficacy of TM to reduce the level of local platelet deposition than commercial 
heparin modified grafts using a novel A-V shunt model in nonhuman primates, which 
more closely mimics the thrombotic stresses encountered during and immediately after 
surgical implantation. 
 On the basis of these results, we detail in Chapter 6 our discovery of a reversible 
surface engineering approach that could extend the lifetime of TM activity on surfaces, 
using a bioorthogonal covalent chemistry scheme that facilitates removal of activity-
depleted TM and regenerating the surface with fresh bioactive TM.  We hypothesized 
that sortase A (SrtA), a house-keeping calcium-dependent cysteine transpeptidase used to 
anchor cell surface proteins in S. Aureus, may enable the regeneration of TM activity on 
modified surfaces.  Although these efforts were limited by the low catalytic activity of 
wild-type SrtA, we demonstrated that a mutant SrtA which exhibited 140-fold higher 
catalytic activity enabled the rapid and repeatable recharging of TM surfaces in vitro.  
Significantly, we were able to demonstrate the in vivo application of this approach to 
 xxx 
modify catheters deployed in the mice.  To our knowledge, these results are the first to 
demonstrate a covalent chemistry approach to repeatably regenerate the activity of 
enzyme surface assemblies by a rapid 2-step strip/recharge cycle.  The capacity to 
recharge solid surfaces in situ under a range of environmental conditions would prolong 
the lifetime of medical device, diagnostics, and artificial organ system designs, as well as 







All artificial organ systems and medical devices that operate in direct contact with 
blood elicit activation of coagulation and platelets, and their long-term use often 
necessitates antithrombotic therapies that carry significant cost and bleeding risk [1, 2].  
Since the clinical inception of fabric grafts in 1952, none of the existing synthetic arterial 
substitutes perform comparably to autologous conduits in small-caliber (< 6 mm id) 
revascularization procedures central to the field of cardiac, vascular, and plastic surgery 
[3].   Poor clinical outcomes are driven by blood-material and tissue-material interactions 
that include rapid thrombotic occlusion, restenosis due to biomechanical mismatch, as 
well as impaired reendothelialization due to a persistent foreign body response to 
synthetic materials many years after implantation [4].  Despite advances in tissue 
engineering approaches that have yielded biomaterials that mimic the bulk properties of 
native tissue and promote healing [5-7], a generally accepted blood compatible material 
does not exist [8].   
In this dissertation, we developed site-specific approaches to covalently attach 
thrombomodulin (TM), a major endogenous inhibitor of blood coagulation localized on 
the endothelial cell surface, on the luminal surface of commercial vascular grafts using 
bioorthogonal chemistry that was compatible with ethylene oxide sterilization.  Notably, 
we demonstrated the superior efficacy of TM to reduce platelet deposition compared with 
commercial heparin modified grafts using a non-human primate model of acute graft 
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thrombosis.  Finally, we optimized a novel reversible chemistry to rapidly and repeatedly 
regenerate immobilized TM, with the potential to significantly extend the lifetime of 
biologically active films. Significantly, the modular nature and broad applicability of the 
approaches described herein could provide a general strategy to engineer biological 
active synthetic materials, which optimize the evolution of host responses at the blood-
material and tissue-material interfaces to promote healing and regeneration. 
1.2. Rationale 
Physiological onset of thrombosis hinges on the generation of thrombin, a central 
mediator that amplifies the intrinsic coagulation cascade, crosslinks fibrin, and activates 
platelets [9, 10].  Surface engineering approaches that mimic the natural mechanism of 
endothelial cells to attenuate thrombin production such as heparin and thrombomodulin 
have yielded promising results [8, 11, 12].   First demonstrated in 1963 [13], heparin 
immobilization has been hypothesized to mimic the antithrombin activity of cell surface 
heparan sulfate proteglycans (HSPG) expressed by the endothelium [14].  The 
physiological role of heparin, produced primarily by mast cells, in hemostasis remains 
unclear [15] as the majority of anticoagulantly active HSPG is not in direct contact with 
flowing blood [16] and knock-out mice lacking the specific pentasaccharide sequence 
that inhibits thrombin do not exhibit a procoagulant phenotype [17].   In contrast, 
thrombomodulin (TM) is a major vasculoprotective molecule localized on the endothelial 
cell surface, and overwhelming evidence indicates that defects therein increase the risk of 
inflammatory disorders and thromboembolism [18].  TM sequesters thrombin’s 
prothrombotic activity and accelerates thrombin’s ability to activate protein C (APC) by 
1000-fold, which inhibits upstream proteases necessary for amplifying thrombin 
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production and represents the primary physiological mechanism by the endothelium to 
regulate hemostasis [19].  Therefore, the reconstitution of TM activity on blood-
contacting surfaces would mimic endogenous mechanisms contained in the endothelial 
surface to actively attenuate thrombin production, and consequently reduce the acute 
thrombotic activation cascades. 
1.3.  Central Hypothesis and Specific Aims 
Our overall objective is to develop a new generation of clinically durable 
synthetic materials that actively and sustainably attenuate thrombus formation elicited at 
the blood-contacting interface.  The central hypothesis of this research is that the 
assembly of biologically active thrombomodulin at the blood-contacting interface to 
attenuate thrombin production will abrogate thrombotic activation cascades.  Our overall 
approach to test this hypothesis is to optimize bioorthogonal chemistry and protein 
engineering approaches to develop a surface engineering platform that maximizes the 
bioactivity of immobilized TM, facilitates sterilization for off-the-shelf availability, and 
sustains TM activity over clinically relevant time scales.  The specific aims of this work 
were: (i) generate a biologically active TM surface assembly by covalent site-specific 
immobilization, (ii) enable clinical translation by optimizing the scalability of TM 
production, maximizing the functional capacity of TM films to inhibit thrombosis, and 
validating a surface coupling chemistry that is compatible with industrial sterilization 
processes, (iii) demonstrate the capacity to repeatably regenerate surfaces with fresh TM 
in an effort to sustain the bioactivity of permanently implanted materials.   
The outcomes of this research are expected to define general surface engineering 
strategies to control the evolution of the biological response at host-material interfaces, a 
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key paradigm in the future design of clinically durable implantable devices, artificial 





In this Chapter, we provide an extensive background review of current synthetic 
materials used in construction of artificial blood vessels, the interplay between platelets, 
coagulation, and inflammation, as well as the surface engineering strategies that have 
been explored to date in an effort to bridge the blood compatibility gap in the design of 
implantable devices and artificial organ systems.   
2.1. Current Synthetic Arterial Substitutes 
Progressive arterial occlusion by atherosclerosis is the leading cause of mortality 
and morbidity in the United States [20].  Despite advances in minimally invasive 
techniques, the traditional practice of surgical bypass or reconstruction of diseased 
vessels has endured as the standard of care in a number of clinical settings [3, 21].  Lack 
of suitable autologous conduits, as well as associated risks involved with graft harvest 
were significant drivers behind development of an artificial vascular prosthesis.  
Synthetic conduits in modern arterial reconstructive surgery were introduced by 
Voorhees and colleagues in 1952 with the development of a vascular graft woven from 
Vinyon-N™ fibers, a polyamide related to nylon-6,6 [22].   Despite successful early 
clinical outcomes, prostheses formulated from Vinyon-N™ lacked long-term durability.  
Within five years, graft dilation and aneurysmal degeneration was frequent with an 80% 
loss in tensile strength [23, 24].  A variety of candidate materials for synthetic arterial 
conduits were examined throughout the 1950s, including solid rigid metals, glass, and 
silk.  Their failure led to the supposition that porosity and resistance to thrombosis were 
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critical features for an arterial substitute.  Innovations in polymer science and engineering 
in the period surrounding World War II led to the synthesis of poly(tetrafluoroethylene) 
(PTFE, GoreTex™) in 1938 and poly(ethylene terephthalate) (PET, Dacron™)  in 1941.  
Both polymers, when engineered as fibers or as a non-woven fabric, proved to be more 
durable and biocompatible than nylon and have remained commercial standards in 
modern vascular surgery.   
The performance of these materials, while adequate in large diameter formats, is 
unacceptable for small-diameter (< 6mm) applications such as coronary and peripheral 
arterial reconstruction or bypass, due in part to activation of the coagulation cascade and 
platelets on the graft surface whose deleterious impact on graft patency is accentuated in 
small-diameter configurations [25, 26].  Prospective randomized clinical studies have 
confirmed that Dacron and expanded PTFE (ePTFE) grafts differ little in their long-term 
performance characteristics when used in the infrainguinal position [27].  The inherent 
thrombogenicity of available polymeric materials and the presence of a chronic injury site 
at the anastomosis due, in part, to a compliance mismatch between the prosthesis and host 
artery, are contributing features for late graft occlusion.  These failure modes manifest 
whether a synthetic conduit is used for lower extremity revascularization or for 
arteriovenous hemodialysis access, even when the prosthesis has an inner diameter of 6 
mm or larger.  Despite significant effort by industrial and academic research groups over 
the past half-century, a durable, synthetic small diameter vascular graft does not exist. 
2.1.1.  Dacron Prosthesis 
Dacron™ is the DuPont trademark for poly(ethylene terephthalate), a highly 
durable polyester thermoplastic polymer that can be processed into synthetic fibers.  
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DeBakey introduced the first knitted Dacron prosthesis in 1957, which was used 
extensively in arterial reconstruction of the thoracic and abdominal aorta, as well as 
proximal peripheral vessels [28].  This pioneering work, combined with developmental 
and clinical studies by Szylagyi, Wesolowski, Sauvage, and Cooley contributed to the 
popularization of Dacron grafts in the early era of artificial blood vessels.   
  Historically, weaving and knitting have been the two common techniques to 
fabricate Dacron fibers into a tubular conduit.  The knit structure involves looping fibers 
in an interlocking chain, which yields a soft and stretchable fabric.  In contrast, a woven 
structure assembles the yarn in an over-and-under pattern in the lengthwise and 
circumferential directions.  Woven grafts are stronger and less porous than knitted grafts, 
but are less compliant and may fray when cut.  Typically, highly porous knitted Dacron 
grafts required “preclotting,” a process which involved exposing the graft to an aliquot of 
the patient’s blood prior to heparinization.  Currently, most commercial knitted grafts are 
impregnated with gelatin [29], collagen [30], or albumin [31].  Despite some evidence 
that coated grafts may induce a greater inflammatory response compared to preclotted 
grafts [32, 33], both display similar patency rates [34, 35].   
Characteristically, knitted grafts incorporate a velour finish, which orients the 
loops of yarn upward, perpendicular to the fabric surface, thereby increasing available 
surface area and enhancing the anchorage of fibrin and cells to promote tissue integration.  
The preference for a velour finish has been primarily motivated by improved handling 
characteristics with little data demonstrating that internal, external, or double velour 
grafts exhibit greater patency rates [36].  Dacron grafts are often crimped longitudinally 
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to increase flexibility, elasticity, and kink resistance.  However, these properties are lost 
soon after implantation, as a consequence of tissue in-growth.  
Recently, several modifications of Dacron grafts have been approved for clinical 
use.  To reduce surface thrombogenicity, grafts coated with bioactive heparin or 
passivated with fluoropolymers have been developed [37].  A silver coated Dacron graft 
has also been introduced to decrease the occurrence of graft infection.  Long-term follow-
up studies will be required to determine if these modifications improve outcomes. 
Early versions of knitted grafts were susceptible to dilatation over time with a 10% to 
20% increase in graft size immediately following implantation [38], followed by slow 
expansion [39].  Nonetheless, correlation of graft dilation and structural failure has not 
been established [40].   All told, the structural integrity of Dacron grafts has been 
reported to be extremely durable.  In 1997, the FDA disclosed a total of 68 cases of 
structural failure occurring at an average of 7.4 years after implantation [41].  A recent 
single center review noted a 0.2% structural failure rate at a mean follow-up of 12 years 
[42]. 
2.1.2.  ePTFE Prosthesis   
Poly(tetrafluoroethylene), or PTFE, is a fluoropolymer that was trademarked as 
Teflon™ by Dupont in the late 1930’s.  It is chemically inert, hydrophobic, and 
mechanically durable.  PTFE was initially used as a fiber in textile based grafts, but today 
is predominantly processed into expanded PTFE (ePTFE) tubes by extruding the polymer 
resin through a die.  ePTFE grafts were first implanted in animals in 1972 [43], and 
Campbell and colleagues reported their first clinical use in 1976 [44].   
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Macroscopically, the ePTFE surface is smoother than Dacron, and the grafts are 
soft and pliable.  On a microscopic scale, the extrusion process results in a porous 
morphology consisting of solid islands or nodes linked by fibrils.  This node-fibril 
structure occupies about 20% of the total volume of the expanded polymer, and results in 
a higher ratio of pores to material than in Dacron grafts.  However, the void space in 
ePTFE grafts is considerably smaller than voids in woven or knitted materials.  Further, 
the inherent hydrophobic nature of the fluoropolymer establishes a natural barrier to 
water that prevents permeation of blood.  Despite the chemical inertness of ePTFE, 
plasma proteins and platelets adhere to the surface and the host response is similar to 
Dacron [45]. 
In standard ePTFE grafts, the fibril length measures about 30 μm, though there 
have been experimental variants with a larger fibril length of 60 μm, which in animal 
models facilitated luminal endothelialization [46].  However, these observations have not 
been replicated in clinical studies.  Thin walled ePTFE has a wall thickness of 200 to 300 
μm, compared to a standard wall thickness of 400 to 600 μm.  This increases the 
compliance of the graft and improves handling, but with some loss of suture retention 
strength and an inability to use the prosthesis for repeated dialysis access.  Clinical 
performance of thin and standard walled ePTFE is otherwise similar [47].  Stretch ePTFE 
is a modification of standard ePTFE where a micro-crimping process is applied to 
compress the fibrils.  This allows the graft to extend longitudinally as the fibrils are 
stretched to their full length, which provides some improvement in handling 
characteristics.  Kink resistance of ePTFE grafts has been improved by the application of 
external plastic rings.  A recognized limitation of ePTFE grafts is their relative stiffness, 
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which leads to a compliance mismatch between the prosthesis and host artery that may 
contribute to anastomotic intimal hyperplasia.  In addition, since ePTFE does not display 
self-sealing characteristics, early access for hemodialysis is precluded due to bleeding at 
the puncture site.  
Despite some evidence that suggests that platelet deposition [48-50] and 
complement activation [51] are lower on ePTFE than Dacron prostheses, the patency 
rates of Dacron and ePTFE grafts are similar [27].  Recently, heparin and carbon coated 
ePTFE prostheses have become commercially available, but little data exists that 
confirms increased patency rates compared to unmodified grafts.  It has been suggested 
that intimal hyperplasia may be related to adverse local hemodynamic effects.  This has 
led to the use of a vein cuff at the distal anastomosis with reports of improved three-year 
patency for below knee femoral-popliteal bypasses (45% vs. 19%) [52].  A recent clinical 
study has demonstrated that grafts,  which incorporate a distal PTFE cuff have similar 
patency rates to those with a vein cuff [53]. 
2.1.3.  Polyurethane Prosthesis 
The development of a polyurethane vascular prosthesis was largely motivated by 
a desire to reduce compliance mismatch.  Polyurethane is more elastomeric than Dacron 
or ePTFE, and has been used as a polymeric coating for pacemaker leads, breast implants 
[54], and barrier films for dermal wounds [55].  Polyurethane is a copolymer that consists 
of three different monomer types: a diisocyanate hard domain, a chain extender, and a 
diol soft domain.  At physiological temperatures, the soft domains provide flexibility 
while the hard domains impart strength.  The most common medical grade polyurethanes 
are based on soft domains made from polyester, polyether, or polycarbonate.  By varying 
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the composition of the monomer repeat units, the mechanical properties of polyurethane 
prostheses can be tuned. 
Polyester based soft domains were used in the earliest generation of polyurethane 
vascular grafts.  Good biocompatibility was observed in vivo, but the hydrolytic 
susceptibility of the ester linkage led to chemical deterioration [56, 57].  In a small 
clinical study of below-knee bypass grafts, more than half occluded within one year [58].  
Biodegradation is also a concern, since some degradation products may be carcinogenic.  
The FDA terminated the use of polyurethane foam in breast implants in 1991 due to the 
release of 2,4-toluene diamine, which caused liver cancer in animals [59].  However, 
most polyurethanes studied today incorporate a different monomeric diamine subunit. 
A more hydrolytically stable polyether based polyurethane graft was later 
developed, but the ether linkage remains susceptible to oxidative degradation in vivo [57].  
Vectra™ (Bard, Inc.) is the only commercially available graft based on polyetherurethane 
and is used solely for hemodialysis access [60].  It may be punctured within 24 hours of 
implantation due to self-sealing characteristics.  A second polyurethane graft, known as 
the Aria™ graft (Thoratec, Inc.) had been subject to clinical study but is not longer being 
produced [61].   
The latest generation of polycarbonate based polyurethanes is inert to both 
hydrolysis and oxidation in both in vitro and animal studies [62-64].  The Corvita™ graft 
(Corvita, Corp.), a composite polyurethane and Dacron prosthesis, did not dilate in dogs 
after a one year implantation period, but is no longer in development [65].  The 
Expedial™ graft (LeMaitre, Inc.) was a polycarbonate based polyurethane graft 
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impregnated with heparin.  This prosthesis underwent evaluation for hemodialysis 
applications, but is no longer under development [66]. 
 A summary of current commercially available vascular grafts is summarized in 
Table 2.1.  Activation of platelets and the coagulation cascade at the blood-contacting 
interface of these grafts is a major cause underlying the acute thrombotic occlusion which 
has precluded their use in small caliber (< 6 mm i.d.) applications, and the crosstalk 
between thrombosis and inflammation may be a contributing factor to the characteristic 
maladaptive healing response that results in poor long-term outcomes in synthetic arterial 
substitutes.  Improvements upon existing synthetic vascular grafts, as well as the 
development of durable small-diameter conduits, will hinge on increasing our 
understanding of the mechanisms behind the onset of these detrimental host reactions, as 




Table 2.1. Vascular grafts commercially available in the United States 
Material type  Company Product Description 
Standard     
ePTFE  Angiotech / Edwards 
Life Sci 
Lifespan Reinforced 
  Atrium Advanta VXT Softwrap technology 
Advanta SST Trilaminate, allows pulsation 
Advanta VS 60/20 µm thru-pore design 
Flixene Laminated with biomaterial film 
  Bard Impra CenterFlex Unmodified 
  Boston Scientific Exxcel Soft 
Vascular Graft 
Unmodified 
  Braun VascuGraft Unmodified 
  Vascutek Maxiflo Ultrathin  Thin wall, external ePTFE wrap 
Maxiflo Wrap Regular wall, external ePTFE wrap 
  WL Gore & Assoc. Gore-Tex Unmodified 
   Gore-Tex Stretch Stretch 
   Gore Intering Unibody, intrawall radially supported 
Dacron  Braun Protegraft Knitted, double velour 
  InterVascular InterGard Ultrathin Unmodified 
  Vascutek VP1200K Unmodified 
Sealed     
ePTFE  Vascutek SealPTFE Ultrathin  Gelatin sealed, thin wall 
   SealPTFE Wrap Gelatin sealed, regular wall 
Taperflo Gelatin sealed, tapered 
Dacron  Atrium Ultramax Knitted, gelatin sealed, double velour 
  Bard Vasculour II Knitted, albumin sealed 
  Boston Scientific Hemashield Gold 
Microvel 
Knitted, collagen sealed, double velour 
Hemashield 
Platinum 
Woven, collagen sealed 
  Braun UniGraft Woven, gelatin sealed, single/double 
velour 
  InterVascular InterGard Woven  Woven, collagen coated 
   InterGard Knitted Knitted, collagen coated 
  Vascutek 
 
 
Gelseal Knitted, gelatin sealed 
Gelsoft Knitted, gelatin sealed 
Gelsoft Plus Köper knitted, gelatin sealed 
Heparin modified 
ePTFE  WL Gore & Assoc. Propaten Carmeda Bioactive heparin coating 
Dacron  InterVascular InterGard Heparin Knitted, collagen coated 
Carbon modified 
ePTFE  Bard Impra Carboflo Carbon coated 
Distaflo Preformed cuff at distal end 
Dynaflo Preformed cuff at distal end 
Silver modified 
Dacron  Braun SilverGraft Antibacterial 
  InterVascular InterGard Silver Antibacterial 
Others     
Collagen-
based 
 Artegraft Artegraft Crosslinked bovine carotid artery 
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2.2.  Interface between Thrombosis and Inflammation 
 Hemostasis is an exquisite orchestration of physical and biochemical forces to 
arrest bleeding.  Trauma initiates local vasoconstriction and enhanced extravasation of 
blood to the surrounding tissue.  The endothelium lining the luminal surface of blood 
vessels can be “activated” or physically denuded by injury to generate a highly 
prothrombotic interface.  As a consequence, circulating platelets bind and activate on the 
injured site, while coagulation is triggered by exposed tissue factor (TF).  These two 
systems are independent but highly complementary.  Platelet phospholipid membrane is 
an optimal substrate to amplify the coagulation cascade, which generates thrombin that 
enables fibrin crosslinking to firmly bind platelet clusters culminating in hemostatic plug 
formation.  Thrombin, in turn, is a powerful physiological activator of platelets, leading 
to the release of molecular mediators that promote hemostatic reactions and initiate an 
inflammatory response. 
 Tantamount to pathogen recognition, “danger” signals elicited by inflammation 
are obligatory for activation of antigen presenting cells (APCs) to direct the maturation of 
naïve precursor T and B lymphocytes.  In the absence of danger cues, quiescent “semi-
mature” APCs maintain peripheral tolerance to self antigens [67].  A growing body of 
evidence suggests that hemostasis, in this regard, tips the balance towards the onset of 
adaptive immunity.  Thrombin’s ability to activate inflammatory mediators, particularly 
protease activated receptors (PAR), as well as osteopontin and chemerin, has emerged as 
a new molecular mechanism contributing to the pathogenesis of a number of immune 
disorders.  In collaboration, platelets express and secrete a complex set of pro-
inflammatory mediators such as serotonin, platelet factor 4, P-selectin, as well as CD154 
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(CD40 ligand), an indispensible co-stimulatory molecule for activation of naïve 
lymphocytes.  A number of recent observations in vivo implicate platelet derived CD154 
in enhancing germinal center formation, protecting against infection, and inducing 
allograft rejection.  This review will summarize and interpret recently accumulated 
evidence that substantiates a previously underappreciated role by hemostatic components 
as adjuvants in the initiation and development of host immune responses.   
2.2.1. Platelets and Coagulation in the Pas de Deux of Hemostasis 
 Current understanding of hemostatic mechanisms is largely based on in vitro 
studies, and their functional significance in vivo remains a topic of ongoing investigation 
[10, 68].  The physiologically important soluble activators of platelets include 
thromboxane A2 (TxA2), adenosine diphosphate (ADP), and thrombin.  Alternatively, 
exposed collagen at sites of vascular injury facilitates site-specific platelet adhesion and 
activation.  Physiological initiation of the coagulation cascade occurs when sub-
endothelial tissue factor (TF) binds factor VIIa, the enzymatically active form of factor 
VII.  The VIIa/TF “tenase” complex converts factor X to Xa, which assembles with 
cofactor Va and Ca2+ on the platelet phospholipid membrane to form a “prothrombinase” 
complex that cleaves prothrombin into active thrombin.  Secondary to VIIa/TF-induced 
onset of coagulation, thrombin production is sustained by an alternate tenase, the 
complex of VIIIa and IXa, and amplified through positive feedback by thrombin’s 
activation of VIIIa and Va, as well as XIa required for IX activation.  Ultimately, 
thrombin cleaves fibrinogen and activates factor XIII to enable fibrin crosslinking.  
Activated platelets further augment hemostasis by secreting their granular cargo 
consisting of TxA2, ADP, thrombin, fibrinogen, as well as factor V.  As a result, small 
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amounts of thrombin can trigger coagulation and platelet activation which rapidly 
intensify in magnitude to generate a hemostatic plug (Figure 2.1).  
 
 
Figure 2.1.  Physiological elaboration of coagulation and platelet activation are 
quarantined by quiescent endothelial cells. Generation of thrombin (Th) from the 
coagulation cascade facilitates fibrin crosslinking to form a hemostatic plug, and is 
intimately linked to activation of platelets through PAR1/PAR4 heterodimers. Self-
reinforcing feedback systems amplify production of Th through its activation of factor 
VIII and V, as well as platelet activation which release agonists such as Th, factor V, and 
ADP. Endogenous regulators of coagulation in the endothelium include heparan sulfate 
proteoglycans (HSPG) that catalyze the inactivation of Th by antithrombin III (AT), as 
well as thrombomodulin (TM), a cofactor for Th that reverses its prothrombotic activity 
to accelerate the generation of activated protein C (aPC) which disrupts formation of 
tenase and prothrombinase complexes. The TM–Th complex also catalyzes formation of 
thrombin-activatable fibrinolysis inhibitor (TAFI) which stabilizes crosslinked fibrin. In 
concert, platelet activation is abrogated by endothelial regulators, such as CD39 that 
hydrolyze ADP to AMP. Mediators of hemostasis are increasingly associated with 
establishing a state of inflammation that is linked to the initiation and development of 







Multiple regulatory mechanisms are present in the vascular endothelium to 
establish an activation threshold for hemostasis.  The endothelium synthesizes 
prostacyclin (prostaglandin I2, PGI2) which limits platelet response to TxA2, nitric oxide 
(NO) that decreases intracellular Ca2+ to suppress αIIbβ3 binding with fibrinogen, and 
expresses ecto-diphosphohydrolase (CD39) to hydrolyze ADP (reviewed in [68]).  
Notably, PGI2 and NO are vasodilators which enhance the convective efflux of 
hemostatic mediators, thus limiting their participation in surface reactions.  Circulating 
antithrombin III irreversibly inactivates thrombin in a process catalyzed by heparan 
sulfate proteoglycans, a constituent of the endothelium.  Thrombomodulin (TM), 
expressed in quiescent endothelial cells, forms a 1:1 complex with thrombin, reversing its 
procoagulant activity to accelerate production of activated protein C (aPC) that 
suppresses coagulation through inactivation of cofactors Va and VIIIa to destabilize 
formation of tenase and prothrombinase complexes. In this role, aPC bound to endothelial 
protein C receptors (EPCR) appears more important than soluble aPC for factor Va 
inactivation.  Furthermore, factor Va associated with the with prothrombinase complex 
on platelets is drastically more resistant to aPC inactivation than factor Va bound to the 
endothelium [69].  The TM-thrombin complex also catalyzes activation of thrombin-
activatable fibrinolysis inhibitor (TAFI) that stabilizes crosslinked fibrin.  Hence, rather 
than competitively inhibiting hemostasis after its onset, physiological regulatory 
mechanisms within the endothelium “cordon off” injury sites where hemostasis is 
elaborated, thereby limiting deleterious systemic thrombosis. 
2.2.2. Protease Activated Receptors at the Nexus between Coagulation and 
Inflammation 
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 Coagulation serine proteases engage cell surface PARs, an emerging signaling 
paradigm affecting the onset of adaptive immunity.  Of the four known PARs, PAR1 can 
be activated by the transient VIIa/TF/Xa complex, thrombin, as well as EPCR-bound aPC 
(see review [69, 70]).  Thrombin’s potent capacity to activate platelets via PAR1 
underscores the intricate ties between the cellular and plasma compartments of 
hemostasis (reviewed in [71]).  Both plasmacytoid and myeloid DCs express PAR1, and 
can be stimulated by thrombin to produce monocyte chemotactic protein-1 (MCP-1), IL-
10, and IL-12 [72].  Thrombin activation of PAR1 in mature DCs can also induce 
expression of CCL18, a potent chemoattractant for immature DCs and T lymphocytes 
[73].  In a xenotransplantation model, proinflammatory MCP-1 cytokine production by 
activated donor endothelial cells required PAR1 engagement [74].  These studies suggest 
that, immediately following tissue injury, the thrombin/PAR1 signaling pathway aids in 
homing and activation of APCs to maximize antigen presentation.  In support of this 
view, PAR1 knockout protected mice against carbon tetrachloride induced liver fibrosis, 
concomitant with a reduction in T cell infiltration [75].  The VIIa/TF/Xa complex can 
additionally activate PAR2.  DC activation and migration to the lymph nodes as well as T 
cell activation were dependent on the engagement of PAR2 in mice [76].  PAR2 and toll-
like receptor (TLR4) have synergistic effects in NFκB induction, a possible mechanism 
for augmenting DC response to “danger” signals [77].  However, it does not appear that 
human DCs express PAR2 [73].   
Activation of platelet PAR1 by thrombin and consequent activation of 
sphingosine kinase leads to production and release of sphingosine 1-phosphate (S1P), an 
essential regulator of vascular permeability as well as immune cell trafficking and 
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differentiation (reviewed in [78, 79]).  Notably, S1P appears to shift the phenotype of 
effector T cells towards Th2 and Th17 while hampering Th1 type responses [78].  S1P’s 
signaling capacity is partially transmitted through a family of five S1P receptors (S1PR) 
which exhibit differential constitutive and inducible tissue expression.  The S1P receptor 
1 (S1PR1) is abundantly expressed in endothelial cells, and both S1PR1 and S1PR3 are 
highly expressed in the lymphoid organs.  S1PR1 signaling was recently shown to be 
critical in maintaining basal vascular integrity and blunting lethal responses to leak-
inducing agents in mice [80].  Immature DCs preferentially express S1PR1, but 
upregulate S1PR3 upon maturation.  Consistent with this observation, thrombin 
stimulation of DCs induced S1P production which activates S1PR3, leading to an 
autocrine amplification of coagulation and inflammation through increased tissue factor 
and IL-1β production [81].  Engagement of lymphocyte S1PR1 was instrumental in 
promoting T cell retention in peripheral tissues in response to inflammation which 
increase S1P levels [82].  S1PR1 also appears responsible for suppressing regulatory T 
cell development and function through activation of the Akt-mTOR pathway [83].   
Downstream PAR1 signaling pathways from activation by thrombin and aPC, two 
opposing forces in the coagulation cascade, exert opposite effects on inflammation.  
Thrombin-PAR1 signaling increased inflammation-induced vascular leakage that is 
dependent on activation of S1PR3, while aPC/EPCR-PAR1 signaling and transactivation 
of S1PR1 produced the opposite effect in LPS challenged mice [84].  While aPC could 
mediate this effect in vivo by blocking thrombin generation, it was demonstrated that 
aPC’s PAR signaling activity was more significant than its anticoagulant function in 
reducing mortality in this model [85].  In addition to the divergent downstream S1P 
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receptor signaling pathways of PAR1, the barrier-protective effects of aPC/EPCR also 
requires the trans-activation of endothelial PAR2 [86].  This is consistent with other 
studies that demonstrate PAR3 heterodimerization with PAR1 to allosterically modulate 
thrombin-mediated PAR1 activation in endothelial cells [87].  Likewise, the PAR4 
heterodimerizes with PAR1 on platelets and enables their activation by thrombin [88].  It 
is increasingly clear that both heterodimerization of PARs and divergent S1PR 
engagement influence the signaling outcome of PAR1 activation.   
2.2.3. Coagulation-activated Mediators in Inflammatory Disorders 
Osteopontin (Opn), a phosphorylated glycoprotein, is traditionally tied to its 
physiological roles in bone and tissue remodeling.  Proteolytic cleavage of Opn by 
thrombin exposes hidden α4β1 integrin (also known as VLA4) and CD44 binding 
domains to enable migration of antigen-specific T cells to sites of inflammation.  
Conversely, TAFI renders thrombin-cleaved Opn inactive to suppress inflammation [89].  
Considerable evidence were compiled recently using several disease models which reveal 
Opn’s role in augmenting Th1 and Th17 mediated immune responses [90].  Antigen-
specific CD4+ and CD8+ memory T cells secreted Opn upon activation and steered 
effector T cells towards a Th1 phenotype by down-modulating their IL-4 production in 
murine models of chronic allergic contact dermatitis (ACD) [91].  Likewise, during the 
sensitization stage of ACD, autocrine Opn production was a vital component for DC 
migration to the skin-draining lymph nodes [92].  In experimental autoimmune 
encephalomyelitis (EAE), Opn was abundantly expressed in mouse DCs, which induced 
IL-17 and IFN-γ production by T cells in a process mediated by integrins, while 
diminishing IL-10 production through CD44 engagement [93].  Further, engagement of 
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type I interferon receptors on DCs suppressed production of Opn and inhibited IL-17 
secretion [94].  In agreement with these observations, interferon β, a standard treatment 
for relapsing forms of multiple sclerosis (MS), decreased Opn and IL-17 production, as 
well as T cell migration [95].  Opn induced NF-κB activation, inhibited pro-apoptotic 
FOXO3A activity, and altered Bim, Bak, and Bax expression, which collectively 
prolonged survival of stimulated CD4+ and CD8+ T cells to exacerbate EAE relapse and 
progression [96].  In light of these discoveries, Opn is increasingly recognized as a 
central mediator of relapsing MS (reviewed in [97]).   
Highlighting the growing importance of bioinformatics in the field of 
immunology, a proteomic analysis of human MS lesions identified tissue factor and 
protein C inhibitor unique to chronic acute plaques.  Respective inhibition of the 
physiological activity of these target molecules with hirudin and aPC significantly 
ameliorated EAE in mice.  aPC exerted these effects by suppressing IL-17 production and 
NF-κB signaling by activated T cells [98].  A potential route by which aPC mediated this 
effect is through attenuating thrombin-mediated activation of Opn.  These results also 
raise the possibility that aPC can directly modulate the functional behavior of immune 
cells, though the extent of this influence remains unexplored.  Indeed, it was 
demonstrated that on leukocytes where EPCR expression is low, the integrin 
CD11b/CD18 could play a bigger role in mediating aPC-PAR1 signaling [99].  Our 
understanding of aPC as an anti-inflammatory mediator is far from complete, and their 
binding partners and signaling pathways in cellular compartment of immunity should 
present exciting new areas of research. 
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Chemerin is a recently characterized chemoattractant that is increasingly studied 
for its role in regulating inflammation.  Similar to Opn, chemerin circulates as an inactive 
precursor that can be activated by serine proteases involved in coagulation and 
fibrinolysis, the most potent of which are factor XIIa and plasmin, and to a lesser extent 
factor VIIa.  Additionally, thrombin-stimulated platelets appear to release partially 
cleaved chemerin [100].  Chemerin signaling via its cognate receptor ChemR23 
(CMKLR1) may be involved in the accumulation of DC in lesions from patients with 
psoriasis [101] as well as oral lichen planus [102].  Emerging evidence also implicate 
chemerin in the development of EAE [103].  Sequential cleavage of chemerin by plasmin 
and TAFI in vitro synergistically enhanced the activity of chemerin to affect 
plasmacytoid DC migration through ChemR23 [100].  The significance of this 
observation in vivo is unclear, as TAFI inhibits plasmin generation.  Surprisingly, 
chemerin can reduce the production of proinflammatory mediators and macrophage 
activation through ChemR23 but requires additional C-terminal processing by cysteine 
proteases [104].  This suggests an intriguing link with the secretion of cysteine proteases 
by Staphylococcus aureus that could inhibit effective host defense to clear infections 
[105].  In view of these observations, chemerin exhibits incredible plasticity to transform 
into ligands that exert opposite effects on inflammation through the same receptor, a 
process that deserves further study. 
2.2.4. Platelet Activation Strengthens Antigen Presentation 
 Platelet activation is increasingly implicated in a number of chronic adaptive 
immune diseases, including inflammatory bowel disease (IBD), atherosclerosis, 
infections, and transplant rejection.  In a mouse model of IBD, depletion of platelets by 
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thrombocytopenia commensurately reduced leukocyte adhesion in the inflamed colonic 
venules [106].  Antibody blockade of TF function significantly blunted colonic 
inflammation induced by dextran sodium sulfate (DSS) in mice.  Remarkably, the 
treatment nearly abolished both leukocyte and platelet recruitment to the venules of 
inflamed colons [107].  Genetic deletion of CD39 significantly exacerbated IBD in mice, 
and lower CD39 expression in humans was correlated with increased susceptibility to 
Crohn’s disease [108].  Activated platelets, which express P-selectin (CD62P), appear to 
directly interact with DCs.  Following initial contact between CD62P and PSGL-1 
expressed on DCs, junctional adhesion molecule C (JAM-C) and Mac-1 mediated firm 
DC adherence to platelets in vitro [109].  JAM-C deficient mice showed decreased 
persistence of specific circulating IgG titers and impaired germinal center formation 
[110].   Elevated soluble CD62P levels, a marker for platelet activation, is associated with 
an increased risk for atherosclerosis in ApoE-/- mice [111].   
 Despite their considerable importance as a neurotransmitter, serotonin (5-HT) is 
increasingly known for its role as an inflammatory mediator.  Platelets sequester 5-HT in 
their dense granules and release them upon activation.  Human monocytes treated with 5-
HT exhibited enhanced capacity to stimulate allogenic T cells in vitro and reduced 
susceptibility to Fas-FasL mediated apoptosis [112].  Exogenous 5-HT induced activation 
of ERK1/2 and NFκB as well as endogenous production of 5-HT in naïve T cells, 
contributing to their activation and proliferation [113].  Interestingly, in a murine model 
of noncytopathic lymphocytic choriomeningitis viral infection, platelet-derived 5-HT 
delayed activated virus-specific CD8+ T cell infiltration but prolonged their persistence 
in the liver primarily through altering the sinusoidal microcirculation [114].  Hence, 5-HT 
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appears to exert proinflammatory effects through physical and biochemical enhancement 
of T cell activation and survival.  
 Platelet-derived CD154 appears to be an important component in directing the 
process of antigen presentation so as to optimize the maturation of naïve adaptive 
immune precursors.  A number of recent observations in vivo implicate platelet derived 
CD154 in enhancing germinal center formation, protecting against infection, and 
inducing allograft rejection.  TLR-4 engagement on platelets induced release of soluble 
CD154, implicating platelet activation in immune response to infections [115].  DCs 
adherent to platelets were able to stimulate lymphocyte proliferation only in the presence 
of CD154 [109].  Platelet-derived membrane vesicles were capable of delivering CD154 
to sites distant from location of activation to stimulate antigen-specific IgG production 
and to enhance CD4+ T cell mediated germinal center formation [116].  Platelet CD154 
secretion correlated with B lymphocyte activation and IgG production [117], and 
augmented cytotoxic T cell response to Listeria challenge [118].  Activation of platelets 
was required for virus-specific cytotoxic T lymphocyte response, a process that depended 
on CD154 [119].  Soluble CD154 induced rejection 30 days following allogeneic cardiac 
transplantation in mice, while platelet infusion had no effect [120].  Thus, in vivo 
activation of platelets from surgical trauma at the time of transplantation could serve as 
the sole exogenous source of CD154 to instigate allograft rejection.  Both CD40-/- and 
CD154-/- mice were significantly protected from DSS induced colitis, concomitant with a 
reduction in inflammatory angiogenesis [121].  Hyperinsulinemia and hyperglycemia 
induced greater circulating levels of CD154+ platelets, as well as tissue factor 
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procoagulant activity, leading to a prothrombotic state that could be linked to the greater 
incidence of atherosclerosis in patients with type 2 diabetes [122, 123].   
2.2.5. Clinical Perspectives 
The link between adaptive immunity and hemostasis has long been suspected 
through observations by transplant surgeons associating acute allograft rejection with 
significant thrombosis.  Despite recent progress, therapeutic targeting of the hemostatic 
system and its related signaling pathways to treat disorders of adaptive immunity has not 
been well defined.  Clinical trials in the last decade have revealed benefits of 
anticoagulants, such as aPC (Xigris®) to treat severe sepsis.  Undesirable bleeding risks 
associated with these formulations may be overcome by engineering newer aPC variants 
with impaired anticoagulant activity but intact PAR signaling capacity [69].  
Alternatively, thrombomodulin exhibits thrombin-dependent, “on-demand” generation of 
aPC and TAFI, whose anti-inflammatory downstream pathways are only beginning to be 
uncovered.  Our laboratory showed exogenous TM infusion enhanced long-term 
engraftment in an allogeneic murine model of intraportal islet transplantation, 
substantially suppressing the hallmark endogenous “danger” signals IL-1β and TNF-α in 
the liver [124].  Risks of bleeding and dosage requirement can be further reduced through 
recombinant TM fusion proteins with targeting moieties for TF [125], as well as 
techniques to site-specifically tether TM to tissue surfaces [126].   
Two decades after their initial discovery, the PAR and downstream S1P signaling 
pathway has emerged as a new paradigm linking inflammation and a plethora of adaptive 
immune disorders.  Phase III clinical trials showed fingolimod (Gilenia®), a synthetic S1P 
analogue, significantly reduced relapse rates in MS patients compared with placebo and 
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IFN β-1a therapy [127, 128].  Fingolimod is an agonist of four of the five S1P receptors 
and influences lymphocyte trafficking, though its immune-modulatory mechanisms are 
currently not fully characterized.  In 2010, a US Food and Drug Administration advisory 
panel unanimously recognized the safety and effectiveness of fingolimod, and 
overwhelmingly recommended its approval as a first-line treatment for relapsing MS.  
Therapeutic intervention with a specific inhibitor of sphingosine kinase-1 has also been 
demonstrated to inhibit production of proinflammatory cytokines in a mouse model of 
sepsis [129].  These encouraging developments have demarcated the lipid metabolic and 
signaling pathways as a new frontier in the quest to create a unified model of 
inflammation onset and resolution. 
In conclusion, recent research substantiates an elegant system whereby activation 
of coagulation and platelets in response to trauma contributes to a state of inflammation 
that is central to the development of an effective host defense response as well as 
numerous adaptive immune disorders (Figure 2.2).  In this regard, the generation of 
thrombin by physiological activation of hemostasis on in injured tissue at the proximal 
anastomosis further exacerbates deleterious thrombotic reactions occurring downstream 
on the surface of synthetic vascular grafts, and may contribute to a prolong state of 
inflammatory response on the surface of synthetic vascular grafts, which do not 
completely re-endothelialize many years after implantation.  We anticipate that the 
evolution of bioinformatics, as well as in vitro and in vivo models of immune dysfunction 
will further expand our understanding of the molecular networks through which 
hemostatic reactions affect the onset of adaptive immunity, as well as our repertoire of 
available drug targets that provide new opportunities to modulate this process. 
 27 
 
Figure 2.2.  Interface between hemostasis and adaptive immunity.  Thrombin 
activation of PARs and pro-osteopontin (proOpn), in concert with platelet derived 
CD154, serotonin (5-HT), platelet factor 4 (PF4), and RANTES, have now been 
discovered to optimize the process of antigen presentation to initiate and possibly steer 
the phenotype of subsequent adaptive immune responses.  Platelets express CD154 which 
can be secreted by TLR4 induction or remotely delivered by platelet derived 
microvesicles (PDMV) to augment both dendritic and B cell activation.  In a similar 
capacity, 5-HT can activate T cells and induce further production 5-HT to amplify this 
process.  PF4 directly interacts with CXCR3 to increase T cell recruitment, or forms 
dimers with RANTES that recruits monocytes and T cells.  Activation of PAR1 on 
dendritic cells (DC) enhanced the production of proinflammatory and prothrombotic 
mediators, a potential feedback system to amplify antigen presentation.  A critical 
signaling pathway downstream of PAR engagement is activation of sphingosine kinase 
(SphK) to activate sphingosine-1 phosphate (S1P) that act on S1P receptors (S1PR).  
Extravasation of inflammatory cells through the endothelium is enhanced by thrombin 
(Th) activation of the S1PR3 pathway, while activated protein C (aPC) maintains the 
endothelial barrier through S1PR1.  Engagement of S1PR1 is responsible for steering T 
helper cells away from Th1 phenotype towards a Th2 type response.  aPC attenuates 
Th17 responses and downregulate T cell activation.  Osteopontin (Opn) has been 
implicated in prolonging of T cell survival and driving a Th17 response.  Chemerin 
depends on precise protease processing to either enhance or attenuate inflammation 
through the same receptor ChemR23.  Activated thrombin-activatable fibrinolysis 
inhibitor (TAFIa) deactivates Opn and inhibits chemerin cleavage by plasmin, which 
yields a proinflammatory ligand for ChemR23.  Substantial crosstalk between the 
hemostatic and adaptive immune compartments is therefore an indispensible component 
in the onset of effective host defense as well as immune dysfunction.  Abbreviations: TF, 
tissue factor; MCP-1, monocyte chemotactic protein-1. 
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2.3.  Passive Thromboresistant Surface Engineering Strategies 
Adsorption and unfolding of plasma proteins on blood-contacting surfaces is the 
fundamental process underlying platelet adhesion and activation of coagulation factors to 
elicit a thrombotic response.  Generally, electrostatic and hydrophobic interactions dictate 
the binding and subsequent folding of proteins, a thermodynamically favorable process 
whereby surface bound water molecules are displaced the by adsorbed species.  Although 
this process may never be completely eliminated, these effects may be reduced by a 
number of surface modification strategies such as PEG, pyrolytic carbon, album, 
phosphorylcholine, as well as ECM based proteins such as elastin. 
2.3.1.  Poly(ethylene glycol) 
In the early 1970s, it was observed that PEG passively adsorbed onto glass 
surfaces prevented the adsorption of viruses, platelets, and thrombin and subsequent 
studies have demonstrated that PEG has among the lowest levels of protein or cellular 
adsorption of any known polymer.  This property was attributed to the presence of a 
hydrophilic ether oxygen in its structural repeat unit, [CH2-CH2-O]n, which leads to a 
water-solvated structure that is capable of forming a “liquid-like” surface with highly 
mobile molecular chains that exhibit no systematic molecular order.  Unlike other 
hydrophilic polymers, such as poly(hydroxyethyl methacrylate) and polyacrylamide, the 
absence of surface charges and the presence of only small hydrophobic methylene groups 
in the structural repeat unit was thought to provide few other sites for protein or cellular 
binding [130].  Surface modification with PEG has been attempted by several methods, 
including bulk modification, covalent grafting, and physical adsorption.  In most cases, 
investigators have been able to demonstrate resistance to protein binding in vitro, 
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however, in vivo results have been inconsistent and clinical studies of a PEG modified 
stent or graft have yet to be performed.  A comprehensive review of the blood 
compatibility of PEG by Lee and colleagues is available elsewhere [131].   
2.3.2.  Albumin Coating 
Albumin as an inert, thromboresistant coating has been pursued since early 
studies of platelet interactions with various adsorbed proteins on artificial surfaces 
established that albumin induced significantly less platelet adhesion compared to other 
plasma proteins, including fibrinogen and gamma-globulin [132-135]. Some groups have 
covalently grafted albumin to surfaces [136-138] while others have modified surfaces 
with long aliphatic chains (C8-C18) or PEG-tethered warfarin to increase selective 
affinity for endogenous albumin [139-144]. Guidoin et al developed a glutaraldehyde-
crosslinked albumin coating later manufactured by Bard, Inc [145, 146].  The Bard 
albumin-coated Dacron prosthesis was evaluated by Kotte-Marchant et al. and displayed 
reduced platelet and leukocyte adhesion and aggregation, as well as fibrin production in 
vitro [147].  In a thoracoabdominal bypass model in dogs, however, only small 
differences were observed between coated and uncoated grafts[148].  In clinical studies, 
Al Khaffaf [149] and Kudo et al [150] have evaluated this prosthesis in the aortic position 
with performance characteristics that are similar to other non-coated vascular prostheses.  
2.3.3.  Carbon Coating 
Pyrolytic, or graphitic, carbon coating of implantable materials has been 
investigated for a variety of blood-contacting devices, including vascular grafts, heart 
valves, and stents [151-153].  In brief, pyrolytic carbon films are produced by chemical 
vapor deposition (CVD) in which a hydrocarbon, such as methane, is heated to its 
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decomposition temperature and the graphitic layer allowed crystallize as a highly ordered 
layer of carbon atoms.  Early animal studies of carbon-coated vascular prostheses 
demonstrated improved patency rates compared to uncoated controls [154, 155].  
However, surface irregularities on carbon-lined ePTFE grafts have contributed to poor 
performance in other investigations [156, 157].  More recently, 15 month implant studies 
in sheep documented reduced platelet adhesion and spreading on carbon-coated polyester 
grafts, but these observations did not affect overall histologic outcomes or patency rates 
[158].  Furthermore, in a prospective, randomized multicenter study conducted in 
Germany, 283 patients received either 6-mm carbon-coated (Carboflow™, Bard, Inc.) or 
uncoated ePTFE grafts (Bard, Inc.) for femoral-anterior tibial artery bypass.  At three-
year follow-up, no significant differences were observed between the two groups with 
respect to patency or limb salvage [159]. 
2.3.4. Phosphorylcholine Coating  
Planar-supported bilayers of phosphatidylcholine (PC), the predominant 
glycerophospholipid found in animal cell membranes, have been shown to reduce protein 
and cell adhesion in vitro [160-164].  It has been proposed that this phenomenon is due to 
the zwitterionic nature of the phosphorylcholine head group that while carrying both 
positive and negative charges is electrically neutral at physiologic pH.  Applications of 
supported lipid films as coatings for implantable devices has been limited by the inherent 
instability of a coating that is formed by individual molecules, which “self-assemble” as a 
monolayer or bilayer film through relatively weak hydrophobic van der Waal interactions 
[165].  Consequently, methods have been to create stable “membrane-mimetic” films 
through protein anchors [166, 167], heat stabilization [168], and in situ polymerization of 
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synthetically modified polymerizable phospholipids [169-174].  In all studies, the protein 
and cell resistant properties of the exposed PC layer were retained.  Since 1984, a variety 
of polymethacrylate and polyurethane based polymers have been synthesized that 
incorporate the phosphorylcholine head group within the polymer backbone [175, 176].  
For example, Yoneyama and colleagues demonstrated excellent in vivo blood 
compatibility of a segmented poly(etherurethane)/2-methacryloyloxyethyl 
phosphorylcholine (MPC) polymer blend processed as a coating for Dacron prostheses 
[177-179].  Chen et al. evaluated a 4 mm diameter ePTFE grafts coated with a copolymer 
of MPC and laurylmethacrylate (LM) in a canine femoral arteriovenous shunt.  
Significantly reduced platelet deposition was demonstrated, as well as limited neointimal 
hyperplasia at anastomotic sites [180, 181].  Similarly, UV polymerizable acrylate-
modified phospholipids assembled on the lumen of an ePTFE graft (d = 4 mm) reduced 
platelet adhesion in an ex vivo baboon femoral arteriovenous shunt model [182].  Direct 
chemical grafting of phospholipids on Dacron and ePTFE have been reported to reduce 
fibrinogen and platelet adhesion in vitro [183] and polyurethane based grafts (d = 2mm) 
modified with PC prevented thrombus formation after 8 weeks in a rabbit model [179].  
2.3.5. Elastin-inspired Surfaces 
Elastin is a constituent structural protein in the vascular wall and elicits minimal 
platelet adhesion and aggregation [184, 185].  Dacron grafts coated with elastin inhibited 
SMC migration, suggesting elastin may also inhibit neointimal hyperplasia [186].  
However, the intrinsic insolubility of elastin makes purification and processing from 
tissue difficult.  This has largely been overcome by the identification of consensus 
sequences involved in the molecular assembly of elastin, which are used to construct a 
 32 
variety of elastin-mimetic protein polymers [187-192].  
Covalent immobilization of poly(VPGVG) on silicone reduced fibrinogen and 
immunoglobulin adsorption, and inhibited the secretion of proinflammatory cytokines 
from monocytes in vitro [193].  In a later study, the passive adsorption of recombinant 
elastin peptides onto polyurethane catheters decreased fibrin deposition and increased 
patency in a rabbit model [194].  Recently, ePTFE grafts (d = 4 mm) were coated with a 
thin film of a recombinant amphiphilic elastin-mimetic protein polymer that inhibited 
platelet deposition in an acute primate ex vivo shunt model [195].   
2.4. Inhibition of Thrombin and Fibrin Formation 
The endothelial cell presents and releases a number of biologically active 
constituents that limit thrombotic responses which can lead to catastrophic graft failure .  
As such, seeding or otherwise reconstituting endothelial cells on a prosthetic surface has 
been actively pursued as a strategy for generating thromboresistant vascular substitutes.  
However, this approach poses its own challenges related to cell sourcing, stability, 
viability, and function [196-198].  Alternatively, promising results have been achieved 
through biologically-inspired or ‘biomimetic’ design, in which antithrombogeneic 
features of the endothelial cell surface are selectively mimicked by introducing bioactive 
molecules, such as heparin, thrombomodulin, or urokinase [199-204] onto the surface of 
synthetic materials. 
2.4.1. Heparin 
The first report of a heparinized surface was published in 1963 by Gott and 
colleagues who demonstrated significantly prolonged in vitro and in vivo clotting times 
on graphite-coated surfaces ionically bonded with heparin [152].  Since then, heparin-
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coating technologies have been developed for a number of blood-contacting devices and 
used most extensively in cardiopulmonary bypass circuits [205, 206].  The literature on 
heparin immobilization is extensive and has been reviewed elsewhere [207-209].  Briefly, 
techniques to immobilize heparin include, but are not limited to, electrostatic self-
assembly via heparin’s negatively-charged sulfate groups [210, 211], covalent grafting 
often via a spacer arm [212-216], integration into a hydrogel network [217], and loading 
into a bulk polymer for controlled release [218].  One technique, which has been 
successfully translated to the clinic, is end-point immobilization, in which the reducing 
end of the linear heparin chain is depolymerized to yield a single reactive aldehyde group 
that can then be conjugated to a primary amine on the graft or stent surface [219-221].   
Several heparin bonded vascular grafts have been recently assessed in clinical 
trials. A prospective randomized multicenter study compared the Intergard™ heparin-
bonded Dacron (HBD) grafts to standard ePTFE for femoropopliteal bypass.  The 
patency of HBD grafts was superior to ePTFE at three years, but a significant difference 
was not observed at five years [222].  Recently, a randomized multi-center prospective 
study found that HBD grafts displayed a five years patency rate in the femoropopliteal 
position that was similar to previously reported performance for standard ePTFE and 
Dacron [223].  A heparin modified ePTFE graft, marketed as Propaten™ (W.L. Gore, 
Inc.), received FDA approval in 2006.  Several nonrandomized clinical trials using 
Propaten™ have reported 1 and 2 year patency rates for femoral-popliteal bypass that are 




Several investigators have immobilized thrombomodulin (TM) onto polymeric 
surfaces in order to generate surfaces that actively limit the local generation of thrombin 
through the production of activated protein C (APC) rather than inactivate thrombin after 
it has already been produced.  Specifically, APC inactivates factors Va and VIIIa, thereby 
limiting Xa and thrombin production.  Kishida and colleagues conjugated recombinant 
human TM to both aminated and carboxylated surfaces, including poly(vinyl amine) and 
poly(acrylic acid) surface-grafted polyethylene and a surface-hydrolyzed poly(ether 
urethaneurea) [227-229].  Similarly, Vasilets et al. reported binding TM onto poly(acrylic 
acid) surface-grafted PTFE [230].  As an alternate approach, Cutler and colleagues 
physically adsorbed and crosslinked soluble human TM onto small caliber ePTFE grafts 
and reported promising short term results in vivo [231].  Other investigators, such as 
Sperling et al [232, 233] and Han et al [234] have tethered TM to surfaces via a PEG 
spacer.  A disadvantage of all of the above strategies is the inherent reduction in 
bioactivity that is associated with immobilization schemes that involve reactions to any 
freely available amino or carboxyl functionality on the protein surface, including those 
near or within the catalytic site of the protein.   
Recently, genetically directed synthesis has been used to create a recombinant TM 
construct comprised of the catalytically active site along with a C-terminal synthetic, 
non-natural amino acid, azido(N3)-methionine.  The azido-functionalized TM construct 
can be coupled to surfaces directly through the C-terminus using highly selective reaction 
schemes with full retention of bioactivity [235, 236].  As an additional strategy, TM-
containing membrane-mimetic surface assemblies have been produced that display 
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prolonged stability and activity in high shear environments [237, 238].  The ability of 
surface bound TM to dramatically reduce tissue factor-induced thrombin production has 
been characterized under both simulated venous and arterial flow conditions [237].   
2.4.3.  Direct Thrombin Inhibitors and Fibrinolytic Agents 
Direct thrombin inhibitors, such as recombinant hirudin (rHir) and argatroban, 
have been used as an additional strategy to produce thromboresistant surfaces.  Seifert et 
al [239] crosslinked hirudin to poly(D,L-lactide-co-glycolide) with glutaraldehyde, and 
LoGerfo and coworkers have grafted rHir to polyurethane and Dacron via a crosslinker 
modified albumin basecoat [240-244].  Several groups have also reported the 
immobilization of urokinase on surfaces to confer local fibrinolytic activity [199-202].  
2.5.  Inhibition of Platelet Adsorption 
The capacity of aspirin to reduce thrombosis of ePTFE vascular prostheses has 
been noted in a number of randomized trials [245].  However, prolonged systemic 
administration of all antiplatelet drugs significantly increases the risk of bleeding and 
gastrointestinal complications.  This has motivated the development of materials that 
locally inhibit platelet activity by surface immobilization of antiplatelet molecules, such 
as prostacylin, or local delivery of antiplatelet agents, including nitric oxide (NO).   
2.5.1. Antiplatelet Drugs 
Direct surface immobilization of antiplatelet agents has been extensively studied.  
Prostacyclin (PGI2) and prostaglandin (PGE1) have been immobilized on albumin 
covered surfaces [246, 247].  Likewise, Dacron and ePTFE grafts have been coated with 
collagen or laminin for covalent conjugation of PGI2 and PGE1 [183].  Dipyridamole has 
also been conjugated to polyurethane vascular grafts with improved patency rates 
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reported in a sheep model [248-250].  Aspirin eluting coatings for sustained release has 
been explored by several groups [251-254]  and applied to Dacron grafts with reduced 
platelet deposition in a canine ex vivo shunt model [255].  Similarly, ePTFE grafts have 
been impregnated with alginate containing the prostacyclin analog, Iloprost™, with 
reduced thrombus formation in vitro [256].   
2.5.2.  Nitric Oxide 
Nitric oxide (NO) inhibits platelet aggregation and prevents smooth muscle cell 
proliferation [257, 258].  Two types of NO donors, diazeniumdiolates ([N(O)NO]-) and 
S-nitrosothiols, have been extensively studied in graft modifications to release and 
generate NO.  Diazeniumdiolate ions are stable solids that readily release NO in 
physiological conditions [259]. The earliest studies involved loading the pores of ePTFE 
grafts with polyethylenimine microspheres that incorporated diazeniumdiolate ions [260, 
261].  The capacity for NO to reduce platelet deposition on grafts was confirmed in a 
baboon ex vivo shunt model.  Diazeniumdiolate has also been conjugated to polyurethane 
grafts that released NO over two months [262, 263].  A major limitation of 
diazeniumdiolate polymers is the leaching of diamine precursors that form carcinogenic 
nitrosamines [264].  This has led to the design of leach-resistant lipophilic 
diazeniumdiolate formulations [265-267].   
S-nitrosothiols are a stable form of NO that is present in circulating blood and 
may act as an NO donor [268, 269].  S-nitrosothiols have been covalently bound on 
synthetic surfaces with satisfactory in vitro bioactivity [270].  However, S-nitrosothiols 
may act as an endogenous reservoir of NO that can be activated by copper (II)-based 
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catalysts [271, 272], cysteine modified polymers [273, 274],  and organoditelluride [275]  
incorporated into polymers.   
2.6. Biohybrid Vascular Grafts 
A guiding principle of graft design since the 1950s has been the notion that the 
presence of an intact, quiescent endothelial lining on the prosthetic graft surface would 
reduce the risk of thrombosis and neointimal hyperplasia.  However, it is now well 
understood that prosthetic grafts do not facilitate reendothelialization many years after 
implantation.  Efforts to overcome this challenge have included both in vitro seeding with 
autologous endothelial cells and surface engineering schemes to induce in vivo 
endothelialization of the graft surface. 
2.6.1  Endothelial Cell Seeding   
In 1978, Herring and coworkers introduced a single-stage technique whereby 
venous endothelial cells were seeded onto grafts with enhanced patency in a canine 
model [276].  While a promising concept, translating these results to the clinic has been 
challenging.  Zilla et al. noted in an early clinical report the absence of a confluent 
endothelial cell lining 14 weeks after bypass grafting [277].  A subsequent clinical study 
revealed that at 30 months the patency of single-stage endothelial cell seeded ePTFE 
grafts in the femoropopliteal position was significantly worse when compared to vein 
bypass (38% vs. 92%) [278].  Similarly, endothelial cell seeded Dacron aortobifurcated 
grafts did not demonstrate improved late outcome [279].  These disappointing outcomes 




Cell density was increased using a two-stage technique [280, 281] and a three to 
four week culture period.  The two-stage technique has yielded encouraging clinical 
results with a randomized study reporting that seeded grafts had greater patency than 
non-seeded grafts at 32 month (85% vs 55%) [282].  In a follow-up report, nine year 
patency was 65% for cell seeded as compared to 16% for non-seeded grafts [283].  In a 
subsequent report, similar primary patency rates were observed for 153 seeded ePTFE 
grafts [284].  A total of 14 patients have received cell seeded 4 mm ePTFE grafts for 
coronary bypass with 91% patency rates noted at 28 months [285].      
Adhesive proteins, such as fibronectin, collagen, and fibrin [286-295], as well as 
adhesive peptide sequences [296-298] have been investigated as coatings to increase cell 
anchorage, but the most appropriate coating for clinical studies is unclear [299].  Other 
techniques, such as electrostatic seeding [300, 301] and shear conditioning [302, 303] 
may also increase cell adhesion.  Phenotypic modulation of cells through genetic 
engineering has been pursued to increase expression of antithrombotic proteins such as 
tissue plasminogen activator [304] and nitric oxide synthase [305].  Endothelial 
progenitor cells (EPC) from either the bone marrow [306, 307] or peripheral blood [308], 
as well as the microvasculature in the omentum or subcutaneous fat have been 
highlighted as potential sources for endothelial cells [309-312]. 
2.6.2. Promoting In Vivo Reendothelialization  
A more recent approach to improve the blood compatibility of implanted 
materials is functionalizing the blood contacting surface with active domains that 
promote natural regenerative processes involved in the healing of damaged endothelium.  
To illustrate, ePTFE grafts have been impregnated with fibrin glue containing fibroblast 
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growth factor-1 (FGF-1) and heparin, which in a dog model promoted transmural 
endothelialization, as well as the proliferation of smooth muscle cells [313-315].  
Polyurethane based grafts coated with heparin and fibroblast growth factor-2 (FGF-2) 
have accelerated transmural endothelialization [316].  ePTFE grafts coated with an anti-
CD34 antibody to capture circulating EPCs increased the rate of endothelialization in 
pigs [317].   
2.7. Summary  
Despite advances in surgical technique and antithrombotic pharmaceutical 
therapy, there remains a need for synthetic small diameter (< 6mm) conduits that perform 
comparably to autologous grafts in the fields of cardiac, vascular, and plastic surgery.  
Efforts to improve the blood compatibility have involved surface engineering techniques 
that incorporate passive mechanisms that inhibit adhesion of proteins and cells, as well as 
active domains that attenuate the platelet and coagulation activation cascades.  While 
endothelial seeding of grafts has achieved encouraging outcomes in the clinic, the 
associated technical complexity remains a significant limitation to the widespread use of 
this approach.  Currently, both heparin and carbon coated grafts have been 
commercialized for clinical use, but more long term evidence is needed to conclusively 
demonstrate their improvement in patency when compared to standard grafts.  
Multifunctional surface modification schemes involving bioactive enzymes, such as 
thrombomodulin and S-nitrosothiols are promising areas of current research.  Despite 
efforts to coat graft surfaces with therapeutics, two key limitations remain: the finite 
reservoir and physiological degradation of immobilized therapeutics that limit the 
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duration of bioactivity, as well as sterilization requirements that may reduce the activity 
of immobilized biomolecules.  
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CHAPTER 3 
LAYER-BY-LAYER ASSEMBLY OF POLYELETROLYTE MULTILAYERS AS 
SUBSTRATE FOR COVALENT IMMOBILIZATION OF BIOMOLECULES 
 
This Chapter details our initial efforts to develop conformal coatings through 
layer-by-layer assembly of polyelectrolyte multilayer films on solid supports, as a means 
to generate chemically reactive anchor sites for immobilizing bioactive molecules.  This 
system provides a facile method to modify medical device materials with a conformal 
coating, whose properties may be engineered by selection or modification of appropriate 
polyelectrolyte components. 
3.1. Introduction 
Layer-by-layer (LbL) deposition of alternating polyelectrolytes has emerged as a 
highly versatile and universal strategy to generate uniform films of controlled thickness 
and structural properties on substrates manifesting a net surface charge.  This simple 
process entails the immersion of the substrate in a charged polymer species followed by 
rinsing to remove non-electrostatically bound polymers and incubation in the oppositely 
charged species.   The universality of this approach is underscored by its applicability to 
any charged molecular species ranging from DNA to proteins, thus facilitating the 
construction of films with diverse architecture and functionality [318].  In particular, 
PEM films have been investigated as protein adsorption resistance on medical device 
surfaces.  PEM films consisting of hyaluronic acid and chitosan were assembled on the 
surface of endovascular stents [319] as well as damaged blood vessels [320] to prevent 
platelet adhesion, which was further enhanced by the additional incorporation of charged 
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nitric oxide donors into the film.  Poly(ethylenimine) and heparin PEMs were similarly 
assembled on stainless steel and prevented platelet adhesion [321, 322].  In an alternative 
approach, the deposition of fibrinogen and platelets were significantly reduced on 
polyurethane surfaces coated with PEM films comprising chitosan and dextran sulfate.  
Importantly, the authors showed that this inhibition property depends on the presence of 
the anionic polyelectrolyte as the outermost layer [323].  Similarly, chitosan/alginate 
microcapsules resist the deposition of fibrinogen but requires that a net negative charge 
be present on the surface [324].  Since our laboratory has observed that PLL is 
significantly cytotoxic [325], a rational approach is generating a PEM film containing the 
anionic polyelectrolyte as the outermost layer.  However, it has been demonstrated that 
positively charged plasma proteins will preferentially deposit on this surface [326], but 
the enhanced adsorption was attenuated by incorporation of PEG as a diblock copolymer 
as the cationic species [327].  Additionally, the choice of anionic polyelectrolyte may 
also play a role, as hyaluronic acid was more effective than PEG and heparin modified 
polyurethane in limiting protein adsorption and platelet adhesion [328].  A rigorous assay 
to determine the extent of protein adsorption on PEM films upon exposure to plasma will 
be required to screen optimal film architectures that minimize these interactions. 
The stability of PEM films can be further improved by crosslinking the 
polyelectrolyte layers with multifunctional linkers.  Oxidation of alginate using sodium 
periodate generates reactive aldehydes that can be used to form stable covalent linkages 
with hydrazides [329, 330].  Hydrogels generated by crosslinking periodate oxidized 
alginate using bis-hydrazide linkers dramatically improved their stability [331]. The 
degree of crosslinking can be further tailored by incorporating linkers with multiple 
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hydrazide motifs to yield much higher stability than bifunctional linkers [332]. In a 
similar capacity, cationic constituents in PEM films have been crosslinked with 
glutaraldehyde [333].  Others have studied the direct covalent layer-by-layer assembly of 
azide and alkyne functionalized polyelectrolytes, which yielded selectively permeable 
membranes and facilitated further post-functionalization with azide modified probes 
[334].  Recently, we have demonstrated the ability to modify both living and nonliving 
substrates with a PEM film that enables covalent immobilization of biomolecules.  
Specifically, we grafted terminally functionalized PEG chains onto PLL to yield a surface 
reactive cationic constituent that formed PEMs with alginate on the surface pancreatic 
islets as well as glass surfaces [335].  The versatility of this approach was illustrated by 
the capacity to generate azide, hydrazide, and biotin anchor sites with the PEM 
architecture that facilitated conjugation of cyclooctyne, aldehyde, and streptavidin 
labeled probes.  Further, it was demonstrated that a PLL-g-PEG-azide can be covalently 
immobilized on amine-reactive surfaces to facilitate covalent conjugation of cyclooctyne 
functionalized IKVAV peptide at highly controlled densities.  Moreover, immobilization 
by copper-free [3 + 2] cycloaddition was highly efficient, evident by observations 
indicating peptide binding to the surface within 15 minutes [336].  Thus, both cationic 
and anionic constituents of PEM films can be derivatized to generate functional motifs on 
the film surface to facilitate immobilization of biomolecules.  Moreover, covalent 
crosslinking using bifunctional linkers would not only improve the stability of films, but 
the incorporation of PEG may further enhance the film’s capacity to resist protein 
adsorption.  Given the broad substrate compatibility of PEM film formation, our 
proposed studies will serve as a starting point to demonstrate the feasibility of depositing 
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conformal PEM films on blood-contacting surfaces that also facilitate functionalization of 
active enzymes to limit the onset and elaboration of thrombotic reactions.  In this regard, 
optimal PEM film architectures may electrostatically incorporate heparin and other 
charged therapeutic drugs such as NO donors, antimicrobial polypeptides [337, 338], and 
DNA [339], or facilitate covalent immobilization of bioenzymes. 
In this report, we showed the exponential growth characteristics of PEM films 
comprising PLL and periodate oxidized alginate, covalent crosslinking of these PEM 
films by hydrazone bond formation using a dihydrazide crosslinker which improved film 
stability, and the formation of PEM films that incorporate heparin on commercial ePTFE 
vascular graft materials.  These outcomes provide a starting point for generating a stable 
PEM film that display a high surface density of chemical anchor motifs for immobilizing 
biologically active molecules which resist thrombosis on the blood-contacting surface of 
implantable medical devices. 
3.2. Results and Discussion 
3.2.1. Assembly of PEM Films on Quartz   
 Oxidized sodium alginate was generated by reaction with sodium metaperiodate, 
which selectively opens sacchaide rings between vicinal diols and leaves two aldehydes 
groups.  In these reactions, molar equivalents of periodate was added to oxidize 1 %, 5 %, 
20 %, and 40 % of the total molar quantity of alginate sugar monomers.  In preliminary 
studies, PEM films were generated by LbL deposition of PLL labeled with FITC (PLL-
FITC) and 40 % oxidized alginate (Alg-CHO (40)) on transparent quartz substrates and 
monitored by UV-vis spectroscopy, as illustrated in Figure 3.1A.   The PEM film 
exhibited exponential growth behavior, and was visibly yellow under ambient light.  
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Notably, after the 10th bilayer of PLL-FITC/Alg-CHO (40), PEM films appeared opaque, 
as evident by substantial increase in absorbance in the visible region (600 nm) in Figure 
3.1B.  At the surface densities achieved after the 10th bilayer, PLL and alginate may be 
undergoing a coacervation process that contributes to the exponential accumulation of 
polyelectrolytes. 
 Next, PEM films containing 10 bilayers of PLL-FITC and 40% alginate were 
covalently crosslinked by reaction with excess adipic dihydrazide (ADH), which forms 
stable hydrazone bonds with the aldehydes generated by alginate oxidation.  This 
crosslinking reaction exhibits a characteristic increase in the UV absorption intensity near 
240 nm (Figure 3.2).  As expected, no change in the PLL content was observed during 
the crosslinking reaction.  Overnight incubation in high ionic strength buffer (5 M NaCl) 
did not substantially remove the crosslinked PEM film deposited on quartz slides, as 
opposed to the immediate and complete desorption observed for noncrosslinked films 
comprising PLL-FITC and non-oxidized alginate. 
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Figure 3.1. Evaluation of layer-by-layer assembly of fluorescein labeled poly(lysine) and 
periodate oxidized alginate (40% oxidation) on quartz surfaces.  (A) Maximal absorbance 
of fluorescein at 495 nm was used to determine growth profile of films.  Absorbance 
expressed as average of 2 independent substrates.  (B) Typical UV spectra of films as 






Figure 3.2. Evaluation of crosslinked polyelectrolyte multilayer (PEM) films assembled 
on quartz substrates. A distinct adipic dihydrazide (ADH) peak at 240 nm was observed 
following crosslinking of PEM films comprising fluorescently labeled poly(L-lysine) 






Interestingly, the film growth characteristics and film stability as measured by 
exposure to high ionic stress environments (5M NaCl) following ADH crosslinking 
appears to depend on the extent of alginate oxidation.  As shown in Figure 3.3, film 
growth increased in proportion to the extent of alginate oxidation up to 20%, but the trend 
was reversed for 40% oxidized alginate (Alg-CHO (40)) as evident by the reduced film 
thickness.  These observations may be attributable to the oxidative cleavage of the 
polysaccharide rings of alginate, which resulted in greater polymer chain flexibility to 
improve the growth of PEM films.  However, these results also suggest a critical 
threshold may exist at 40% oxidation, where the increased polymer flexibility may result 
in electrostatic repulsion that decreases the quantity of adsorbed alginate per layer.  In 
contrast, film stability appears to be maximal following ADH crosslinking for the 40% 
oxidized alginate.  Stability decreased in a manner commensurate with the reduction in 
extent of alginate oxidation, with 5% oxidized alginate films being the least stable as 
summarized in Table 3.1.  These results strongly suggest that while film growth may be 
impaired by loss in structural integrity of the polysaccharide chain, the increase in 
aldehydes motifs in the high oxidation variants afforded greater film stability due to 
increased covalent crosslinking with ADH.     
  
 49 
Table 3.1. Stability of adipic dihydrazide crosslinked PEM films containing PLL-FITC 
and oxidized alginate with varying degrees of oxidation 
  
 % of 10 bilayer FITC signal (Abs495 nm) 
following overnight 5M NaCl exposure 
PLL-FITC + Alg-CHO (5) 37.8 
PLL-FITC + Alg-CHO (10) 57.5 
PLL-FITC + Alg-CHO (20) 65.5 




Figure 3.3. Layer-by-layer deposition of PLL-FITC and 5%, 10%, 20%, and 40% 
oxidized alginate was monitored by UV-vis absorption.  Films were crosslinked by 
250mM ADH for 3 hours and subsequently exposed to 5 M NaCl overnight.  (A) Signal 






We also observed that PEM films containing oxidized alginate were more 
resistant to degradation under high ionic conditions, even in the absence of ADH 
crosslinking.  Measurement of film integrity by UV spectroscopy over time suggests that 
with a 30 minute exposure time in 5 M NaCl, PEM films fabricated from PLL and 40% 
oxidized alginate (Alg-CHO (40)) was more resistant to degradation than PLL and non-
oxidized alginate, as shown in Figure 3.4.   
These observations indicate that the aldehydes generated from alginate oxidation, 
which undergoes Schiff Base formation with primary amines on PLL, may have 
improved the stability of the PEM films.  However, due to the inherent instability of 
Schiff Base forming reactions due to hydrolysis, crosslinking by ADH was required to 
sustain the stability of PLL/Alg-CHO films beyond 2 hours.  In addition, we observed 
that oxidized alginate yielded greater film growth as evident by higher PLL-FITC 
incorporation than non-oxidized alginate in Figure 3.4, which is likely a result of the 
greater polymer chain flexibility of oxidized alginate that enables greater deposition of 
polymers on the solid substrates. 
 The exponential growth of PEM on quartz slides may afford a surface 
modification strategy to yield high density of reactive anchor sites for biomolecule 
immobilization.  Moreover, studies performed on quartz substrates indicate covalent 
crosslinking may be a feasible strategy to influence film stability as well as growth 





Figure 3.4. Evaluation of crosslinked polyelectrolyte multilayer films assembled on 
quartz substrates. ADH crosslinked films were substantially more robust to degradation 














3.2.2. Assembly of PEM Films on ePTFE Grafts 
As a step towards translating these findings as a viable surface engineering 
strategy to modify the blood contacting interface of implantable medical devices, we 
assessed the PEM assembly on the lumen of commercial expanded 
poly(tetrafluoroethylene) (ePTFE) vascular grafts.  Fluorescently labeled 
poly(ethylenimine) (PEI) served as the precursor layer and polycation in our efforts to 
generate PEM films, which incorporated heparin as the polyanionic component as 
illustrated in Figure 3.5.  Detection of surface modification was carried out by UV 











Using an automated dip-coating system, which incubates samples in a solution of 
polyeletrolytes followed by incubation in multiple wash reservoirs, 8 or 16 bilayers of 
alternating FITC labeled PEI and heparin were assembled on the luminal surface of 
ePTFE grafts.  In agreement with results from PEM film formation on quartz slides, the 
quantity of polymer deposited as PEM was substantially higher for 16-bilayer films than 
8-bilayer (Figure 3.6).  As expected, PEM films did not form in the absence of the one of 
the polyelectrolyte components, in this case the polyanionic heparin.  Cumulative layer-
by-layer deposition yielded a visually yellow and highly wettable film on the surface of 
the ePTFE graft, as illustrated in Figure 3.7.  Moreover, the PEM films assembled using 
this approach were susceptible to degradation in 5M NaCl, further supporting the PEM 
nature of these films (Figure 3.7).  These results suggest that a uniform PEM film 
containing heparin could be assembled on ePTFE surfaces.     
Mechanical stability of PEM films was evaluated by subjecting coated ePTFE 
graft segments to 1000 s-1 shear at 37 ºC for 24 h.  These conditions were generated by 
connecting the graft segment in line with a perfusion loop housed in an incubation 
chamber.  DPBS was circulated through the graft segment to mimic the physiological pH.  
Fluorescent imaging of the luminal surface of graft samples (Figure 3.8) provided 
qualitative evidence that the PEM film was mechanically stable under the shear stresses 
generated by this system.  Further enhancement of film stability could be achieved by 
generating PEM films comprising PEI and oxidized heparin, however, it is unclear 




Figure 3.6. (A) En face and (B) fluorescent imaging of polyelectrolyte film coating on 
the luminal surface of 4 mm i.d. ePTFE grafts.  (i) Control film fabricated by deposition 
of 8 layers of fluorescein labeled poly(ethylenimine) (FITC-PEI); (ii) alternating 
deposition of 8 bi-layers of FITC-PEI and heparin; (iii) alternating deposition of 16 bi-
layers of FITC-PEI and heparin; and (iv) control films fabricated by deposition of 16 
layers of FITC-PEI. 
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Figure 3.7. (A) En face and (B) fluorescent imaging of polyelectrolyte film coating on 
the luminal surface of 4 mm i.d. ePTFE grafts fabricated by alternating deposition of 16 
bi-layers of fluorescein labeled poly(ethyleneimine) (PEI) and heparin (i) and after 









Figure 3.8. Fluorescent imaging of 16-bilayer PEI/heaprin films on the luminal surface 
of 4 mm i.d. ePTFE vascular grafts before (i) and after (ii) mechanical shear stress at 




The exponential growth PEM film assembly on solid supports may be a strategy 
to maximize the density of surface anchor sites for covalent immobilization of 
biomolecules.  We show that PEM films comprising alternating PLL and periodate 
oxidized alginate can be stabilized by covalent crosslinking through hydrazone bond 
formation using a dihydrazide linker.  Formation of PEM films that incorporate heparin 
may be translated to modify commercial ePTFE vascular graft materials, and preliminary 
results show that these films could withstand the mechanical shear stresses encountered 
in the arterial vasculature.  These outcomes support the future investigation of PEM films 
as a general strategy to provide a base coating for immobilizing biologically active 
molecules. 
3.4. Methods 
3.4.1. Synthesis and Characterization of Oxidized Alginate  
Sodium metaperiodate (Pierce) oxidation of sodium alginate was carried out using 
reaction conditions previously reported [165, 186].  Briefly, sodium alginate 
(NovaMatrix, 75 – 220 kD) was dissolved at 1% w/v in deionized water, and sodium 
metaperiodate was added to yield final molar equivalents of 1 %, 5 %, 20 %, and 40 % 
with respect to the total moles of sugar residues, and stirred in the dark at room 
temperature for 24 hours.  An equimolar amount of ethylene glycol (Sigma) was added to 
quench excess periodate for 1 hour, and the solution was placed in Slide-A-Lyzer dialysis 
cassettes (Pierce) with a molecular weight cutoff of 3.5 kD, and dialyzed against double 
deionized water for 3 days.  Dialysis buffer was exchanged twice a day.  Subsequently, 
oxidized alginate variants were snap frozen in liquid nitrogen and lyophilized to yield a 
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white product.  The degree of alginate oxidation generate reactive aldehydes was 
determined by quantifying the number of aldehydes using t-butyl carbazate (Sigma) as 
reported elsewhere [165].  Briefly, excess carbazate was added to oxidized aldehyde 
allowed to react overnight.  Unreacted carbazate was determined using a TNBS solution 
(Sigma) and measuring the absorbance of the trinitrophenyl derivatives that forms at 
334nm.  Aqueous formalin solutions were used to generate standard curves correlating 
aldehyde concentration with TNBS signal. 
3.4.2. Synthesis and Characterization of FITC Labeled PLL and PEI   
 To facilitate characterization of the layer-by-layer assembly of polyelectrolytes, 
PLL and PEI (Sigma) were labeled with FITC (Pierce Biotechnology) according to 
manufacturer’s instructions.  A stock solution of FITC in DMSO was added at a 
stoichiometric ratio corresponding to 1% (0.01 molar equivalents) of the primary amine 
repeats in PLL or PEI (1 : 2 : 1 ratio of primary : secondary : tertiary amines) dissolved in 
PBS buffer (pH 7.4), and reacted in the dark for 24 h at RT.  The unreacted FITC was 
removed by dialysis using Slide-A-Lyzer Dialysis Cassettes with a 3.5 kD MWCO 
(Pierce Biotechnology), and the final FITC-PLL or FITC-PEI was lyophilized to yield 92 
% and 97 % product, respectively. 
 The extent of labeling of PLL or PEI with FITC was determined using a standard 
curve of correlating the absorbance intensity at 494nm of FITC versus known solution 
concentrations of FITC.  The final extent of labeling of PLL labeling was 0.65 % and the 
final extent of labeling of PEI primary amine labeling was 0.52 %.  A typical regression 




� = 0.0086 × 𝐴𝐴494𝑛𝑛𝑚𝑚 + 0.000096 
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3.4.3. Assembly of PEM Films on Quartz and ePTFE 
Fluorescein labeled PLL (PLL-FITC, Sigma, 12kD) and 40% oxidized alginate 
(Alg-CHO) was used in initial studies to evaluate PEM film growth on quartz.  Quartz 
slides (Chemglass, 1mm thick) were cut into 2.5cm x 1cm substrates and cleaned using 
Piranha solution to oxidize the surface.  Briefly, slides were incubated in an ammonium 
hydroxide/hydrogen peroxide/water (1:1:5 volume ratio) mixture at 80C for 10 minutes, 
followed by incubation in a sulfuric acid and hydrogen peroxide (7:3 volume ratio) 
mixture at 80C for 10 minutes.  Slides were thoroughly rinsed with deionized water 
following each step, and as a final step rinsed in 200 proof ethanol before drying under a 
stream of argon.  Prior to PEM assembly, slides were treated with a precursor bilayer of 
poly(diallyldimethylammonium chloride) (PDDA, Sigma, 200 – 350kD) for 30 minutes, 
rinsed in deionized water, and incubated in 0.15% sodium alginate in phosphate buffered 
saline for 20 minutes to generate a negatively charged surface.  For ePTFE graft 
modification, 4 mm i.d. ePTFE grafts (Bard) were cut into ~2 – 3cm segments and 
directly mounted on the automated coating system without any pre-treatment. 
Substrates were coated with PEM assemblies using a custom-built automated 
slide coater assembled using two BiSlide assemblies and stepper motors (Velmex Inc, 
Bloomfield NY).  The coater comprises two linear, screw driven actuators combined to 
allow horizontal and vertical translation of substrates, which are mounted vertically on a 
lever using customized clips.   Substrates were immersed in and removed from polymer 
and wash solutions at a rate of 1.3 cm/s using the vertical actuator, and translated 
horizontally between solution reservoirs at a rate of 5.1 cm/s.  Programming of substrate 
coating procedures was carried out using COSMOS software per manufacturer’s 
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instructions (Velmex Inc).   PLL-FITC or PEI-FITC at 1mg/ml and 40% oxidized Alg-
CHO (2.5mg/ml), non-oxidized alginate (2.5 mg/ml), or heparin (2.5mg/ml), were 
deposited on quartz substrates by alternating incubations for 5 minutes.  Between each 
layer, substrates were rinsed by four 1 minute incubations in fresh PBS.   
Film growth on quartz was monitored every 2 bilayers in a UV-spectrometer 
(Cary 50, Varian Inc) using a custom jig that allows absorbance measurement of quartz 
slides submerged in a solution of PBS.  PLL/Alg-CHO films show an exponential growth 
profile as determined by the maximal adsorption of FITC at 495 nm.  Film growth on 
ePTFE grafts after assembly of PEM was measured by first cutting the graft segment 
lengthwise in two halves to expose the luminal surface.  A short-wave UV lamp was used 
to illuminate the PEI-FITC component for imaging. 
3.4.4. PEM Film Stability and Crosslinking    
Oxidized alginate films were crosslinked by incubating films in 250 mM adipic 
dihydrazide (ADH, Sigma) in PBS (pH 7.4).  Stability of films was evaluated by 
incubation in 5 M NaCl solution for up to 21 hours.  ADH incorporation into the film was 
evaluated by measuring the absorbance at 240 nm.  Mechanical stability of PEM films 
assembled on the luminal surface of ePTFE grafts was determined by connecting a 
segment of modified graft in-line with a peristaltic pump (Variable Flow Chemical Pump, 
VWR) that maintained a 400 ml/min flow rate, as well as a ~300 ml reservoir of DPBS.  
The setup was placed in an incubator at 37 ºC and the graft was perfused for 24 hours. 
  




A BIOLOGICALLY ACTIVE SURFACE ENZYME ASSEMBLY THAT 
ATTENUATES THROMBUS FORMATION 
 
Activation of hemostatic pathways by blood-contacting materials remains a major 
hurdle in the development of clinically durable artificial organs and implantable devices.  
We postulate that surface-induced thrombosis may be attenuated by the reconstitution 
onto blood contacting surfaces of bioactive enzymes that regulate the production of 
thrombin, a central mediator of both clotting and platelet activation cascades.  
Thrombomodulin (TM), a transmembrane protein expressed by endothelial cells, is an 
established negative regulator of thrombin generation in the circulatory system.  
Traditional techniques to covalently immobilize enzymes on solid supports may modify 
residues contained within or near the catalytic site, thus reducing the bioactivity of 
surface enzyme assemblies.  In this report, we present a molecular engineering and 
bioorthogonal chemistry approach to site-specifically immobilize a biologically active 
recombinant human TM fragment onto the luminal surface of small diameter prosthetic 
vascular grafts.  Bioactivity and biostability of TM modified grafts is confirmed in vitro 
and the capacity of modified grafts to reduce platelet activation is demonstrated using a 
non-human primate model.  These studies indicate that molecularly engineered interfaces 
that display TM actively limit surface-induced thrombus formation. 
4.1.  Introduction 
 The molecular engineering of biologically active surface assemblies that control 
host reactions at tissue-material interfaces may be an important step in the development 
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of clinically durable artificial organs and implantable devices [340, 341].  In this regard, 
pathological thrombus formation on materials in direct contact with blood has precluded 
development of a clinically durable small-diameter (< 6 mm inner diameter) arterial 
prosthesis critical to the fields of cardiac, vascular, and plastic surgery, and has 
necessitated adjunctive antithrombotic therapies that increase bleeding risk and 
healthcare costs for numerous cardiovascular procedures [8, 342].  The onset and 
amplification of thrombogenesis on blood-contacting materials involves concomitant 
activation of platelets and elaboration of the coagulation cascade to generate thrombin 
and fibrin, culminating in hemostatic plug formation [343].  Thrombin serves as a central 
initiator, amplifier, and effector molecule at the nexus of these pathways by crosslinking 
fibrin, directly triggering platelet activation that lead to a local burst of thrombin 
production,[344] and eliciting inflammatory reactions [345] that influence long-term 
healing characteristics of implanted materials [346].  Therefore, a rational approach to 
improve blood compatibility and long-term durability of blood-contacting materials may 
entail the incorporation of endogenous regulators of thrombin production, normally 
active within the endothelial cell membrane, onto synthetic molecularly engineered 
surfaces.   
Heparan sulfate proteoglycans (HSPG) in the arterial wall accelerates thrombin 
inactivation by antithrombin III, a mechanism Gott and coworkers first replicated on 
artificial surfaces by heparin immobilization in 1963 [347].  However, the physiological 
significance of HSPG remains poorly understood, since the majority of anticoagulantly 
active HSPG is not in direct contact with flowing blood [348], and thrombin becomes 
resistant to inhibition by the heparin-antithrombin III complex upon binding to fibrin 
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[349].  Alternatively,  surface-bound direct thrombin inhibitors, such as hirudin [239, 
240, 350, 351] and its analogues [352], as well as argatroban [353, 354], and 
benzamidine [355] quench the activity of locally produced thrombin.  However, a 
potential constraint of these approaches is the inability to generate a continuous surface 
reservoir of direct thrombin inhibitors that would be required to curtail self-reinforcing 
thrombin generation cascades which are rapidly amplified upon initiation.  Hemostatic 
occlusion in the arterial circulation is actively regulated by the protein C (PC) pathway, 
whereby activated protein C (aPC) inactivates precursors requisite for amplification of 
coagulation and thrombin formation [356].  Endothelial cells that line the vascular system 
express thrombomodulin (TM), a transmembrane protein that binds thrombin as a 1:1 
stoichiometric complex.  In the process of sequestering thrombin, TM limits its capacity 
to activate platelets or to otherwise serve as a prothrombotic factor.  More importantly, 
TM accelerates thrombin’s ability to produce aPC by 1000-fold [19].  Hence, we 
postulate that engineering blood-contacting surfaces, which display biologically active 
TM assemblies would locally generate aPC “on demand”, thereby, inhibiting thrombin 
generation. 
Traditional techniques to immobilize active enzymes on solid supports, such as 
passive adsorption or covalent ligation via free amino or carboxyl residues[357] have 
been reported to generate surfaces modified with TM [228, 230-233, 358-360].  
However, these covalent ligation approaches randomly orient immobilized enzymes and 
potentially modify residues contained within or near the catalytic site [361], consequently 
reducing optimal surface activity that could otherwise be achieved by these enzyme 
assemblies.  Emerging advances in bioorthogonal chemistry and molecular engineering 
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provides an opportunity to site-specifically tether large enzymes onto surfaces.  The azide 
(-N3) group is absent from biological systems and was first explored as a bioorthogonal 
handle with Staudinger Ligation [362].  Further application of this chemistry to 
immobilize proteins containing an azide-modified C terminus has been performed on 
glass surfaces modified with triphenylphosphine [363, 364], but thiol reagents used in 
expressed protein ligation to generate the azide moiety may perturb the folding and 
catalytic activity of bioenzymes rich in disulfide bonds [365], including TM [366].  An 
alternative strategy that first converted a single lysine residue to azide facilitated 
immobilization of an active enzyme by traceless Staudinger Ligation on glass, which 
maximized its bioactivity relative to random coupling via amine residues [367].  
However, a possible limitation of this approach is the lack of site-specificity when 
multiple lysines are present in larger biomolecules, such as TM. 
Our laboratory has generated a truncated 15 kDa human TM fragment containing 
the soluble extracellular epidermal growth factor-like domains 4 through 6 (EGF4–6) 
[235], which displays the requisite binding sites for thrombin and protein C necessary to 
catalyze production of aPC [368].  Using site-specific incorporation of the non-canonical 
methionine surrogate azidohomoalanine [369] we have generated a TM variant 
expressing a single C-terminal azide moiety (TM-N3).  In this report, we immobilize 
recombinant TM-N3 by Staudinger Ligation onto the luminal surface of polyurethane 
coated expanded poly(tetrafluoro-ethylene) (ePTFE) vascular grafts (Figure 4.1).  
Further, we demonstrate the capacity of these surfaces to generate aPC and confirm the 
stability of TM surface assemblies in vitro.  The ability of TM modified grafts to inhibit 
thrombosis in vivo was demonstrated using a non-human primate model. 
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Figure 4.1.  Reaction sequence to covalently immobilize recombinant human 
thrombomodulin (TM) onto the luminal surface of expanded poly(tetrafluoroethylene) 
(ePTFE) grafts: (1) generation of polyurethane (PU) coating on ePTFE graft lumen; (2) 
isocyanate activation of PU with hexamethylene diisocyanate; (3) immobilization of 
amino-PEG11-triphenylphosphine (NH2–PEG11–TPP) linker; (4) Staudinger Ligation of 





4.2.  Results and Discussion 
4.2.1.  Coating of ePTFE Grafts with a Polyurethane Film 
Although inert PTFE surfaces may be modified by high energy radiation to 
generate reactive chemical handles [370], translation of these techniques to ePTFE 
vascular prostheses on clinically relevant length scales has been difficult.  Therefore, an 
extrusion method was used to deposit a thin coating of medical grade Elasthane 80A 
polyurethane (PU) onto the luminal surface of ePTFE grafts that could then be readily 
modified by chemical techniques [371].  Scanning electron microscopy (SEM) confirmed 
deposition of a smooth, uniform ~50 µm PU film that penetrated the porous node-fibril 
architecture of ePTFE (Figure 4.2).   
As expected, PU coating thickness was proportional to the quantity of material 
deposited and uniform along the length of the prosthesis (Figure 4.3).   Attenuated total 
reflectance IR (ATR-IR) spectroscopy was performed on PU coatings on ePTFE (Figure 
4.4a), as well as model thin films generated by solvent casting of PU onto glass substrates 
(Figure 4.4b).  A hydrogen-bonded urethane N–H peak at 3320 cm-1 that is characteristic 
of PU was observed, as were peaks at 2885 and 1535 cm-1 corresponding to C–H 
stretching and C–H–N bending, respectively.  Additional PU peaks were detected at 1591 
cm-1 (C=C, aromatic ring), 1110 cm-1 (C–O–C, stretch), 1730 cm-1 (urethane C=O, free 
from hydrogen bonding), and 1710 cm-1 (urethane C=O, hydrogen bonded), consistent 





   
   
 
Figure 4.2.  Scanning electron microscopy of polyurethane (PU) coating on (a) the edge 
of ePTFE graft at 100x, and on (b) the luminal surface at 100x and (c) 2000x.  Scale bars: 




Figure 4.3.  Light microscopy of thin cross sections of polyurethane (PU) coated ePTFE 
grafts.  (a) Interface between opaque ePTFE graft wall and transparent 2-layer PU lining 
observed at 4x.  (b) Mean ± standard deviation of PU thickness measured at 4 positions 
per cross section and 1cm intervals along 8cm ePTFE graft segment coated with 2, 3, and 
4 deposited layers of PU on top of a base extruded layer.  (c) Interface between opaque 
ePTFE graft wall and transparent 4 layer PU lining observed at 20x.  Scale bars: (a) 500 








Figure 4.4.  Attenuated reflection infrared spectroscopy of (a) polyurethane (PU) coated 
on the luminal surface of ePTFE grafts and (b) thin solvent cast PU films.  Representative 
spectra given for (i) PU, (ii) PU subjected to isocyanate activation with hexamethylene 





4.2.2.  Chemical Modification of ePTFE Grafts 
Amine-reactive isocyanate groups were generated on PU coated grafts using a 
rotary reactor, which facilitated uniform mixing of reagents (Figure 4.5) [182].   PU 
coated grafts were incubated for 1 h with hexamethylene diisocyanate (HDI) in the 
presence of triethylamine (TEA) at 50 °C , as demonstrated elsewhere [373].  ATR-IR 
spectroscopy detected a distinct peak at 2260 cm-1 corresponding to –N=C=O (Figure 
4.4).  A heterobifunctional linker comprised of a poly(ethylene glycol) (PEG) spacer with 
amino (–NH2) and triphenylphosphine (TPP) end groups (NH2–PEG11–TPP) was used to 
derivatize accessible surface isocyanates (Scheme 1), as confirmed by loss of the –
N=C=O peak by ATR spectroscopy (Figure 4.4).    
Consistent with this finding, X-ray photoelectron spectroscopy (XPS) revealed a 
sharp decrease in the C (285eV) to O (532eV) ratio (Figure 4.6a-c and Table 4.1) and the 
presence of distinct phosphorous peaks (P2p at 133eV and P2s at 200eV) (Figure 4.6c).  
The absence of fluorine peaks (Figure 5a-c) further confirmed complete coverage of 
ePTFE by the PU thin film.  High resolution C 1s XPS (Figure 4.6d-f and Table 4.1) 
revealed a dramatic increase in N–C=O (289.0eV) intensity and increased ether carbon 
content (C–O, 286.4eV) after immobilization of the PEG linker.  These observations 
confirm the initial generation of reactive isocyanates followed by the display of TPP 
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PU [a] 81 17 1.6 4.8  65 13 1.1 
PU–NCO 
[b] 
86 13 0.70 6.6  74 6.0 9.2 
PU–TPP 
[c] 
70 24 4.6 2.9  50 45 2.8 






Figure 4.5.  Reactor setup for chemical derivatization of PU modified ePTFE grafts.  (a) 
4 mm i.d. ePTFE grafts were chemically modified using a custom reactor design 
comprising (i) reactor housing for ePTFE graft and a (ii) DC motor that is coupled to a 
(iii) form-fitting rotator clamp for graft reactors to facilitate rotation along the axial 
length of grafts.  (b) Inner construction of reactor housing for ePTFE graft comprising (i) 
barbed Kynar plugs to seal both ends of tubular reaction vessel; (ii) inner 5 mm i.d., 7 





Figure 4.6.  Survey and high resolution X-ray photoelectron spectroscopy (XPS) of PU 
modified ePTFE grafts.  Survey XPS were performed on the ePTFE graft lumen 
following (a) surface coating with PU, (b) subsequent isocyanate modification, and (c) 
NH2–PEG11–TPP linker immobilization.  Corresponding high resolution C 1s XPS were 
performed on the ePTFE graft lumen following (d) surface coating with PU, (e) 
subsequent isocyanate modification, and (f) NH2–PEG11–TPP linker immobilization. 
 
 75 
4.2.3.  Staudinger Ligation of Azide Probe on ePTFE  
A fluorescent azide probe was used to initially assess the specificity of small 
molecule immobilization by Staudinger Ligation [374].  Rhodamine B and its azide 
analogue tetramethylrhodamine 5-carbonyl azide (Rh-N3) were reacted in parallel with 
PU films functionalized with TPP.  Following extensive rinsing in methanol, it was 
evident that only Rh-N3 was covalently immobilized to TPP modified PU films (Figure 
4.7a).  This result was semi-quantitatively corroborated by UV-Vis spectroscopy (Figure 





Figure 4.7.  Feasibility of immobilizing azide probes by Staudinger Ligation on 
polyurethane films.  (a) Visual confirmation of solvent cast PU films derivatized with 
TPP and reacted with either (left) rhodamine B or (right) rhodamine azide. (b) Solvent 
cast thin PU films activated with TPP anchor groups were reacted with either rhodamine 
B or rhodamine azide and analyzed by UV-Vis spectroscopy.  (c) En face examination of 
TPP modified grafts following reaction with (i) rhodamine B or (ii) rhodamine azide and 




4.2.4.  Immobilization of Thrombomodulin  
TPP modified grafts were exposed to recombinant TM expressing either a single 
C-terminal azide moiety (TM-N3) or a native methionine (TM-methionine).  Following a 
phosphate buffered saline (PBS, pH 7.4) rinse for 24 h, the capacity to activate PC was 
assessed in vitro. Grafts reacted with TM-N3 afforded a 30-fold increase in their capacity 
to activate aPC as compared to grafts incubated with TM-methionine (~0.4 vs ~12 ng 
aPC cm-2 min-1, p<0.01; Figure 4.8a).  The density of covalently bound TM was 
measured using a horseradish peroxidase (HRP) conjugated antibody that recognizes the 
human TM EGF5–6 domain.  Surface density of TM-N3 was ~170 fmol/cm2 after 
subtracting background binding of antibody to unmodified PU (Figure 4.8b) [375].  The 
aPC generating capacity reported herein is greater than that previously reported for 
random immobilization strategies [364, 367].  Since the minimum aPC flux required to 
inhibit thrombosis has not been established, predicting in vivo performance is not 
feasible. 
Biostability was assessed by subjecting TM-modified grafts to PBS at a shear rate 
of 500 s-1 and 37 °C for 24 h, as well as to an additional 2 week period in PBS at 37 °C. 
Catalytic activity remained nearly constant indicating that covalently immobilized TM-
N3 was unaffected by short-term exposure to arterial shear, as well as extended 
incubation under physiologically relevant pH and temperature conditions (Figure 4.8c).  
Notably, random amine-crosslinking techniques used to immobilize TM on ePTFE 
resulted in a 50 % reduction in surface activity following exposure to mechanical shear 
for 7 hours at 37 °C [376].  Others have reported a ~30 % reduction in activity when TM 




Figure 4.8.  Measurement of thrombomodulin (TM) cofactor activity to generate aPC, 
TM surface density, and stability of immobilized TM on modified ePTFE grafts.  (a) 
Catalytic activity of TPP modified ePTFE grafts reacted with recombinant TM 
expressing a C-terminal azide moiety (TM-N3) or TM containing its native C-terminal 
methionine.  (b) Surface density of TM on grafts was quantified using a TM antibody and 
compared with background binding of antibody to bare PU coated ePTFE.  (c) Graft 
activity measured as a percentage of initial levels following 24 h of mechanical shear at 
500 s-1 at 37 °C and subsequent 2-week incubation in PBS at 37 °C.  Data represents 
mean ± standard deviation for n ≥ 3 samples.  Statistical difference (p < 0.01) versus 




4.2.5.  In Vivo Performance of ePTFE Grafts Modified with Thrombomodulin 
   The ex vivo femoral arteriovenous shunt model provides a means to assess the 
thrombogenicity of blood contacting materials under dynamic arterial flow conditions, 
particularly when implanted in sub-human primates, such as the baboon, whose 
hemostatic system closely resembles that of man [377-380].   Platelet binding to PU 
coated PTFE grafts (4 mm i.d.) was assessed using an arteriovenous perfusion chamber 
and compared to responses observed to unmodified Dacron grafts (Figure 4.9) [195, 378].  
Cumulative platelet deposition on PU coated ePTFE was substantially lower than on 
Dacron grafts (0.0082 vs 1.5 billion/cm2).   
Since the level of platelet deposition on PU coated ePTFE grafts is too low to 
gauge the therapeutic efficacy of immobilized TM, we explored thrombus growth in a 
perfusion system in which a test graft was interposed between a collagen coated ePTFE 
graft, as a thrombogenic source, and a distal expansion chamber (Figure 4.10) [377, 378].  
TM modified ePTFE grafts reduced platelet deposition in the distal expansion chamber 
by nearly 50% when compared to unmodified PU coated grafts (n=4, p < 0.05).  Since 
thrombin is an important physiological agonist for platelet activation [344], the measured 
reduction of platelet deposition in the distal expansion chamber suggests that substantial 
levels of aPC are generated from the TM modified surface.  In addition to attenuating 
thrombosis, local generation of aPC may influence the healing characteristics of 
implanted grafts, as late prosthetic graft failure has been attributed to progressive intimal 
hyperplasia, a process exacerbated by thrombin and platelet derived pro-inflammatory 





Figure 4.9.  Real time platelet deposition on modified ePTFE grafts in the absence of an 
upstream thrombus source in the baboon shunt model. (a) Shunt configuration for testing 
thrombogenicity of 4 mm i.d. tubular materials.  (b) Representative photo of a 7 cm 
length bare PU coated ePTFE graft split in half lengthwise following 1 h perfusion at 100 
mL/min; Arrow points in direction of blood flow.  (c) Comparison of platelet deposition 
on bare PU coated 4 mm i.d. ePTFE (ePTFE + PU) with plain 4 mm i.d. Dacron grafts.  
Each data point represents mean ± standard deviation for n ≥ 3 samples.  Statistical 





Figure 4.10.  The biological function of TM modified ePTFE grafts was evaluated using 
a three-compartment thrombogenic device inserted into chronic arteriovenous shunts in 
baboons.  (a) A 2 cm x 4 mm inner diameter (i.d.) segment of collagen coated ePTFE 
serving as a thrombin source was connected upstream of a 7 cm x 4 mm i.d. segment of 
test graft, and the therapeutic function of aPC generated in situ was detected in a 1 cm x 
10 mm i.d. distal expansion chamber.  Arrow points in direction of blood flow.  (b) 
Representative photograph of the entire chamber assembly that tested a 7 cm TM 
modified ePTFE graft split in half lengthwise following perfusion for 1 h at 100 mL/min.  
Arrow points in direction of blood flow.  Real-time platelet deposition (c) in the upstream 
collagen coated 4 mm i.d. ePTFE segment; (d) in the thrombus tail developing distal to 
collagen coated ePTFE; and (e) in the 10 mm i.d. expansion chamber distal to TM 
modified ePTFE grafts (PU + TM) compared with bare PU coated ePTFE controls.  Each 
data point represents mean ± standard deviation of 4 independent studies.  Statistical 





4.3.  Conclusions 
We have presented a biomimetic surface engineering approach that combines 
molecular engineering and orthogonal chemistry strategies to site-specifically 
functionalize clinical vascular prostheses with recombinant human TM that exhibit 
biocatalytic activity and biostability in vitro.  Moreover, we have devised and tested a 
robust, clinically relevant in vivo model of vascular graft thrombosis in non-human 
primates that facilitated evaluation of the therapeutic function of bioactive TM surface 
assemblies.  The data presented herein indicate that biologically active TM surface 
assemblies reduces the thrombogenic properties of blood contacting surfaces despite the 
presence of an upstream thrombin generating stimulus.  The modular nature of 
heterobifunctional linker design, combined with recent advances in chemoselective 
techniques to modify peptides and proteins [382, 383], will undoubtedly expand the 
utility of bioenzyme surface assemblies to a range of clinically important host-material 
interfaces.   
4.4.  Methods 
4.4.1.  Expression of TM-N3 and TM-methionine  
All reagents were purchased from Sigma-Aldrich, St Louis and used without 
further purification unless otherwise noted.  Expression and purification of recombinant 
TM-methionine and TM-N3 are similar to a previous report [384].  A fresh LB agar plate 
was streaked with methionine auxotrophic cells containing the appropriate TM vector and 
incubated at 37 °C overnight.  Next, a single cell colony was inoculated into 50 ml of 
Novagen media supplemented with 0.4% glucose and 50 μg/ml ampicillin (Calbiochem) 
and cultured at 37 °C, 225 RPM, for 16 h.  25 ml of fully grown starter culture (OD600 = 
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1.20) was added per 500 ml of Novagen media (Overnight Express Autoinduction 
System, Novagen) supplemented with 0.4% glucose and 50 μg/ml ampicillin, and 
cultured at 37 °C, 225 RPM.  Upon cell growth to OD600 = ~0.9, IPTG was added at a 
final concentration of 1mM to induce TM-methionine expression.  After 4 h at 37 °C, the 
cells were sedimented by centrifugation for 25 min at 1650 RCF at 4 °C.  Alternatively, 
TM-N3 was generated by spinning down the initial OD600 = 0.9 cells culture to obtain a 
cell pellet which is resuspended in fresh Novagen media lacking methionine.  After 
incubation at 37 °C, 225 RPM for 20 minutes for cells to exhaust residual methionine 
from the media, azidohomoalanine was added at a final concentration of 100 mg/L 
culture, and IPTG was added at a final concentration for 1 mM, the expression was 
induced for 4 h at 37 °C, 225 RPM.   
The collected cell pellets were stored at 4C overnight and their periplasmic 
proteins extracted by osmotic shock protocol.  Cell pellets were warmed to room 
temperature and re-suspended in 40 ml/g cells of 0.5 M Sucrose, 0.03 M Tris-HCl (pH 
8.0) at a final pH of 8.0 per gram of cells.  Suspended cells were evenly distributed into 
round bottom centrifuge tubes (60 mL per tube).  120 µL of 500 mM sucrose was added 
to each tube to achieve final 1mM EDTA concentration and incubate with gentle shaking 
for 10 minutes at RT.  The cell suspension was centrifuged at 3,500x RCF for 10 min at 
10 °C, and the supernatant was decanted.  The cell pellet was rapidly resuspended in 25 
ml/g cell pellet ice-cold, distilled water (40 mL per tube is sufficient) for 10 minutes, and 
the cell suspension was centrifuged at 3,500x RCF for 10 min at 4 °C. 35ml of 
supernatant was removed per tube immediately and transferred to clean round bottom 
centrifuge tubes.  These were clarified by further centrifugation at 25,000x RCF for 25 
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min at 4°C, and sterilized using a 0.22 µm filtration system.  Anti-FLAG immunoaffinity 
chromatography (Sigma) was performed on the clarified supernatant per manufacturer’s 
instructions.  SDS-PAGE analysis, and total protein quantification were performed using 
standard Bradford assay (Biorad) following protocols from the manufacturer. 
4.4.2.  Synthesis of NH2–PEG11–TPP 
NH2–PEG11–TPP was synthesized by reaction of O-(2-aminoethyl)-O’-[2-(Boc-
amino)ethyl]decaethylene glycol with a pentafluorophenyl ester of triphenylphosphine 3 
shown in Figure 3.11 (TPP) [374] in CH2Cl2 and 3 equiv 2,6-lutidine at 25 °C for 12 h, 
followed by removal of the Boc protecting group using CF3COOH and purification by 
column chromatography.   
 A solution of NaNO2 (0.90 g, 13 mmol) in 5 ml of H2O was added dropwise to a 
solution of 1-methyl-2-aminoterephthalate (1 Aldrich # 393673) (2.5 g, 12.8 mmol) in 25 
ml of cold concentrated HCl. The mixture was stirred for 30 min at room temperature and 
then filtered through glass wool into a solution of KI (10 g, 60.2 mmol) in 15 mL of H2O. 
The dark red solution was stirred for 1 hour and then diluted with CH2Cl2 (200 ml) and 
washed with saturated Na2SO3 (2 x 20 ml). The organic layer was washed with water (2 x 
20 ml) and saturated NaCl (1 x 20 ml). The combined aqueous layers were back extracted 
with CH2Cl2 (40 ml). The combined organic layers were dried over Na2SO4 and 
concentrated. The crude product was dissolved in a minimum amount of MeOH and H2O 
was added until the solution appeared slightly cloudy. Cooling to 4 °C and subsequent 
filtration afforded 2.8 g (70%) of a yellow solid. 




Figure 4.11. Synthesis of triphenylphosphine 3 
To a flame-dried flask was added 2 (300 mg, 1.00 mmol), dry MeOH (3 ml), 
triethylamine (0.3 ml, 2 mmol), and palladium acetate (2.2 mg, 0.010 mmol). While 
stirring under an atmosphere of Ar, diphenylphosphine (0.17 ml, 1.0 mmol) was added to 
the flask by means of a syringe. The resulting solution was heated at reflux overnight, 
and then allowed to cool to room temperature and concentrated. The residue was 
dissolved in 250 ml of a 1:1 mixture of CH2Cl2/H2O and the layers were separated. The 
organic layer was washed with 1 M HCl (1 x 10 ml) and concentrated. The crude product 
was dissolved in a minimum amount of methanol and an equal amount of H2O was 
added. The solution was cooled to 4 oC for 2 hours and the resulting solid was collected 
by filtration. The pure product 3 (Figure 4.11) was isolated.  1H-NMR (CDCl3, 400 
MHz) δ 3.75 (s, 3H), 7.28-7.35 (m, 11H), 7.63-7.67 (m, 1.5 Hz, 1H), 8.04-8.07 (m, 1.5 
Hz,1H).  HRMS (ESI): Calculated for C21H18O4P: 365.0943 [M+H]+; found 365.0923. 




The triarylphosphine derivative 3 was converted to the corresponding PFP 
activated ester 4 in Figure 4.12.    
Synthesis of PFP-activated ester of triphenylphosphine 
 
 
Figure 4.12. Synthesis of PFP activated ester 4 
 
Triarylphosphine 3  (300 mg, 0.82 mmol) was dissolved in THF (6.4 mL) under 
argon. Triethylamine (167 mg, 1.65 mmol) was added, followed by a drop-wise addition 
of pentafluorophenyl trifluoroacetate (Aldrich# 377074, 277 mg, 0.99 mmol) over a 
period of 2 minutes. The reaction was stirred at room temperature for 30 minutes and 
then concentrated. Purification by silica gel chromatography (1:1 ethyl acetate:hexanes) 
afforded phosphine-PFP 4 (300 mg, 69% yield) as a solid.  IR (thin film): 1766, 1725, 
1521, 1052 cm-1.  1H NMR (400 MHz, CDCl3): δ 3.68 (s, 3H), 7.38-7.32 (m, 10H), 7.71 
(t, 1H, J = 3.9), 8.08 (app t, 2H, J = 3.0); 13C NMR (75 MHz, CDCl3): d 15.29, 30.02, 
52.76, 66.26, 125.24, 129.05, 129.50, 129.86, 130.29, 131.26, 132.18, 134.18, 136.71, 
136.84, 138.23, 139.78, 141.60, 142.87, 142.94, 161.99, 166.75; HRMS (ESI): 
Calculated for C27H17O4PF5: 531.0779 [M+H]+; found 531.0774.  The activated ester 4 
can be used for the amide coupling reaction with various PEG linkers to form the 
corresponding PEG-Phosphine derivatives.   
Synthesis of PFP-active ester 4 
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PFP active ester 4 when reacted with amino-dPEG12-t-boc-amine 5, an amide 
bond formation takes place to afford the compound 6.  Subsequent removal of Boc group 
by reaction with TFA provided the desired NH2–PEG11–TPP 7.  The chemical scheme 
and experimental procedure are outlined in Figure 4.13 below.  PFP-ester 4 (312 mg, 
0.587 mmol) and amino-PEG12- t-boc-amine 5 (Aldrich# 77090, 315 mg, 0.489 mmol) 
were dissolved in 4 mL of CH2Cl2 and 2,6-lutidine (204 ul, 3 equiv.) was added under 
argon at room temperature. The resulting mixture was stirred for 12 h at room 
temperature.  Solvent was evaporated under vacuum and the residue was purified by 
column chromatography to afford the product 6 as pale yellow oil. 
Synthesis of NH2–PEG11–TPP Linker 
 
 
Figure 4.13. Synthesis of NH2–PEG11–triphenylphosphine  
Removal of Boc group
To the stirred solution of compound 6 in CH2Cl2 (0.7 ml/1 mmol) was added 
CF3COOH (0.7 ml/1 mmol).  The resultant mixture was stirred at room temperature for 4 
h.  After this time, the volatiles were removed under vacuum and the crude product was 
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dissolved in CH2Cl2, washed with NaHCO3, brine and dried (Na2SO4).  Purification by 
column chromatography afforded the desired product in 79-81% yield in 2 steps.  1H 
NMR (400 MHz, CDCl3): δ 8.10 (dd, 1H, J = 3.6, 8), 7.83 (dd, 1H, J = 1.6, 8.4), 7.39-
7.28 (m, 11H), 6.81 (m, 1H), 3.80 (brs, 2H), 3.76 (s, 3H), 3.70-3.49 (m, 46H), 2.97 (t, 
2H, J = 5.2).  HRMS (ESI): Calculated for C45H68N2O14P: 891.4408 [M+H]+; found 
891.4396. 
4.4.3. Modification of ePTFE Grafts 
A 5% w/v solution of Elasthane 80A (Polymer Tech, Berkeley) in N,N-
dimethylformamide (DMF) was prepared by dissolving pellets with vigorous shaking for 
24 hours at room temperature.  The PU solution was extravasated through 4 mm i.d. 
ePTFE thin wall vascular grafts (Bard, Tempe) that is clamped shut at one end by forcing 
the solution through the graft pores using a 3 ml standard Luer lock syringe.  Following 
extravasation, the coated graft segment was drained of excess PU solution and dried 
under vacuum at 60 °C for 20 min by hanging the graft segment on a rack using alligator 
clips.  Additional PU was deposited in multiple flow-through/drying cycles over the base 
layer, and dried overnight under vacuum at 60 °C.  The final coating should appear shiny 
and clear and completely covers the luminal surface of the ePTFE graft. 
 PU coated graft segments were inserted into tubular reactors as depicted in 
Figure 4.5 and rotated at 500rpm for surface reactions.  Each reactor was fabricated using 
acetone/ethanol cleaned tubing parts obtained from McMaster Carr.  To ensure complete 
sealing, barbed plugs were inserted at the ends of the reactor chamber one end at a time.  
To modify the PU coating on grafts, HDI (16% v/v) and TEA (4% v/v) solution in 
anhydrous toluene was added to the chamber and rotated at 50 °C for 1 h.  After this step, 
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the graft was removed from the chamber and rinsed in anhydrous toluene for 6 h with 1 
exchange of fresh wash toluene.  Isocyanate activated grafts were then reacted in the 
same reactor setup constructed with fresh parts with NH2–PEG11–TPP linker (10 mg/mL) 
and TEA (1% v/v) in anhydrous toluene at 40 °C overnight, rinsed with toluene for 6 h, 
and dried under vacuum at 25 °C overnight.  TPP activated grafts were reacted with a 1 
mg/mL dilution of tetramethylrhodamine-5-carbonyl azide (Invitrogen, Carlsbad) in 1:4 
tert-butanol/PBS at 37 °C for 24 h followed by rinsing in multiple exchanges of methanol 
for 24 h, or reacted with 20 µM TM-N3 in PBS at 37 °C for 24 h and rinsed with 50ml 
PBS in a Falcon tube under constant rotation for 24 h.  Grafts coated with PU and 
activated with TPP were reacted with rhodamine B or TM-methionine as controls. 
4.4.4.  Modification of Polyurethane Films 
Thin clear PU films were solvent cast by drying 12.5 % w/v Elasthane 80A in 
DMF for 24 h at 60 °C on an acetone/ethanol cleaned glass Petri dish under vacuum.  The 
films were removed with a razor and cut into rectangular test samples.  Films were 
subjected to isocyanate, TPP, and rhodamine reactions in a glass vial.  Briefly, PU films 
were immersed in dry toluene solution containing HDI (16 % v/v) and TEA (4 % v/v) at 
50 °C for 1 h and rinsed in toluene for 6 h.  The films were then immersed in dry toluene 
containing 10mg/mL NH2–PEG11–TPP linker and 1 % TEA and toluene at 40 °C 
overnight, rinsed with toluene for 6 h, and dried under vacuum at 25 °C overnight.  TPP 
activated films were reacted with 1 mg/mL tetramethylrhodamine-5-carbonyl azide 
(Invitrogen, Carlsbad) in 1:4 tert-butanol/PBS at 37 °C for 24 h followed by rinsing in 
multiple exchanges of methanol under vigorous shaking for 24 h. 
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Rhodamine modified thin films were characterized by UV-Vis spectroscopy 
(Cary 50 Bio UV-visible spectrophotometer, Varian) using a jig built in-house.  An 
adaptor for the UV-Vis spectrometer was redesigned to hold the film segment in place 
between two quartz slide pieces.  UV-Vis spectroscopy was performed on plain solvent 
cast PU films, PU films modified with TPP, and TPP modified films reacted with either 
rhodamine-azide or control rhodamine B.   
4.4.5.  Surface Analysis  
An in-lens field-emission SEM (ISI DS-130F Schottky Field Emission SEM) 
operated at 10 kV was used to examine the graft luminal surface.  Graft samples were 
first prepared by cutting with a razor blade to expose the luminal surface as well as the 
cross section of the graft wall, and sputter coated with gold. 
Light microscopy images of serial thin sections of modified grafts were used to 
determine PU thickness.   Samples were prepared by manually cutting graft segments into 
~ 0.5 mm thick rings, which were mounted on a glass slide and imaged by standard light 
microscopy.  Due to the opaqueness of the ePTFE graft component, visualization of the 
clear PU coating was achieved by focusing the image at the surface of the coating. 
ATR-IR spectra were acquired using a FTS-4000 FT-IR spectrometer (Bio-Rad, 
Hercules) equipped with a wide-band MCT detector, collected with 100 scans at 2 cm−1 
resolution.  XPS data were recorded on an Axis Ultra X-ray photoelectron spectrometer 
(Kratos Analyticals, UK) equipped with a monochromatized Al Kα X-ray source.   
4.4.6. TM Graft Cofactor Activity Assay 
A 4 mm graft segment was cut using a clean razor blade from the fabricated TM 
grafts, and incubated in 200 µL of 0.2 µM human protein C (Calbiochem, Gibbstown), 5 
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mM calcium chloride, and 2 nM human α-thrombin (Haematologic Technologies, Essex 
Junction) in Tris buffer (20 mM Tris, 100 mM NaCl, pH 7.5) with 0.1% bovine serum 
albumin (BSA) at 37 °C for 1 h, and quenched with 2 IU/mL human anti-thrombin III 
(American Diagnostica, Stamford) for 5 min.  The generation of aPC was quantified 
using 0.2 mM of an enzymatically digestible chromogenic substrate, Spectrozyme PCa 
(American Diagnostica).  TM activity was assayed after grafts were exposed for 24 h to 
PBS at 37 °C and 500 s-1 shear, as well as after incubation in PBS with 0.02% sodium 
azide at 37 °C over a two week period.   
4.4.7. Determination of TM Surface Density 
All assay reactions were run in a 96-well plate, per manufacturer’s instructions 
(American Diagnostica, Stamford).   Moles of EGF5-6 domains bound to test grafts were 
calculated by a standard curve generated by ELISA using known concentrations of TM 
provided by the manufacturer.  At the end of each assay, graft segments were flattened 
between glass slides and scanned at 600 dpi using a HP ScanJet 5370C scanner and the 
reactive area of each test sample was measured using ImageJ software.  Representative 




   
Figure 4.14.  Representative image of graft segments used for measuring TM surface 
density.  (A) 600dpi image generated using a scanner; (B) ImageJ software was used to 
convert images to 8-bit and the threshold was adjusted to 165 for area measurement. 
 
 
4.4.8. In Vivo Baboon Arteriovenous Shunt Model 
In vivo functional capacity of TM modified ePTFE grafts were evaluated as 
previously described [195, 378].  All studies were approved by the Institutional Animal 
Care and Use Committee at Oregon Health and Science University.  Grafts were 
interposed into a permanent Silastic arteriovenous shunt that had been surgically 
implanted between the femoral artery and vein in male Baboons (Papio papio). 
Circulating platelet concentrations averaged ~300,000 platelets/μL.  Ketamine 
hydrochloride (10 mg/kg intramuscularly) was given as a preanesthetic agent, and the 
operation was performed under general 1% halothane anesthesia.  Mean blood flow rate 
through the shunt was measured continuously using a Doppler ultrasonic flow meter and 
held constant by an external screw clamp at 100 mL/min.  
Autologous platelets were radiolabeled one day prior to shunt study with Indium-
111 oxine and re-injected into the baboon.  Forty-five milliliters of whole blood were 
initially withdrawn into syringes containing 5 mL of 3.8% sodium citrate anticoagulant. 
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The blood was centrifuged at 160 RCF for 15 min and the platelet rich plasma (PRP) 
transferred to a 50 mL sterile tube to which was added PGE1 to a final concentration of 4 
ng/mL PRP and centrifuged at 1500 RCF for 25 min. The platelet pellet was resuspended 
in plasma to a platelet concentration of 1×1010 and 1000 μCi of indium-111 tropolone 
(111InCl3, Amersham Co.) was added to the platelet suspension.  Following 10 min 
incubation at room temperature, 3 mL of platelet-poor plasma was added and the platelets 
were incubated for an additional 2 min. A small aliquot was removed to determine 
labeling efficiency and the PRP was centrifuged at 1500g for 10 min to remove excess 
111In. The platelets were resuspended in 5 mL of reserved plasma and reinjected into the 
baboon. Platelet function is not altered by this technique, when studied by either 
thrombin stimulated platelet release of 14C serotonin or by morphological studies of dense 
body distribution.  Platelet labeling efficiency ranged between 80% and 90%. 
Platelet deposition in the individual compartments of the shunt assembly was 
measured over a 60-minute perfusion period using a high sensitivity 99Tc collimator and 
scintillation camera (GE 400T, General Electric) imaging of the 172 keV 111In g photon 
peak at 5-min intervals [195].  Immediately before imaging, a 5 min image was acquired 
of a 3 mL blood sample (blood standard). Images were obtained continuously with data 
storage at 5 min intervals.  
Deposited 111In-platelet activity was calculated by subtracting the blood standard 
activity from all dynamic study images.  Data were converted, at each time point, to total 
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4.4.9. Statistical Analysis 
Two-tailed student’s t-test assuming unequal variances was used to test for 
statistical significance between the means of two groups.  
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CHAPTER 5 
IMMOBILIZATION OF ACTIVELY THROMBORESISTANT ASSEMBLIES ON 
STERILE BLOOD CONTACTING SURFACES 
 
In this Chapter, we describe our efforts to optimize the production of azide-tagged 
thrombomodulin (TM), as well as surface chemistry schemes that would enable the site-
specific immobilization of TM in a manner that facilitates terminal sterilization of 
medical device surfaces.  Through this process we developed a general method to 
conjugate a single azide motif to the C-terminus of TM using the bacteria transpeptidase 
Sortase A.  This approach facilitates expression of TM without the use of non-natural 
azido-tagged amino acid analogues, and is compatible with eukaryotic expression 
systems typically used in the biopharmaceutical industry.  Moreover, we developed a 
surface modification strategy whereby sterically strained cyclooctyne motifs covalently 
immobilized on the luminal surface of 4 mm i.d. ePTFE grafts retained their capacity 
undergo [3+2] cycloaddition with azide-tagged TM after ethylene oxide sterilization, the 
current industry standard used in sterilization of synthetic vascular grafts.  We 
demonstrated for the first time the superior efficacy of TM to reduce the level of local 
platelet deposition than commercial heparin modified grafts using a novel A-V shunt 
model in nonhuman primates, which more closely mimics the thrombotic stresses 
encountered during and immediately after surgical implantation. 
5.1. Introduction 
All artificial organ systems and medical devices that operate in direct contact with 
blood elicit activation of coagulation and platelets with long-term use [11, 12], often 
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necessitating antithrombotic therapies that carry significant cost and bleeding risk [1, 2].  
Since the clinical inception of fabric grafts in 1952, none of the existing synthetic arterial 
substitutes perform comparably to autologous conduits in small-caliber (< 6 mm) 
revascularization procedures central to the field of cardiac, vascular, and plastic surgery 
[3].   Poor clinical outcomes are driven by blood-material and tissue-material interactions 
that include rapid thrombotic occlusion, restenosis due to biomechanical mismatch, as 
well as impaired reendothelialization due to a persistent foreign body response to 
synthetic materials many years after implantation [4].  Despite advances in tissue 
engineering approaches that have yielded biomaterials that mimic the bulk properties of 
native tissue and promote healing [5-7], a generally accepted blood compatible material 
does not exist [8].   
Physiological onset of thrombosis hinges on the generation of thrombin, a central 
mediator that amplifies the intrinsic coagulation cascade, crosslinks fibrin, and activates 
platelets [9, 10].  Biomimetic surface engineering approaches that reconstitute the natural 
mechanism of endothelial cells to attenuate thrombin production, such as heparin and 
thrombomodulin, have yielded promising results [8, 11, 12].   First demonstrated in 1963 
[13], heparin immobilization has been hypothesized to mimic the antithrombin activity of 
cell surface heparan sulfate proteglycans (HSPG) expressed by the endothelium [14].  
The physiological role of heparin, produced primarily by mast cells, in hemostasis 
remains unclear [15] as the majority of anticoagulantly active HSPG is not in direct 
contact with flowing blood [16] and knock-out mice lacking the specific pentasaccharide 
sequence that inhibits thrombin do not exhibit a procoagulant phenotype [17].   In 
contrast, thrombomodulin (TM) is a major vasculoprotective molecule localized on the 
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endothelial cell surface, and overwhelming evidence indicates that defects therein 
increase the risk of inflammatory disorders and thromboembolism [18].  TM sequesters 
thrombin’s prothrombotic activity and accelerates thrombin’s ability to activate protein C 
(APC) by 1000-fold, which inhibits upstream proteases necessary for amplifying 
thrombin production and represents the primary physiological mechanism by the 
endothelium to regulate hemostasis [19]. 
Clinical implementation of strategies reported to date on the immobilization TM 
has been primarily limited by two main factors: the inherent reduction in activity 
associated with schemes that non-specifically react with free amino, carboxyl, or thiol 
motifs contained near the catalytically active site [230, 233, 358-360, 376, 385], and the 
necessity for terminal sterilization by industry standards, which mainly comprise ethylene 
oxide and radiation that may disrupt the chemical structure and activity of surface-bound 
biomolecules [386-388].  We were first to demonstrate a bioorthogonal strategy to site-
specifically tether recombinant human TM via a single C-terminal azide motif by 
Staudinger Ligation on the luminal surface of 4 mm i.d. expanded 
poly(tetrafluoroethylene) (ePTFE) grafts, and validated the biological activity of TM to 
reduce thrombosis in a nonhuman primate model [389].  However, auxotrophic 
incorporation of a single non-canonical azido-alanine in TM is difficult to implement at 
industry scales, and restricts the scope of suitable candidate enzymes for surface 
immobilization to those with a single C-terminal methionine.  In this work, we first 
optimized the production of TM-N3 using a general enzymatic transpeptidation approach 
with an evolved mutant of S. Aureus sortase A (SrtA) exhibiting 140-fold higher catalytic 
activity than wild-type.  We then demonstrated a surface chemistry platform using strain-
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promoted [3+2] cycloaddition that facilitates terminal sterilization by ethylene oxide, and 
validated the superior in vivo thromboresistant characteristics of thrombomodulin 
compared with commercially available heparin modified ePTFE grafts. 
5.2. Results and Discussion 
5.2.1. Sortase-catalyzed Tagging of Thrombomodulin with Azide 
As a replacement for auxotrophic incorporation of non-canonical azide-tagged 
amino acids to produce TM-N3, we first benchmarked a site-specific protein labeling 
system using the S. Aureus sortase A (SrtA).  SrtA is a calcium-dependent cysteine 
transpeptidase that anchors proteins containing a C-terminal LPXTG motif (where X 
denotes any amino acid) by breaking the threonine-glycine bond and forming a new 
amide bond with the nucleophilic group of the pentaglycine portion of lipid II [390-392].  
However, the low catalytic activity of wild type (WT) SrtA (kcat/Km LPETG ~ 200 M-1 s-1) 
has necessitated high molar excess of enzyme and long reaction times [393].   Recently, 
the development of a general yeast display system has facilitated directed evolution of 
WT SrtA to generate a pentamutant SrtA variant (5’ SrtA) which exhibited 140-fold 
increase in catalytic activity [394].  We hypothesized that the incorporation of a small 
LPETG motif at the C-terminus of TM would not affect its catalytic activity, and would 
facilitate the tagging of pentaglycine modified probes that contain bioorthogonal handles 
such as biotin, as outlined Figure 5.1 below. 
 In our initial effort, we expressed a recombinant human TM fragment containing 
the minimal fragment for antithrombotic activity (TM456) [235, 395] and a single C-
terminal LPETG motif (TMLPETG) in the periplasm of E Coli (Figure 5.2), and purified by 
immunoaffinity chromatography.  TMLPETG exhibited no difference in its catalytic 
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activity to generate activated protein C in the presence of thrombin and calcium relative 
to previous batches of TM456 generated in our lab [235].  Detailed sequence of the 




Figure 5.1.  (A) Sortase catalyzed transpeptidation of biotinylated pentaglycine peptide 






Figure 5.2.  (A) SDS-PAGE gel tracking of FLAG-tagged TMLPETG purification by anti-
FLAG immunoaffinity chromatography.  Lanes: 1 – MW markers, 2 – TMLPETG.  (B) 
Western blot of purified TMLPETG using an antibody that recognizes TM456.  Lanes: 1 – 




                        
Figure 5.3.  Sortase catalyzed transpeptidation of TMLPETG with NH2-(Gly)5-Lys-biotin 
(GGG-biotin) nucleophiles.  Top: western blot analysis to detect presence of biotin using 
streptavidin-AP conjugate; bottom: molar ratios of the TMLPETG, WT SrtA, and biotin 









To confirm the sortase-catalyzed transpeptidation of nucleophiles to site-
specifically label TMLPETG, we synthesized a NH2-(Gly)5-Lys-biotin probe.  As a starting 
point, we tested the ligation of TMLPETG with 2 or 5 molar equivalents WT SrtA and 10 or 
100 molar equivalents of NH2-(Gly)5-Lys-biotin reacted for 2 or 20 hours (Figure 5.3). 
We observed that 10 molar equivalents of NH2-(Gly)5-Lys-biotin and 2-fold 
molar excess sortase relative to TMLPETG was required to achieve maximal 
transpeptidation.  Increasing the quantity of NH2-(Gly)5-Lys-biotin further did not 
improve yields, which may be due to the high specificity of the sortase enzyme towards 
the oligoglycine nucleophiles (Km).  However, due to the low catalytic activity of wild-
type sortase (kcat), a total reaction time of 20 hours appeared necessary to achieve 
maximal labeling yields, despite simultaneously increasing the amount of sortase to 5-
fold and the nucleophile to 100-fold excess relative to TMLPETG.  Therefore, it appears 
that a 2-fold molar excess sortase, 10-fold molar excess oligoglycine nucleophile, and 20 
hour reaction time are required to maximize yields. 
As shown in Figure 5.4, during the course of these studies, we unexpectedly 
observed that the 5’ SrtA catalyzed ligation of a commercially available NH2-PEG3-
biotin with nearly equal efficiency as NH2-(Gly)5-Lys-biotin peptide, at the reaction 




Figure 5.4.  Sortase catalyzed transpeptidation of pentaglycine and alkyl-amine 
nucleophiles tagged with biotin.  Western blot analysis of TMLPETG reacted with either 









Simple alkyl-amine nucleophiles have previously been shown to be 
suitable, though less efficient, nucleophile substrates for wild-type SrtA [393], and in 
general they have been regarded as a non-specific side product of transpeptidation 
involving oligoglycine nucleophiles.  Due to their synthetic simplicity, ligation of simple 
PEG-amines afforded by 5’ SrtA may provide a versatile and general approach to modify 
a range of biomolecules containing a C-terminal LPETG motif.  We validated this 
approach by first demonstrating the capacity of 5’SrtA to ligate a commercial NH2-PEG3-
N3 to TMLPETG, to generate a single C-terminal azide motif, which successfully reacted 
with a Biotinylated dibenzocyclooctyne (DBCO) probe as visualized by western blotting 
(Figure 5.6) as well as biotin quantification assay which showed ~10-fold increase in the 
fraction of TM tagged with azide compared with auxotrophic incorporation of 
azidohomoalanine. 
Next, we optimized the reaction conditions to tag TMLPETG with azide by 
performing reactions with a 5kDa PEG-amine, which would result in an increase in the 
molecular weight of the TMLPETG upon forming the TM-PEG conjugate.  By running 
parallel reactions using wild type and 5’ SrtA and measuring the formation of TM-PEG 
conjugate on a SDS-PAGE gel, we were able to verify the substantially higher reactivity 
afforded by 5’ SrtA to PEGylate TMLPETG with a 5kDa PEG-amine, which appeared to 
reach ~80% completion after only 2h, compared with WT SrtA under the same 
conditions (Figure 5.7).   





Figure 5.6.  Strain-promoted [3+2] cycloaddition of dibenzocyclootyne-biotin (DIBO-







Figure 5.7.  SDS-PAGE gel tracking of pentamutant (5’) or wild-type (WT) S. Aureus 
sortase A (SrtA) catalyzed transpeptidation of an amine-PEG113 (MW 5kDa) to 
thrombomodulin expressing a C-terminal LPETG peptide motif (TMLPETG) over a 16 






Further supporting the superior performance of 5’ SrtA in transpeptidation 
reactions involving alkylamine nucleophiles, it was found that the efficiency of TMLPETG 
PEGylation with PEG-amines was improved slightly when the molar excess of WT SrtA 
used in these studies by 20-fold, but still required 24h reaction time to reach the same 
level achieved by 5’ SrtA after 2 h (Figure 5.8).  These results support the use of 5’ SrtA 
as a highly active transpeptidase to covalently modify the C-terminus of TMLPETG with 
alkylamine nucleophiles, which are synthetically simpler to generate than pentaglycine 
peptides.  Moreover, we have demonstrated a rapid and straightforward approach to site-
specifically PEGylate TMLPETG.  Due to the short length of the sortase recognition motif 
LPETG and fast reaction times afforded by 5’ SrtA, a feasible future direction would be 
translating this technique for PEGylation of a broad range of protein therapeutics in the 
biopharmaceutical industry is to tailor stability and half-life characteristics.   
We next optimized the reaction concentrations of the amine nucleophiles required 
to achieve maximal transpeptidation after 2 h reaction time.  TMLPETG was reacted with 
0.1 molar excess 5’ SrtA and either 1-fold, 10-fold, or 100-fold molar excess 5kDa PEG-
amine for 2h.  These studies show that the 100-fold molar excess of alkyl-amine 
nucleophiles was a requisite reaction parameter in this approach, as 1 and 10 molar 
equivalents of 5kDa PEG-amine did not facilitate significant levels of the 




Figure 5.8.  SDS-PAGE gel tracking of wild-type (WT) S. Aureus sortase A (SrtA) 
catalyzed transpeptidation of an amine-PEG113 (MW 5kDa) to thrombomodulin 
expressing a C-terminal LPETG peptide motif (TMLPETG) for 2 h or 20 h reaction time.  




Figure 5.9.  SDS-PAGE gel tracking of pentamutant S. Aureus sortase A (5’ SrtA)-
catalyzed transpeptidation of 1x, 10x, or 100x molar excess amine-PEG113 (MW 5kDa) 
relative to thrombomodulin expressing a C-terminal LPETG peptide motif (TMLPETG) for 
5 min or 2h reaction time.  Notations: M – molecular weight markers. 
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We observed the formation of slight quantities of higher molecular weight 
proteins, as evident by staining at ~40kDa, when lower quantities of alkylamine 
nucleophiles were present.  This minor product may be due to 5’ SrtA catalyzed 
conjugation of TMLPETG to either the ε-amine of lysine residues or the N-terminal amine 
present on TMLPETG or 5’ SrtA.  A 100-fold molar excess of alkylamine nucleophiles 
appears to minimize these side reactions.   
The high molar excess of required nucleophiles may be due to the high Km, GGG = 
2,900 µM exhibited by 5’ SrtA, which was about 20 times higher than WT SrtA [394].  
We do not anticipate this will be a significant hurdle in our studies, as the high molar 
excess of unreacted biotin or azide tagged PEG-amine probes can be easily removed by 
established dialysis methods due to their small molecular weight (< 1 kDa).  While 
sortase-catalyzed transpeptidation with primary amines on the LPETG tagged protein to 
form protein-protein conjugates does occur, this is highly inefficient perhaps due to steric 
hindrance or suboptimal pKa, which both influence the nucleophilic resolution of the 
sortase acyl-intermediate.  The His-tagged 5’ SrtA was removed by applying the crude 






Figure 5.10.  SDS-PAGE gel tracking of the removal of 5’ SrtA (~17kD) from the crude 




5.2.2. Immobilization of Azide Tagged Molecules by Copper-free Click Chemistry 
We next focused our efforts to optimize the surface chemistry to tether TM-PEG-
N3 to the luminal surface of small-diameter ePTFE grafts.  Since terminal sterilization of 
modified surfaces is a crucial enabling step in the clinical translation of our approach, we 
transitioned away from Staudinger Ligation due to the tendency of triphenylphosphines 
to degrade by air oxidation [396].  Emerging copper-free strain promoted [3+2] 
cycloaddition is increasingly utilized in as a bioorthogonal chemistry method in 
biological applications [397].  Optimization of strain promoted cyclooctynes has yielded 
variants that exhibit substantially higher reaction kinetics than Staudinger Ligation, while 
maintaining similar levels of bioorthogonality [398].  DBCO has been among the most 
well characterized alkynes suitable for strain promoted [3+2] cycloaddition and has been 
commercialized for cell imaging applications [399].  We synthesized a DBCO-PEG11-
NH2 linker that enabled the functionalization of the luminal surface of 4 mm i.d. ePTFE 
vascular grafts as well as thin solvent-cast polyurethane films with DBCO anchor groups 
using an approach reported previously [389] and outlined in Figure 5.11.  
We hypothesized that DBCO modified substrates could be sterilized with ethylene 
oxide without affecting its reactivity with azide-tagged biomolecules, and as a first step, 
we tested the conjugation of rhodamine-azide (Rh-N3) to thin polyurethane films 
modified with DBCO.  Using a similar sequential surface modification approach as 
outlined in Figure 5.11 for polyurethane coatings, we modified thin polyurethane films 
with DBCO and performed standard ethylene oxide (EtO) sterilization protocol, and 
reacted films with azide tagged rhodamine as a colorimetric readout.  UV-vis absorbance 
of modified films was measured using an adaptor built in house, which showed that EtO 
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sterilization did not diminish the quantity of immobilized Rh-N3 (Figure 5.12), and 
moreover, non-specific reactivity with rhodamine B was minimal.   
Next, we quantitatively determined the stability of the cyclooctyne modified 
surfaces and further demonstrated the broader applicability of this surface engineering 
platform to attach azide-PEG3-biotin on ePTFE grafts modified with cyclooctyne.  We 
developed a streptavidin-HRP based quantification system to measure the surface density 
of biotin on small ePTFE segments, which corroborated our qualitative findings with 
rhodamine-azide by demonstrating no significant change in the immobilized biotin 
surface density on ePTFE grafts surfaces subjected to ethylene oxide sterilization (Figure 
5.13).  The combination of these results show that terminal ethylene oxide treatment is a 
viable method to sterilize cyclooctyne modified surfaces without reducing their capacity 
to immobilize azide-tagged biomolecules. 
Covalent immobilization of TM-N3 was validated on 4 mm i.d. ePTFE grafts 
modified with DBCO.  Non-specific reaction of DBCO with TMLPETG was minimal, and 
EtO sterilization did not diminish the activity of subsequently immobilized TM-N3 
(Figure 5.14A), as measured by the capacity of TM grafts to generate activated protein C 
in the presence of thrombin, protein C, and calcium.  TM grafts exhibited ~15 ng aPC 
cm-2 min-1 activity, or about 25% higher than previous levels generated by Staudinger 
Ligation of TM-N3 [389].   Using azide tagged rhodamine as a colorimetric readout, we 
confirmed the uniformity and specificity of the copper-free cycloaddition reaction on 




Figure 5.11.  Surface reaction scheme to modify the lumen of expanded 
poly(tetrafluoroethylene) vascular grafts with dibenzocyclooctyne (DBCO) that 
facilitates strain-promoted [3+2] cycloaddition to immobilize any azide-modified 




Figure 5.12.  UV-vis spectroscopy of polyurethane (PU) films functionalized with 
dibenzocyclooctyne (DBCO) and reacted with rhodamine-azide (Rh-N3) or rhodamine B 




Figure 5.13.  Surface density of biotin-PEG3-N3 immobilized on EtO treated and non-






Figure 5.14.  (A) Surface bioactivity of thrombomodulin to produce activated protein C 
(aPC) immobilized on EtO treated and non-treated ePTFE grafts modified with DBCO.  






5.2.3. Biological Function of Modified ePTFE Grafts to Resist Thrombosis 
 Next, we tested the functional capacity of TM modified ePTFE grafts to inhibit 
thrombosis in vivo.  Chronic arteriovenous shunt models in baboons, whose hemostatic 
systems most closely mirror that of man [400], are routinely used to assess the 
thrombogenicity of blood contacting materials under dynamic flow in vivo.  We have 
previously demonstrated a multi-compartment shunt configuration that inserted an 
upstream prothrombotic graft segment that served as a source of thrombin generation to 
test the therapeutic function of aPC generated in a downstream TM graft segment [389].  
Due to the presence of tissue injury at the graft anastomosis which express highly 
thrombogenic tissue factor and collagen motifs [401], this shunt configuration (Figure 
5.15) may be more representative of the in vivo thrombogenic stress exerted on implanted 
graft materials. Thrombogenicity of materials was evaluated by radioscintigraphy 
measuring the real-time deposition of radio-labeled autologous platelets on the luminal 
surface of plain ePTFE, TM modified ePTFE, as well as commercial heparin modified 
ePTFE.   
 In our model, an upstream segment of Dacron served as a thrombogenic stress 
source, which was prone to platelet deposition as evident by steady accumulation over a 1 
h perfusion period (Figure 5.16A).  In this model, TM modified 4 mm i.d. ePTFE graft 
segments significantly reduced the deposition of platelets on the plain ePTFE graft 
surface by nearly 80% (Figure 5.16B), which was significantly greater than the ~50% 
reduction in platelet deposition on commercial heparin modified ePTFE relative to plain 
ePTFE graft.  These results support our hypothesis that a surface TM assembly attenuates 
thrombogenesis at a blood-contacting interface.  In our previous surface chemistry 
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platform where TM-N3 generated by incorporation of azidohomoalanine was site 
specifically immobilized by Staudinger Ligation, no change in platelet deposition was 
observed downstream of a thrombogenic graft source [389].  This may be a consequence 
of the ~25% improvement in the catalytic activity of the TM grafts generated by the 




Figure 5.15.  Baboon arteriovenous shunt model and the 2-compartment test bed to 
measure the real time deposition of platelets on modified expanded 
poly(tetrafluoroethylene) (ePTFE) grafts in the presence of an upstream prothrombotic 




   
     
Figure 5.16.  (A) Quantity of platelets deposited over a 1 h perfusion period on the 
Dacron segment.  (B) Quantity of platelets deposited over a 1 h perfusion period on plain 
ePTFE controls, heparin modified Propaten grafts, and TM modified grafts.  Notations: * 
p < 0.05, ** p < 0.01. 
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 Although minimal deposition of platelets has been observed in the past on heparin 
modified ePTFE in a primate A-V shunt model [402], this model lacked the upstream 
Dacron segment which provided a more robust test bed in our model as it is more 
representative of tissue trauma and injury at the anastomosis.  However, due to the 
complexities involved in the activation of thrombosis in vivo, the impact on long term 
patency and performance of small diameter vascular grafts from the reduction in platelet 
deposition afforded by TM immobilization will need to be evaluated in surgically 
implanted bypass configurations in relevant animal models. 
5.3. Conclusions 
 In summary, we have described a surface engineering platform that enables the 
attachment of biologically active enzymes on terminally sterilized materials, and 
demonstrated the superior in vivo thromboresistant efficacy of a TM film compared with 
current commercial heparin coatings on the luminal surface of small diameter 
commercial ePTFE grafts.  Although further studies are required to evaluate the impact of 
our surface engineering strategy on long term durability, we anticipate the combination of 
our approach to attenuate acute thrombosis with emerging development in bioactive 
surface modifications that induce spontaneous endothelialization [403] would produce a 
new generation of blood-compatible materials to improve the performance of implantable 
devices and artificial organ systems.   
5.4. Methods 
5.4.1. Generation of TMLPETG   
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The minimal fragment of human thrombomodulin, the epidermal growth factor-
like domains 4 – 6 (TM456) was cloned into the Sigma pFLAG ATS expression vector.  
Amino acid changes relative to the native TM456 sequence is colored red: 
TMLPETG (15.2 kDa) 
MKKTAIAIAVALAGFATVAQA
Note that highlighted in blue and underlined is the OmpA tag that facilitates 
transport of TMLPETG to the periplasmic space of E Coli to optimize folding, this 
sequence is cleaved in final mature TMLPETG.  The FLAG peptide sequence is 
DYKDDDDK at the N-terminus.  It has been previously demonstrated that the 






404].  A second mutation was made to convert the internal RH sequence, which is an 
active trypsin cleavage site, to GQ.  The additional sequence at the C-terminus includes a 
GGGGSGGGGS spacer and the LPETG sortase recognition motif.  An extra glycine was 
added at the C-terminus as this was previously demonstrated to maximize sortase 
activity. 
Following transformation of chemically competent cells, a fresh LB agar plate 
was streaked with methionine auxotrophic cells containing the appropriate TM vector and 
incubated at 37 ºC overnight. Next, a single cell colony was inoculated into 50ml of 
Novagen media supplemented with 0.4 % glucose and 50 μg/ml ampicillin and cultured 
at 37 ºC, 225 RPM, for 16 h.  25 ml of fully grown starter culture (OD600 = 1.20) was 
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added per 500 ml of Novagen media supplemented with 0.4 % glucose and 50 μg/ml 
ampicillin, and cultured at 37 ºC, 225 RPM.  Upon cell growth to OD600 = ~0.9, IPTG 
was added at a final concentration of 1mM to induce TMLPETG expression, and the culture 
was incubated for an additional 4 h at 37 ºC, 225 RPM.  Cell cultures were centrifuged at 
4,000x RCF at 4 ºC for 10 minutes and stored at 4 ºC. 
Standard osmotic shock protocol was performed on stored cell pellets to extract 
the crude periplasmic proteins.  Cell pellets were first warmed to room temperature and 
re-suspended in 40 ml/g cells of 0.5 M Sucrose, 0.03 M Tris-HCl (pH 8.0) at a final pH 
of 8.0 per gram of cells.  Suspended cells were evenly distributed into round bottom 
centrifuge tubes (60 mL per tube).  120 µL of 500 mM sucrose was added to each tube to 
achieve final 1 mM EDTA concentration and incubate with gentle shaking for 10 minutes 
at RT.  The cell suspension was centrifuged at 3,500x g for 10 min at 10 °C, and the 
supernatant was decanted.  The cell pellet was rapidly resuspended in 25 ml/g cell pellet 
ice-cold, distilled water (40mL per tube is sufficient) for 10 minutes, and the cell 
suspension was centrifuged at 3,500x RCF for 10 min at 4 °C.  35 ml of supernatant was 
removed per tube immediately and transferred to clean round bottom centrifuge tubes.  
These were clarified by further centrifugation at 25,000x RCF for 25 min at 4 °C, and 
sterilized using a 0.22 µm filtration system.  Anti-FLAG immunoaffinity chromatography 
(Sigma) was performed on the clarified supernatant per manufacturer’s instructions.  
SDS-PAGE analysis, and total protein quantification were performed using standard 
Bradford assay (Bio-Rad) protocols from the manufacturer. 
5.4.2. Bacterial Expression of 5’ Sortase and Wild-type Sortase 
 125 
  The amino acid sequence of the wild-type sortase and 5’ sortase is provided 
below: 












E. coli BL21 transformed with pET29 wild-type sortase or 5’ sortase expression 
plasmids were cultured at 37 °C and 225 RPM in LB media supplemented with 50 μg/mL 
kanamycin.  Upon OD600 = 0.8, IPTG was added to a final concentration of 0.4 mM and 
protein expression was induced for 3 h at 30 °C. The cells were harvested by 
centrifugation and resuspended in lysis buffer (50 mM Tris pH 8.0, 300 mM NaCl 
supplemented with 1 mM MgCl2, 2 units/mL DNAseI (NEB), 260 nM aprotinin, 1.2 μM 
leupeptin, and 1 mM PMSF). Cells were lysed by sonication on ice and the clarified 
supernatant was purified by column chromatography using Cobalt Talon Resin (Clontech 
Laboratories) following the manufacturer’s instructions. Fractions that were >95 % 
purity, as judged by SDS-PAGE, were consolidated and dialyzed against Tris-buffered 
 126 
saline (25 mM Tris pH 7.5, 150 mM NaCl) using PD-10 columns (GE Healthcare) and 
stored as 5 mg/ml stocks at 4 °C. 
5.4.3. Sortase-catalyzed Transpeptidation 
 TMLPETG was reacted with 0.1 or 2 molar equiv WT or 0.1 molar equiv 5’ SrtA 
and 1, 10, or 100 molar equiv NH2-PEG5kDa (Nektar) at room temperature.  At various 
reaction time points, a 2 µg aliquot was removed and frozen at -80 °C.  Upon completion 
of the study, all aliquots were thawed at room temperature and incubated at 100 °C in 1x 
reducing buffer (Fisher Scientific), and run on a 12 % Tris PAGE gel (Biorad) and 
visualized by Coommassie staining. The stained gels were dried and scanned at 1200 dpi 
on an Epson Perfection 1660 photo scanner, and quantification of the extent of TM-PEG 
formation relative to unreacted TMLPETG was performed using the Gel Analyzer function 
in ImageJ software. 
 To generate TM-PEG3-N3 using sortase catalyzed transpeptidation, TMLPETG was 
reacted with 0.1 molar equivalent 5’ SrtA and 100 molar excess NH2-PEG3-N3 (Sigma) 
for 2 h at room temperature.  The crude reaction mixture was run through a 
chromatography column containing Cobalt Talon Resin, and the flow through was 
collected and dialyzed against TBS buffer (20 mM Tris pH 7.5, 100 mM NaCl).  
Following 2 days of dialysis with regular buffer exchanges approximately every 8 h, the 
final reaction mixture was concentrated and the final yield determined by total protein 
quantification per manufacturer’s protocol (Bio-Rad). 
 The extent of azide tagging of TMLPETG was determined by incubating the final 
reaction mixture with excess DBCO-biotin (Invitrogen) overnight at 37 °C.  Unreacted 
DBCO-biotin was removed by 2x sequential dialysis using Zeba Spin Desalting Columns 
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with a 7 kDa MWCO (Fisher Scientific).  Final concentration of the dialyzed reaction 
mixture was determined by total protein quantification per manufacturer’s protocol (Bio-
Rad).  The extent of biotinylation of TM-N3 by DBCO-biotin was determined using a 
fluorescent biotin quantification kit per manufacturer’s instructions (Fisher Scientific).   
5.4.4. Synthesis of NH2-PEG11-CyO 
 The activated cyclooctyne was synthesized according to a previously published 
protocol.  NH2-PEG11-CyO was synthesized by reaction between the activated 
cyclooctyne and t-Boc-N-amido-dPEG11-amine (Quanta BioDesign, Powell) followed 
by TFA deprotection as detailed previously. 
 5.4.5. Modification of ePTFE Grafts  
Following conformal coating of the luminal surface of 4 mm i.d. ePTFE grafts 
with a 50 µm thick polyurethane coating as detailed elsewhere, grafts where incubated 
with 16 % v/v hexamethylene diisocyanate and 4 % v/v triethylamine in anhydrous 
toluene for 1 h at 50 °C.  Following rinsing in toluene, grafts were reacted with NH2-
PEG11-CyO at 5 mg/ml in anhydrous toluene with 1 % v/v DMSO for 16 h at 40 °C, then 
rinsed in toluene and dried under vacuum for 24 h at RT.   
Ethylene oxide sterilization was carried out by the Beth Israel Deaconess Medical 
Center.  For rhodamine binding studies, CyO modified ePTFE grafts were reacted 
1mg/ml tetramethylrhodamine-5-carbonyl azide in 1:4 tert-butanol/TBS at 37 °C for 24 h 
followed by rinsing in methanol for 2 days.  For TM binding studies, CyO modified 
ePTFE grafts were reacted with 20 µM TM-PEG3-N3 in TBS at 37 °C for 24 h and rinsed 
with TBS for 24 h.  For biotin binding studies, CyO modified ePTFE grafts were reacted 
with biotin-PEG-N3 in TBS at 37 °C for 24 h followed by rinsing in TBS for 24 h. 
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5.4.6.  Modification of Polyurethane Films 
Thin clear PU films were solvent cast by drying 12.5 % w/v Elasthane 80A in 
DMF for 24 h at 60 °C under vacuum.  Films were subjected to isocyanate, TPP, and 
rhodamine reactions using identical conditions as graft substrates, and characterized by 
UV-Vis spectroscopy (Cary 50 Bio UV-visible spectrophotometer, Varian) using an 
adaptor built in house that comprises two quartz slides to sandwich the modified PU 
films. 
5.4.7. Graft aPC Generation Assay 
A 4 mm segment was incubated in 200 µL of 0.2 µM protein C (Calbiochem, 
Gibbstown), 5 mM calcium chloride, and 2 nM α-thrombin (Haematologic Technologies, 
Essex Junction) in Tris buffer (20 mM Tris, 100 mM NaCl, pH 7.5) with 0.1 % bovine 
serum albumin at 37 °C for 1 h, and quenched with human anti-thrombin III (American 
Diagnostica, Stamford) at 120 µg/mL final concentration for 5min.  The concentration of 
aPC was determined using Spectrozyme PCa (American Diagnostica) at 0.2 mM and 
extrapolating the rate of absorbance at 405 nm increase with a standard curve.  TM 
activity was assayed after coated grafts were exposed to 24 h of 500 s-1 shear with PBS at 
37 °C generated by a peristaltic flow loop, and after grafts were incubated in PBS over 
two weeks at 37 °C. 
5.4.8. In Vivo Baboon Arteriovenous Shunt Model 
Chronic exteriorized Silastic tubings were implanted in male baboons as 
described previously [27, 29].  All studies were approved by the Institutional Animal 
Care and Use Committee at Oregon Health and Science University.  Mean blood flow 
rate through the shunt was measured continuously using a Doppler ultrasonic flow meter 
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and held constant by an external screw clamp at 100 ml/min.  Autologous platelets were 
radiolabeled one day prior to shunt study with Indium-111 oxine and re-injected into the 
baboon [29].  Platelet deposition on test surfaces was measured over a 60-minute 
perfusion period using a high sensitivity 99Tc collimator and scintillation camera (GE 
400T, General Electric) imaging of the 172 keV 111In g photon peak at 5-min intervals.  
Thrombogenic devices were assembled and inserted into shunts similar to previous 
configurations [27] and detailed below. 
5.4.9. Preparation of Thrombosis Test Devices 
  The device consists of 3 parts: (1) 2 cm, 4 mm i.d. Dacron segment, (2) a test 
segment of 4 mm i.d. thin wall ePTFE control graft of 7 cm length, or 4 mm i.d. TM or 
Propaten heparin coated graft of identical length, (3) 1 cm, 10 mm i.d. chamber 
constructed from ePTFE graft material. 
 A 4 mm i.d. Teflon rod was inserted into a 6in. length of 4 mm silicone tubing 
until it protrudes about 3 cm beyond the silicone.  A thin bead of undiluted silicone glue 
was placed around the silicone tubing edge and a 2 cm Dacron segment was slid onto the 
rod into the glue until some of the glue squeezes out.  More glue was placed around the 
joined section and smoothed out.  This joint was cured for several hours and covered with 
thin diluted silicone glue, and then cured overnight. 
 Test graft segments were glued to the Dacron section in the next step.  First, a 3-4 
mm sleeve of silicone tubing 4.76 mm i.d. / 7.94 mm o.d. was cut, and slid over one end 
of the test segment.  A bead of silicone glue (undiluted) was placed on the other end of 
the Dacron segment with the rod still extending through the Dacron.  The test segment 
was then slid onto the rod and pushed into the glue, and the small tubing ring was slipped 
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onto the rod over the test segment until it fits snugly next to the Dacron segment.  More 
thick glue was placed around this joint and smoothed out, and another thin bead of thick 
glue was placed next to the silicone ring around the test segment.  This setup was let cure 
for several hours, and the whole Dacron segment was covered with thin glue and cured 
overnight, and the rod was then removed. 
 The expansion chamber parts were prepared by cutting a 2 cm length of 10 mm 
i.d. ePTFE graft using a new razor blade, and the center 1 cm section was marked by 
placing small dots circumferentially around the outside of the graft segment and set aside. 
 A 4 mm i.d. silicone tubing was inserted into another silicone tubing of 6.35 mm 
i.d. and 9.53 mm o.d. tubing about 7 mm deep.  Both tubing were cut about 5 mm from 
the end of the larger diameter tube.  The 4 mm i.d. tubing that is protruding about 5mm 
from the large tubing end was cut to leave a 1 cm section.  A short 4 mm Teflon rod was 
inserted from the blunt end onto the just prepared section protruding about 5mm, and a 
304 mm segment of silicone tubing 4.76 mm i.d. and 7.94 mm  o.d. was slipped over the 
free end of the test section of ePTFE.  A bead of glue was placed on the end of the short 
segment on the rod and slipped on the ePTFE section over the rod butting the ends, and 
then the sleeve was slipped onto the rod to form a seal.  More thick glue was placed 
around this joint and smoothed out.  A thin bead of thick glue was placed on the ePTFE 
graft next to the sleeve to form a seal, and cured for several hours.  Next thin glue was 
spread carefully in a line around the 9.53 mm o.d. tubing about 2 mm from the end.  The 
expansion chamber segment prepared earlier was slipped over this section up to the 
dotted line, and sealed with thin glue and dried overnight. 
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 The Teflon rod was removed and 10 µL of Chronolog collagen (1 mg/mL) was 
placed on the inside of the chamber on the silicone tubing and let dry.  The other side of 
the chamber was prepared by inserting a 4 mm i.d. silicone tubing into a 6.35 mm i.d. and 
9.53 mm o.d. tubing about 7 mm deep, and both tubing were cut about 5mm from the end 
of the larger diameter tube in a similar fashion as described above.  A line of thin glue 
was placed around the 9.53 mm o.d. large tubing and inserted into the open end of the 
expansion chamber up to the marked end leaving a 1 cm chamber section.  Thin glue was 
used to seal the joint and this was cured overnight, and the device was then inserted into 
the A-V shunt.  
5.4.10. Statistical Analysis 
Two-tailed student’s t-test assuming unequal variances was used to test for 
statistical significance between the means of two groups.  
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CHAPTER 6 
A RECHARGEABLE SURFACE ENGINEERING PLATFORM ENABLED BY 
DIRECTED EVOLUTION OF STAPHYLOCOCCUS AUREUS SORTASE A 
 
Enzyme immobilization has shaped the development of modern industrial 
catalysis and bioprocess engineering, and is revolutionizing the design of medical device, 
diagnostics, and artificial organ systems.  Long term performance of bioactive surface 
enzyme assemblies is limited due to degradation in the operating environment by stresses 
that include, among others, oxidation, hydrolysis, and proteolysis.  In this work, we 
present a bioinspired surface engineering platform utilizing reversible sortase-catalyzed 
transpeptidation to regenerate immobilized enzymes by a repeatable charge/strip cycle.  
The enhanced activity and bioorthogonality of a mutant sortase generated by directed 
evolution was an enabling step in facilitating the in vivo immobilization and removal of 
biomolecules on medical catheters deployed in mice.  These findings establish a new 
reversible enzyme immobilization paradigm, which may broadly impact the performance 
characteristics of solid-supported enzymes as components in emerging biomedical 
technologies or industrial bioprocesses. 
6.1  Introduction 
 Medical devices in blood contacting applications such as extracorporeal support 
systems, vascular access, and permanent implants are prone to life threatening 
complications initiated by maladaptive host biological responses at the blood-material 
interface [346, 405].  Immobilization of bioactive molecules and drug eluting assemblies 
on implantable devices has yielded promising combination products that mitigate 
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thrombotic cascades and detrimental inflammation [11], enhance device integration and 
regeneration of healthy tissue [5, 403], and inhibit microbial colonization [406].  Clinical 
translation of these strategies for permanent implants has been constrained, in part, by the 
limited therapeutic duration afforded by a finite surface reservoir of bioactive agents, as 
well as degradation of surface components following exposure to the physiological 
environment [70, 407].  Efforts to improve biostability and bioactivity have included the 
manipulation of surface properties such as hydrophilicity, charge, and topography [408], 
immobilization chemistry [409, 410], as well as rational and evolutionary protein 
engineering [411].  Despite advances in these areas, a surface coating for implantable 
devices that reliably retains biological activity for a commercially and clinically viable 
time scale have not been developed.  As a potential workaround, systemic delivery of 
bioactive therapeutic payloads that target the blood contacting surface of the implant 
facilitates in situ regeneration of bioactivity.  This concept has been explored extensively 
in alternate clinical applications such as targeted drug delivery [412, 413], molecular 
imaging [414], and minimally invasive cell therapy [415].  In the present study, we report 
for the first time a highly specific, covalent, and rapidly “rechargeable” surface 
engineering platform that enables regeneration of depleted or degraded biomolecules at a 
blood-material interface in vivo. 
Current techniques to covalently modify surfaces with bioactive compounds have 
largely involved bioconjugate techniques that link nucleophilic motifs such as amines, 
thiols, and hydroxyls to their partner electrophiles [416].  Abundant presentation of these 
motifs in the complex chemical landscape of biological systems reduces the efficiency of 
targeting payloads for regenerating these device surfaces [417].  Recent advances in rapid 
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and highly bioorthogonal chemistries, notably Staudinger Ligation and copper-free click 
cycloaddition [418], have facilitated coupling of azide-tagged targets in living systems.  
These irreversible bond-forming reactions would increase the complexity of regenerating 
the covalent chemical anchor sites in vivo.  Our platform is inspired by the 
Staphylococcus Aureus sortase A (SrtA), a calcium dependent cysteine transpeptidase 
which catalyzes covalent ligation of a specific “sorting motif” LPXTG (where X denotes 
any amino acid) on substrate proteins to oligoglycine nucleophiles [419].  Due to the 
synthetic simplicity of incorporating oligoglycine and LPXTG motifs on biomolecules, as 
well as the very limited occurance of sorting motifs in native proteins, SrtA-catalyzed 
transpeptidation is increasingly used in a range of biotechnology applications including 
protein purification, labeling, as well as immobilization on solid supports as reviewed 
elsewhere [393, 420].  However, the low catalytic activity of wild type (WT) SrtA 
necessitates high molar excess of the enzyme as well as long incubation times to 
approach reaction completion, thereby, limits the effectiveness of this system [393].  We 
show that an evolved pentamutant SrtA (5’SrtA) variant which exhibited 140-fold higher 
LPETG-ligation activity than WT SrtA [394] was a critical enabling technology for ex 
vivo and in vivo modification of oligoglycine modified surfaces.  We demonstrate the 
superior capacity of 5’ SrtA over WT SrtA to catalyze multiple cycles of rapid assembly 
of LPETG tagged recombinant human thrombomodulin (TM) on pentaglycine modified 
surfaces (Figure 6.1), as well as regeneration of the pentaglycine motifs by stripping the 
immobilized TM using 5’SrtA and triglycine (GGG) peptide (Figure 6.2).  The 
performance of this rechargeable surface engineering platform was further validated in 
vivo by 5’SrtA-catalyzed reversible modification of cannulated catheters in mice. 
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Figure 6.1.  Reaction scheme to modify polyurethane with pentaglycine (GGGGG) 
peptide motifs.  (1) hexamethylene diisocyanate / triethylamine; (2) DBCO-amine / 





Figure 6.2.  Reaction scheme to charge and strip pentaglycine (GGGGG) modified 





6.2.  Results and Discussion 
6.2.1. Reversible Assembly of TMLPETG on Model Surfaces 
 In order to demonstrate the rechargeable surface assembly of biologically active 
enzymes, we have expressed and purified a C-terminal LPETG tagged recombinant 
human thrombomodulin fragment (TMLPETG), which represents a major physiological 
anticoagulant mechanism localized on the endothelial cell lining [19, 356].  Blood-
contacting materials functionalized with TM by our lab and others exhibited resistance to 
thrombosis in vitro and in vivo [228, 230-233, 358-360, 421].  5’ SrtA was generated by 
directed evolution using a yeast display system as described previously [394].  5’SrtA 
enhanced the covalent immobilization density of TMLPETG on model pentaglycine 
modified surfaces by ~10-fold compared to WT SrtA under the same reaction conditions 
(Figure 6.3A).  Further increasing the quantity of WT SrtA used in these reactions by 20-
fold was only able to achieve 40% of the benchmark immobilization density achieved by 
5’SrtA.  By shifting the reaction equilibrium using excess triglycine peptide in solution, 
the immobilized TMLPETG could be stripped off by 5’SrtA to regenerate the pentaglycine 
surface anchors.  On the model pentaglycine surfaces, 5’SrtA dramatically improved the 
surface stripping efficiency compared with WT SrtA, achieving nearly complete removal 
of immobilized TM (Figure 6.3B).  After 1 hour reaction time, 5’SrtA-catalyzed 
immobilization of TMLPETG approached ~50% of levels achieved after 16 hours of 
reaction (Figure 6.4).  The rapid kinetics of 5’SrtA-catalyzed immobilization approached 
that of avidin-biotin mediated immobilization of biotinylated TM in a parallel reaction.  
Following SrtA-catalyzed stripping to regenerate pentaglycine anchor motifs on model 
surfaces, additional recharging using 5’ SrtA and fresh TMLPETG was demonstrated 
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without significant decreases in the surface density. This charge/strip cycle of TMLPETG 
can be repeated at least 10 times (Figure 6.5).   
To assess the feasibility of translating our platform for in vivo surface 
modification, the reaction media was switched to whole blood diluted to 50% with 
5’SrtA, TMLPETG, and heparin without additional calcium. Following 1 hour reaction at 
37 ºC, we observed a decrease in surface coupling efficiency of 5’SrtA, which required a 
5-fold greater concentration to generate similar surface densities as the Tris buffer 
system.  The TM surface density levels achieved by 5’SrtA were ~20-fold higher relative 
to WT SrtA under identical conditions (Figure 6.6).  Increasing the molar excess of WT 
SrtA 20-fold yielded ~60% of the benchmark surface density generated by 5’ SrtA.  
These results highlight the impact of rapid kinetics and substrate specificity afforded by 
5’ SrtA to modify surfaces in the presence of extremely heterogeneous whole blood 





Figure 6.3.  Sortase-catalyzed rechargeable assembly of LPETG labeled 
thrombomodulin (TMLPETG) on pentaglycine modified model surfaces.  (A) 
Immobilization of 1µM TMLPETG on pentaglycine coated microwells using 0.1 molar 
equivalents evolved 5’ sortase, 0.1 and 2 molar equivalents wild-type (WT) sortase, or no 
sortase as a negative control.  (B) Following immobilization of 1µM TMLPETG on 
pentaglycine coated microwells using 0.1 molar equivalents evolved 5’ sortase, removal 
of bound TM was carried out using 20 µM of either evolved 5’ sortase or WT sortase 





Figure 6.4.  Sortase-catalyzed binding of TMLPETG on pentaglycine modified model 
surfaces following 1 and 16 hour reaction were compared with the binding of TM-biotin 
directly on streptavidin coated microwells.  In parallel, TMLPETG was incubated in 
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Figure 6.5.  Sequential 5’ sortase-catalyzed charging (filled red diamonds) and stripping 








                
 
Figure 6.6.  Direct sortase-catalyzed assembly of TMLPETG in 50% v/v heparinized whole 
blood (20 U heparin/mL blood) at 37°C for 1 hour without additional calcium.  Evolved 
and wild-type (WT) sortases were tested at 2 different TMLPETG concentrations as well as 
TMLPETG/sortase ratios, as summarized in the table of reaction conditions.   





6.2.2. Sortase-catalyzed Modification of Catheters In Vivo 
Recharge of oligoglycine modified catheters deployed in mice with LPETG-
tagged probes was tested as a proof-of-concept.  We modified polyurethane catheters 
with pentaglycine anchor motifs using a sequential scheme similar to a previous report 
(Figure 6.1) [389].  Free isocyanate motifs were first generated on the catheters by 
reacting hexamethylene diisocyanate with the polyurethane, and subsequently converted 
to dibenzylcyclooctyne (DBCO) anchor sites using a commercial amino-DBCO linker.  
Commercial rhodamine-azide was used as a test probe to verify the azide-reactivity of 
DBCO modified catheters (Figure 6.7).  We then reacted NH2-GGGGG-N3 to DBCO 
modified catheters to display the pentaglycine motifs for SrtA-catalyzed transpeptidation.  
Optimal reaction parameters that maximize SrtA-catalyzed charging and stripping of 
catheters were first determined ex vivo by fluorescent detection of a biotin-LPETG probe 
using Cy3-labeled streptavidin (Figure 6.8 – 6.10).  Using these optimal reaction 
conditions as a starting point, we performed deployment of pentaglycine-modified 
catheters in the vena cava of mice and verified the in vivo capacity of 5’SrtA-catalyzed 
transpeptidation to reversibly immobilize LPETG-tagged probes (Figure 6.11A).  
Immobilization of biotin-LPETG on GGG-catheters for 1 hour following remote IV 
delivery through the penile vein was verified using streptavidin-Cy3 and fluorescent 
imaging (Figure 6.11B).  Removal of LPETG-tagged Alexa Fluor 750, a near IR 
fluorescent probe, by remote IV delivery of GGG peptide and 5’SrtA was monitored by 
real time fluorescent in vivo imaging, which showed a surface depletion half life of 
approximately 50 minutes (Figure 6.12).  Local delivery of reagents for 
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charging/stripping GGG modified catheters was demonstrated using biotin-LPETG 







Figure 6.7.  Verification of the presence of dibenzocyclooctyne (DBCO) motifs on the 
surface of polyurethane catheters following modification.  (i) DBCO catheters reacted 
with rhodamine azide; (ii) plain catheter reacted with rhodamine azide; (iii) DBCO 






              
Figure 6.8.  (A) Merged fluorescent and bright field microscopy of polyurethane 
catheters modified with pentaglycine motifs, and reacted with various concentrations of 
biotin-LPETG peptide for 30 minutes or 1 hour.  Pentamutant sortase was kept at a 
constant 0.1 molar equivalent ratio relative to biotin-LPETG. Cy3-streptavidin was 
incubated at 0.1mg/ml with catheters for 30 minutes to assess the surface density of 
biotin.  (B) Fluorescence intensity was measured using Image J and expressed as mean ± 




Figure 6.9.  (A) Merged fluorescent and bright field microscopy of polyurethane 
catheters modified with pentaglycine motifs, reacted with biotin-LPETG, and finally with 
various concentrations of GGG peptide and 5’ SrtA as summarized in (C).  Cy3-
streptavidin was incubated at 0.1mg/ml with catheters for 30 minutes to assess the surface 
density of biotin.  (B) Fluorescence intensity was measured using Image J and expressed 





Figure 6.10.  (A) Merged fluorescent and bright field microscopy of polyurethane 
catheters modified with pentaglycine motifs, reacted with biotin-LPETG, and finally with 
various concentrations of GGG peptide and 5’ SrtA as summarized in (C).  Cy3-
streptavidin was incubated at 0.1mg/ml with catheters for 30 minutes to assess the surface 
density of biotin.  (B) Fluorescence intensity was measured using Image J and expressed 






Figure 6.11.  Sortase-catalyzed reversible covalent assembly of LPETG labeled probes 
on pentaglycine modified catheters deployed in vivo.  (A) A 1 F catheter modified with 
GGG peptide was inserted into the iliac vein and deployed ~1 cm into the inferior vena 
cava of heparinized C57BL/6 mice.  Administration of all reagents was carried out 
directly through the catheter or remotely through the penile vein.  (B) Charge reaction 
was tested by remote IV delivery of biotin-LPETG peptide (50 µg) and 5’ SrtA (70 µg) 







Figure 6.12.  Catheters modified with GGG peptide and conjugated with LPETG labeled 
Alexa Fluor 750 was stripped using remote IV delivery of triglycine (400 µg) and 5’SrtA 
(700 µg).  (A) The NIR fluorescent signal from the modified catheter was monitored 
using the Maestro multi-spectral fluorescence imaging system, and (B) quantitative 








Figure 6.13.  Fluorescent imaging of cannulated catheters subjected to in vivo 
modification by sortase-catalyzed transpeptidation.   Biotin-LPETG probes were used to 
functionalize GGG modified catheters via transpeptidation, and streptavidin-Cy3 was 
used to detect the presence of biotin.  (A) A fully biotinylated catheter, (B) a biotinylated 
catheter deployed in a mouse with intravenous injection of 400µg triglycine and 700µg 5’ 
SrtA, (C) a GGG modified catheter deployed in a mouse with intravenous injection of 
50µg biotin-LPETG and 70µg 5’ SrtA, (D) a GGG modified catheter deployed in a 
mouse with intravenous injection of 250µg biotin-LPETG and 350µg 5’ SrtA.  Arrows 
bracket the insertion length of the catheter into the mouse vena cava. 
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6.3.  Conclusions 
Immobilization of TM at blood-contacting interfaces may be a key step in the 
development of a new generation of blood compatible synthetic materials[11, 389].  In 
particular, we have recently demonstrated in a clinically relevant baboon shunt model of 
acute graft thrombosis the superior efficacy of immobilized TM to reduce deposition of 
platelets, compared with commercial heparin modified grafts.  Long term bioactivity of 
TM films may be depleted over time by the harsh in vivo environment.  A two-step 
strip/recharge cycle to regenerate immobilized TM may be a potential strategy to extend 
the life time of bioactive films in vivo.  We conclusively showed the enhanced efficacy of 
the evolved sortase variant 5’SrtA over WT SrtA in our demonstration of reversible 
immobilization of TM in vitro.  Notably, the covalent bond-forming kinetics of 5’SrtA-
catalyzed transpeptidation was similar to avidin-biotin binding interactions.   
Although we demonstrated the robust regenerative capacity of pentaglycine 
surfaces over repeated strip/recharge cycles without reducing the fresh TM surface 
densities in vitro, the efficacy of 5’SrtA will likely decrease over time in vivo as 
suggested by the reduced immobilization efficiency of 5’SrtA in whole blood.  
Transpeptidation efficiency in vivo may be reduced by competitive surface adsorption of 
blood constituents that sterically hinder access to the LPETG sorting motif, and possibly 
competitive substrate competition due to presence of alkylamine nucleophiles that also 
react with SrtA [422].  Further enhancement of the catalytic activity and specificity of 
5’SrtA by directed evolution under serum conditions as well as at 37 ºC are underway to 
overcome these limitations. 
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The animal model used in this study was intended as a proof of concept system to 
validate the reversible 5’SrtA’s catalyzed transpeptidation in vivo, and does not fully 
recapitulate the operative time and conditions of clinical procedures.  Although remote 
IV delivery of reagents was tested to validate our approach, local recharging strategies 
may maximize the concentration at the catheter site and thereby shorten the reaction 
times observed in vivo.  Moreover, by isolating the site of reaction, the likelihood of 
systemic exposure to 5’SrtA will be minimized.  The immunogenicity of systemically 
delivered sortase is unknown and would require further evaluation. 
In summary, we have determined that SrtA-catalyzed transpeptidation of LPETG-
tagged agents on pentaglycine modified surfaces enables the capacity to engineer highly 
specific, covalent, and rapidly rechargeable surfaces that can undergo regeneration of 
depleted or degraded biomolecules at a blood-material interface.  An evolved SrtA 
(5’SrtA) was a critical enabling technology in the demonstration of this concept both in 
vitro as well as in vivo.  Due to the facile incorporation of the LPETG and oligoglycine 
tags to therapeutic payload, as well as the relatively ease to introduce oligoglycine 
functionalities onto medical device surfaces, we anticipate this strategy may be applied to 
stripping and regenerating any of a number of potential film constituents that display 
finite stability or activity. 
6.4. Methods 
6.4.1. Peptides   
Synthesis of NH2-GGGGG-N3, NH2-GGGGG-biotin, biotin-LPETG, and NH2-
LPETG was performed off-site (Genscript, Piscataway), and LPETG tagged Alexa Fluor 
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750 was synthesized using NH2-LPETG and Alexa Fluor 750 succinimidyl ester per 
manufacturer’s instructions (Invitrogen, Carlsbad). 
6.4.2.  Expression of TMLPETG and Sortase Variants 
Detailed DNA sequence, bacterial expression and purification of TMLPETG and 
sortase variants are provided in the methods section of Chapter 5.  Briefly, the DNA 
sequence encoding for the human thrombomodulin epidermal growth factor like domains 
4 – 6 was cloned into pFLAG ATS expression vector (Sigma).  BL21 E Coli (Sigma) 
were transformed with expression plasmid and grown in minimal M9 media 
supplemented with 19 amino acids and 100 µg/ml ampicilin at 37 ºC until OD600 reaches 
~0.8.  IPTG was added to a final concentration of 1mM, the protein expression was 
induced for 4 hours at 37 ºC.  Following cell harvest by centrifugation, the periplasmic 
protein crude was obtained by osmotic shock as detailed elsewhere, and TMLPETG was 
purified by anti-FLAG immunoaffinity chromatography following manufacturer 
instructions (Sigma).  Fractions >95% purity as judged by SDS-PAGE were dialyzed 
against Tris buffer (20 mM Tris, 100 mM NaCl, pH 7.5).  TMLPETG activity was similar 
to previous TM variants developed in our lab which match the full length TM activity.   
6.4.3. Immobilization of TMLPETG on Model Substrates 
Direct sortase-mediated immobilization of TMLPETG on pentaglycine surfaces was 
tested in streptavidin coated 96-well microplates (Pierce, Rockford).  NH2-GGGGG-
biotin was incubated at 200 µM for 1 hour in each well, and washed with TBS (20 mM 
Tris, 100 mM NaCl, pH 7.5) with 0.05 % Tween 20.  1 µM TMLPETG was immobilized by 
0.1 µM or 2 µM SrtA for 1 hour at room temperature.  Stripping of immobilized TM was 
performed using 20 µM SrtA and 1 mM triglycine peptide (Sigma).  SrtA-catalyzed 
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assembly of TMLPETG in heparinized whole blood (20 U/ml freshly drawn blood obtained 
from healthy volunteer by venipuncture) diluted 50% v/v with normal saline containing 
the appropriate SrtA, TMLPETG, or GGG reagents was carried out at 37 °C for 1 hour 
without additional calcium.  The surface density of bound TMLPETG was determined per 
manufacturer’s instructions (American Diagnostica, Stamford).   Moles of EGF5-6 
domains bound to each microwell were calculated by a standard curve generated by 
ELISA kit using known concentrations of TM provided by the manufacturer.   
6.4.4. Modification of Catheters In Vitro 
Polyurethane mouse arterial catheters (SAI Infusion) with a 1F tip were modified 
with DBCO anchor motifs.  Catheters were first reacted with 16% v/v hexamethylene 
diisocyanate (HDI) and 4% v/v triethylamine (TEA) in toluene at 50 °C for 1 h and 
rinsed in toluene for 6 h.  Isocyanate activated catheters were reacted with 1 mg/ml 
DBCO-amine linker (Click Chemistry Tools, Scottsdale) and TEA (1% v/v) in toluene at 
40 °C overnight, rinsed with toluene for 6 h, and dried under vacuum at 25 °C overnight.  
DBCO activated catheters were reacted with 1 mg/ml tetramethylrhodamine -5-carbonyl 
azide (Invitrogen, Carlsbad) in 1:4 tert-butanol/PBS at 37 °C for 24 h followed by rinsing 
in methanol for 24 h to confirm surface cyclooctyne reactivity.  DBCO activated 
catheters were reacted with NH2-GGGGG-N3 at 37 °C overnight, and rinsed in TBS 
buffer (20 mM Tris pH 7.5, 100 mM NaCl).  Pentaglycine modified catheters were 
incubated with biotin-LPETG or LPETG-labeled Alexa Fluor 750 peptide (2 µM to 100 
µM) and 0.1 molar equivalents of 5’ SrtA with relative to the LPETG probe 
concentration for 30 minutes or 1 hour, and rinsed for 4 hours in TBS.  Biotinylated 
catheters were incubated in 0.1 mg/ml streptavidin-Cy3 in TBS with 0.05% Tween 20 for 
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30 min, and rinsed overnight in TBS.  Imaging of catheters was carried out using the 
Zeiss Discovery V20 Stereo Microscope, and quantitative image analysis by ImageJ was 
performed to compare the fluorescence intensity between samples. 
6.4.5. Deployment of Catheters in Mice 
Modified polyurethane mouse arterial catheters (SAI Infusion) with a 1F tip were 
first perfused with 2U of heparin, then clamped shut at the infusion end.  The procedure 
begins with opening the mouse abdomen and tying off one branch of the femoral vein 
with a suture.  Next, both the vena cava and the remaining branch of the femoral vein was 
clamped approximately 1cm from the aortofemoral bifurcation.  A separate suture was 
placed closer to bifurcation to provide support for the catheter, which was deployed 
approximately 0.5cm deep into the vena cava followed by releasing of the clamps.  The 
catheter was then delivered 1 – 1.5 cm deep into the vena cava.  
6.4.6.  Dosing of Reagents in Mice 
A 200µl dose of sortase, LPETG tagged probe, and 20U of heparin was injected 
intravenously into the mouse circulation through the catheter.  The dosage required for a 
mouse blood volume of 2 ml was calculated using the optimized concentrations of 
sortase, GGG peptide, and biotin-LPETG from in vitro catheter modification studies.  
After reaction, the catheter was removed and incubated in streptavidin-Cy3 (30 min) and 
washed with buffer (2 h).  Fluorescent and brightfield microscopy images were merged to 
detect biotin groups on the catheter surface.  A Maestro Multi-Spectral in vivo 
fluorescence imaging system with near-IR filter sets was used to detect the Alexa Fluor 
750 modified catheters deployed in the mouse vena cava.  Images were taken using a 
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monochromatic 12-bit camera, and analyzed using ImageJ to quantitatively compare the 
level of fluorescence signal on the catheters. 
6.4.7. Statistical Analysis 
Two-tailed student’s t-test assuming unequal variances was used to test for 




CONCLUSIONS AND FUTURE DIRECTIONS 
 
7.1. Conclusions 
Synthetic conduits in modern arterial reconstructive or bypass surgery based on 
Teflon and Dacron polymers have largely remained unchanged since their inception half 
a century ago, and their incompatibility in small-diameter (< 6 mm id) applications such 
as coronary and lower extremity arterial bypass has been well documented.  Despite 
significant progress towards understanding the physiological elaboration of thrombotic 
cascades elicited by synthetic materials, as well as efforts to functionalize the surface of 
implantable devices with bioactive therapeutics, a generally accepted blood-compatible 
material does not exist.  This status quo has necessitated the use of pharmaceutical 
antithrombotic therapies with substantial cost burdens and bleeding risks in order to 
prolong the life time of synthetic vascular grafts, as well as other implantable devices and 
artificial organ systems that operate in direct contact with blood.  
In this dissertation, we developed surface engineering platforms inspired by 
natural mechanisms contained in the endothelial lining of the circulatory system that 
attenuate thrombosis.  In contrast with heparin, thrombomodulin (TM) is the major 
endogenous inhibitor of thrombin production localized on the endothelial cell surface.  
We developed covalent chemical coupling strategies to immobilize TM on blood-
contacting interfaces, and validated their capacity to inhibit platelet deposition in a 
clinically relevant baboon shunt model of acute graft thrombosis.  Moreover, we 
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demonstrated a reversible chemoenzymatic approach to regenerate depleted surfaces, 
with the potential to extend the life time of biologically active films. 
During the course of these studies, it became apparent that the highly modular 
nature of chemoenzymatic bond-forming reaction enabled by directed evolution of the 
calcium-dependent cysteine transpeptidase Sortase A could be broadly applied in site-
specific bioconjugation as well as surface immobilization reactions.  As such, the 
synthetic simplicity of incorporating LPXTG and oligoglycine sorting motifs would 
facilitate sortase-catalyzed covalent modification of a range of candidate biomolecules, 
such as bioenzymes, peptides, and polysaccharides.  Consequently, the sortase-catalyzed 
bioconjugation schemes presented here have established the use of reversible 
chemoenzymatic bond-formation as a paradigm for future design of medical device, 
diagnostics, drug delivery, and artificial organ systems, as well as development of more 
efficient solid-supported catalysts in industrial bioprocess engineering operations. 
In the first phase of this dissertation, we aimed to optimize surface modification 
strategies to maximize the surface density of anchor sites available for assembly of 
bioactive enzymes.  Layer-by-layer assembly of polyelectrolytes has emerged as a 
powerful and facile method to generate nanoscale architectures on a broad range of 
substrates.  We tested the application of this strategy to incorporate a reservoir of the 
highly negatively charged heparin as a film component.  The exponential growth nature 
of these films may maximize the surface density of chemical handles for downstream 
functionalization.  Film growth behavior of PEM films incorporating heparin was 
explored, and the growth of PEM films on quartz substrates and ePTFE were 
characterized.  Importantly, we showed that simple hydrazone bond forming reactions 
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could covalently crosslink oxidized polysaccharide components to improve the stability 
of the films on quartz substrates, and preserve the primary amine sites on the polycations 
for bioconjugate coupling.  These strategies were translated to modify the luminal surface 
of commercial ePTFE grafts, which yielded films of excellent uniformity and acceptable 
stability under sustained high shears.  Fluorescent probes were conjugated to the primary 
amine on the polycation as a demonstration of the potential anchor site density that could 
be generated on the luminal surface of commercial ePTFE vascular grafts, and the 
outcomes reported here motivate future work to optimize the covalent immobilization of 
biomolecules on these films. 
In the second phase of this dissertation, we hypothesized that the immobilization 
of active catalysts that inhibit generation of thrombin can be assembled on the luminal 
surface of synthetic vascular grafts to abrogate coagulation activation cascades.  
Thrombomodulin, a transmembrane cofactor for thrombin that catalyzes production of 
activated protein C, represents a major physiologically active mechanism on the 
endothelial cell surface to prevent undesirable thrombosis in the circulatory system.  We 
successfully expressed a recombinant human TM fragment (TM456) that contains the 
minimal fragment necessary for catalytic activity, as well as a single C-terminal azide 
which was incorporated by auxotrophic expression in E Coli with the methionine 
analogue homoazidoalanine.  Site-specific immobilization of TM-N3 on the luminal 
surface of commercial 4 mm i.d. ePTFE vascular grafts was carried out by a sequential 
chemical modification procedure that yielded the requisite triphenylphosphine motifs 
necessary for bioorthogonal covalent conjugation to azide, otherwise known as 
Staudinger Ligation.  Using this approach, we were able to demonstrate site-specific 
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immobilization of TM-N3 surface assemblies, which exhibited minimal change in activity 
following 24 h of 500 s-1 fluid shear at 37 °C, as well as after 2 additional weeks of 
incubation at 37 °C in PBS.  These results indicate that the covalent linkage of TM-N3 to 
the graft surface remains stable under prolonged exposure to in vivo arterial shear rates as 
well as physiological pH and temperature.  Moreover, TM modified ePTFE grafts 
exhibited reduced capacity to elicit deposition of platelets compared with non-TM grafts 
in a multi-chamber A-V shunt model in nonhuman primates.  These results indicate that 
the site-specific immobilization thrombomodulin reconstitutes its antithrombotic activity 
to the blood-contacting interface, and may represent an important paradigm in the future 
design of blood-compatible materials. 
  In the third phase of this work, we focused on improving the surface activity of 
TM modified grafts by optimizing both the surface coupling chemistry, as well as 
recombinant engineering of TM-N3.   Specifically, a substitute for auxotrophic expression 
to generate TM-N3, which limits scalability and the selection of bioenzymes that could be 
immobilized, was optimized.  Chemoenzymatic coupling schemes are highly specific and 
rapid, and the bond-forming reaction catalyzed by the calcium-dependent cysteine 
transpeptidase S. Aureus Sortase A has emerged as a powerful tool to covalently modify 
or immobilize proteins containing a short LPXTG “sorting motif”.  We successfully 
expressed a recombinant TM456 variant containing a C-terminal LPETG motif in E Coli 
as a proof of concept.  Notably, this TMLPETG construct could be potentially expressed in 
eukaryotic systems to optimize folding and post-translational modification, and may be a 
key step in adapting our method to standard protein production methods in the 
biopharmaceutical industry.  We unexpectedly discovered that a mutant sortase A (5’ 
 161 
SrtA) variant, which exhibited enhanced catalytic activity, facilitated efficient covalent 
coupling of simple PEG-amine nucleophiles when they are reacted in high molar excess 
relative to TMLPETG.  We confirmed this approach using both a 5kD PEG-amine as well 
as azido-PEG3-amine, which provided an alternate route to generate a single C-terminal 
azide motif on TM for immobilization on medical device surfaces.  Moreover, the 
luminal surface of ePTFE vascular grafts could be modified with dibenzocyclooctyne 
(DBCO) motifs, which facilitate copper-free [3+2] cycloaddition to conjugate azide-
tagged TM.  Following exposure to standard ethylene oxide treatment, immobilized 
DBCO motifs on the luminal surface of commercial vascular grafts retained their 
capacity to undergo [3+2] cycloaddition to bind azide-tagged TM as well as other 
biomolecules such as biotin and rhodamine.  Therefore, copper-free click chemistry 
provides a potential route to enable the clinical translation of our platform to satisfy the 
requisite terminal sterilization procedures used in industrial medical device 
manufacturing processes.  Notably, TM grafts fabricated using this platform significantly 
reduced platelet deposition compared with commercial heparin coated vascular grafts, as 
well as plain grafts in vivo.  The non-human primate model we used to test the blood 
compatibility of heparin and TM modified materials was the first to incorporate a 
thrombotic stress source that is more characteristic of the anastomotic tissue injury that 
occurs during and after graft implantation. 
Long term performance of bioactive surface enzyme assemblies is limited due to 
degradation in the operating environment by stresses that include, among others, 
oxidation, hydrolysis, and proteolysis.  In the final phase of this work, we developed a 
reversible surface engineering approach that could extend the lifetime of TM activity on 
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surfaces, using a bioorthogonal covalent chemistry scheme that facilitates removal of 
activity-depleted TM and regenerating the surface with fresh bioactive TM.  We 
hypothesized that by shifting the reaction equilibrium of sortase A (SrtA), a house-
keeping calcium-dependent cysteine transpeptidase used to anchor cell surface proteins in 
S. Aureus, a two-step strip/charge cycle could be performed to regenerate immobilized 
TM.  Although these efforts were limited by the low catalytic activity of wild-type SrtA, 
we demonstrated that a mutant SrtA which exhibited 140-fold higher catalytic activity 
enabled the rapid and repeatable recharging of TM surfaces in vitro.  Significantly, we 
were able to demonstrate the in vivo application of this approach to modify catheters 
deployed in the mice.  To our knowledge, these results are the first to demonstrate a 
covalent chemistry approach to repeatably regenerate the activity of enzyme surface 
assemblies by a rapid two-step cycle.  The capacity to recharge solid surfaces in situ 
under a range of environmental conditions would prolong the lifetime of medical device, 
diagnostics, and artificial organ system designs, as well as solid supported enzymes in 
industrial bioprocess applications.  
7.2. Future Directions 
Our long term goal is to develop a small-diameter synthetic conduit that performs 
comparably or superior to autologous vessels in vascular reconstructive surgery.  We 
anticipate this will involve the combination of advances in (1) material science and tissue 
engineering to generate scaffolds which match the mechanical attributes of the native 
artery and satisfy surgical requirements such as burst strength and suture retention, as 
well as industrial manufacturing specifications such as scalability, off-the-shelf 
availability, and sterility; and (2) surface engineering approaches to incorporate 
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therapeutic biomolecules that minimize deleterious short term inflammatory and 
thrombotic cascades, and promote the regeneration of cellular components of the native 
blood vessel, in particular, a confluent endothelial lining to maintain long term blood 
compatibility.   
Our specific objective is to develop a surface engineering platform that 
maximizes the functional activity and duration of biologically active components critical 
to limiting the elaboration of inflammatory and thrombotic cascades, as well as 
promoting the regeneration of cellular and matrix components critical to restoring the 
surface characteristics of the native blood vessel.  Towards this end, we propose three 
major areas for future exploration: (1) maximize the biological activity and 
manufacturing scalability of thrombomodulin using eukaryotic cell lines that conform to 
current industry standards for recombinant human protein production; (2) directed 
evolution of sortase A to generate a family of highly active and bioorthogonal variants 
that facilitate rapid surface modification in vivo, as well as assembly of heterofunctional 
surface components that combine the antithrombotic function of TM with bioactive 
factors that control inflammation and promote regeneration of the endothelial cell lining; 
and (3) development of conformal film coating strategies that maximize the surface 
density of anchor sites for immobilization of bioactive components, and minimize 
perturbation to the underlying architecture of the synthetic material component. 
 First, the production of recombinant TMLPETG will be optimized using appropriate 
expression systems at scales suitable for industry manufacturing.  Soluble recombinant 
human thrombomodulin has been explored by a number of pharmaceutical companies 
(Recomodulin by Asahi Kasei Pharm, Tokyo, Japan; Solulin by Schering, Berlin, 
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Germany; rTM by Eli Lilly), and the production of TM has been primarily carried out in 
eukaryotic expression systems, such as mammalian and insect cell lines, that optimize the 
folding of the ~120 amino acid TM456 fragment which contains 9 disulfide bonds that 
are essential for biological activity.  Currently, the periplasmic expression system in E 
Coli suffers from poor yield, due in part to the highly inefficient purification protocol that 
likely generates a mixture that includes a substantial portion of misfolded TM456.  
Moreover, it has been demonstrated that several post-translational modifications to TM 
may be essential for biological activity, and current E Coli expression systems generally 
lack the necessary cellular machinery to achieve these modifications.  Therefore, a 
reasonable next step to maximize the activity of TMLPETG is to optimize the amino acid 
sequence of TM to recapitulate the post-translational modifications and express the final 
construct in eukaryotic systems that maximize yields and folding of the TM product. 
 Second, the general directed evolution system based on yeast display that was 
recently developed could be utilized to further evolve orthogonal sortase variants with 
altered substrate specificity and enhanced catalytic activity.  Transpeptidation by sortase 
A is suitable for a broad range of candidate biomolecules due to the synthetic simplicity 
of incorporating a C-terminal LPETG tags on compounds such as TM, heparin, CD39, 
PEG, and other peptides.  In addition, increasing the catalytic activity of the existing 5’ 
SrtA may improve the stripping efficiency in our current surface recharge scheme.  
Specifically, mutant 5’ SrtA libraries cloned in yeast cells will be subjected to 
evolutionary pressure to enhance the affinity for LPESG, LAETG, or LAESG substrates 
in the presence of competing LPETG peptide at 37C in serum, in order to enrich mutants 
for maximal activity under simulated in vivo conditions.  The surviving sortase genes 
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from the first phase will be diversified by gene shuffling, and subjected to greater 
evolutionary pressure for overall catalytic activity, by increasing selection stringency, 
reducing substrate concentration, and shortening reaction time with each successive 
round.  We postulate that these efforts will yield highly efficient transpeptidation 
catalysts that recognize unique peptide motifs.  These evolved sortase variants may be a 
key step in generating multimeric and/or heterofunctional bioenzyme assemblies that 
synergize the activity of surface enzyme assemblies which resist platelet and coagulation 
activation cascades, as well as biofilm formation, to improve the durability of implantable 
medical devices that operate in contact with blood.  
 A final area for future research will be the optimization of conformal coatings 
strategies that are suitable for generating high densities of anchor motifs to immobilize 
desired biomolecules with minimal impact on the bulk material properties.  This set of 
parameters may be essential in future effort to synergize bioactive surface properties with 
bulk properties that optimize both blood-material and tissue-material interactions.  In this 
dissertation we have demonstrated the layer-by-layer assembly of polyelectrolyte 
multilayers on ePTFE grafts.  Alternatively, generation of reactive chemical groups by 
high energy methods, such as plasma irradiation or electron beams, may provide highly 
stable anchor sites but must be engineered to minimize risk of degrading the structural 
integrity of the underlying material.  Chemical vapor deposition methods could also be a 
viable strategy to generate thin conformal coatings for immobilization of biomolecules, 
however, the challenge of generating a uniform coating on the luminal surface of vascular 
grafts remains a major hurdle.  Another option is the use of mussel adhesive peptides 
motifs to generate conformal films, though the stability of these strategies in the harsh 
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physiological environment has not been validated.  The testing and optimization of these 
conformal surface modification strategies may ultimately yield a platform that is 
compatible with any number of synthetic or biological materials used in the construction 
of implantable medical devices and artificial organs. 
 In summary, future efforts to achieve our goal of developing a small-diameter 
synthetic arterial substitute will hinge on the optimization of 3 major areas: the bioactive 
therapeutic production (TM, heparin, CD39, etc), the surface coupling chemistry (copper-
free click, sortase, etc), as well as the surface coating methodology (PEM, plasma, CVD, 
etc) to maximize the surface activity and duration, as well as adaptability across synthetic 
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